data_2l34_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2l34 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.82 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.7 p -55.6 -39.81 56.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 C-N-CA 120.614 -0.434 . . . . 0.0 109.851 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -52.86 -50.3 64.06 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.96 -38.77 73.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 122.029 0.919 . . . . 0.0 109.028 179.116 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.75 -35.6 90.16 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 42.0 mm -67.44 -43.16 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.792 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.45 -42.69 81.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.516 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -55.85 -43.36 74.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.32 -30.44 76.1 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.56 -48.31 80.04 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.2 mp -60.36 -39.76 88.31 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.0 t -60.66 -40.72 85.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.742 179.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.483 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.0 mt -64.48 -44.44 91.0 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.784 0.326 . . . . 0.0 110.921 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 m -59.81 -52.31 66.0 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.695 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.4 t -72.31 -27.92 27.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -178.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 29.6 tp -69.38 -56.17 8.25 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.498 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.2 mm -70.03 -40.73 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.567 -179.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.86 -39.22 80.7 Favored 'General case' 0 C--O 1.231 0.111 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.171 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.6 tp -69.56 -35.46 75.42 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.48 -56.01 19.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.223 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.406 ' CG2' ' N ' ' A' ' 28' ' ' TYR . 7.6 m -65.41 -43.15 94.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.113 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.68 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.406 ' N ' ' CG2' ' A' ' 27' ' ' VAL . 91.5 t80 -61.01 -45.35 95.17 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.951 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.3 t80 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.198 -179.416 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.791 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 7.6 p -57.78 -48.2 84.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.382 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -51.1 -46.74 61.95 Favored 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.32 -29.7 70.05 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.851 0.834 . . . . 0.0 109.34 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.67 -35.62 86.21 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -70.31 -45.21 76.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 119.298 -0.382 . . . . 0.0 111.218 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 3.0 m -60.94 -40.52 85.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 C-N-CA 118.529 -1.268 . . . . 0.0 109.602 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 71.4 t -55.95 -45.38 80.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -26.12 69.78 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.483 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 10.5 t70 -66.3 -48.73 69.41 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.2 mp -61.52 -39.61 91.67 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -66.89 -29.86 47.7 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.162 179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.5 tt -71.37 -52.57 17.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.982 0.42 . . . . 0.0 110.543 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.8 m -59.14 -46.09 89.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.874 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -69.76 -30.94 46.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.2 tp -68.47 -55.3 12.28 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.368 -178.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 16.9 mt -71.77 -39.97 69.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.439 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -62.1 -36.35 81.44 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.021 0.439 . . . . 0.0 110.024 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 33.6 tp -71.24 -37.51 71.99 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.34 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.783 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 35.7 m -65.87 -36.86 78.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.855 -0.338 . . . . 0.0 110.792 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.3 t80 -60.18 -47.51 85.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 70.1 t80 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.622 179.962 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.562 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.48 ' CG1' ' N ' ' A' ' 9' ' ' LEU . 11.0 p -63.91 -47.14 91.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.48 ' N ' ' CG1' ' A' ' 8' ' ' VAL . 1.5 mm? -55.48 -48.78 74.02 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.603 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.95 -37.93 67.09 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.06 -36.1 92.42 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 43.8 mm -65.15 -45.67 93.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.32 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -58.95 -41.26 82.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.085 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.5 t -55.7 -40.32 59.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -32.6 84.72 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 178.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.51 -48.82 80.16 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -61.19 -39.8 91.55 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.662 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 69.8 t -60.24 -43.47 93.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.713 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 32.8 mt -62.36 -43.69 98.22 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.911 0.386 . . . . 0.0 110.481 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -56.93 -51.41 69.25 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.077 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -69.3 -34.91 65.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 32.6 tp -64.61 -57.62 8.59 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -178.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.5 mm -68.47 -38.35 79.11 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.493 -179.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.65 -39.65 77.5 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.455 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.28 -38.36 78.32 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.41 -53.53 53.55 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.46 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 29.2 m -62.56 -46.03 97.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.612 -179.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 83.9 t80 -61.19 -43.87 98.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.308 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.4 t80 . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.157 -179.247 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.596 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 14.7 p -51.83 -38.54 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.573 -0.451 . . . . 0.0 109.875 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -55.19 -51.08 67.66 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.6 -39.56 64.98 Favored 'General case' 0 C--O 1.242 0.663 0 CA-C-O 121.862 0.839 . . . . 0.0 109.506 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.86 -43.02 94.93 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 114.568 -1.196 . . . . 0.0 110.147 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . 0.409 ' O ' ' N ' ' B' ' 15' ' ' GLY . 1.8 mp -62.44 -42.38 95.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.493 0 C-N-CA 120.208 -0.597 . . . . 0.0 109.452 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 44.0 t -49.65 -50.85 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 C-N-CA 119.94 -0.704 . . . . 0.0 109.146 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.02 -33.85 47.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' B' ' 12' ' ' ILE . . . -64.95 -39.91 96.81 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.412 ' C ' ' OD1' ' B' ' 16' ' ' ASP . 8.1 t0 -61.68 -45.47 93.86 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.14 0.495 . . . . 0.0 109.932 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.19 -42.54 98.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.519 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.0 t -71.86 -26.47 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.403 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.0 tt -73.56 -54.14 8.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 18.6 m -60.11 -45.89 91.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.298 179.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 92.3 t -66.29 -44.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.838 -179.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.8 tp -58.97 -57.93 10.91 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 13.4 mt -65.93 -40.44 87.47 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.948 -179.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.22 -33.07 65.01 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -68.68 -43.81 75.35 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.44 -52.91 42.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.676 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.0 m -63.16 -42.07 95.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.809 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -55.39 -46.77 76.52 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.38 . . . . 0.0 110.782 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 86.4 t80 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.754 -179.906 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.771 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -49.2 -42.25 15.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.065 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -52.16 -52.48 51.63 Favored 'General case' 0 CA--C 1.537 0.474 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.4 -37.85 62.86 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.09 0.947 . . . . 0.0 109.145 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.89 -37.42 94.33 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.711 -1.132 . . . . 0.0 110.311 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 43.0 mm -65.3 -43.19 95.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.011 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -57.53 -43.15 82.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 C-N-CA 119.016 -1.074 . . . . 0.0 108.601 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.3 t -54.68 -43.79 67.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.19 -32.45 82.58 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -60.57 -48.91 79.69 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -62.08 -38.41 88.71 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.5 t -61.89 -41.81 92.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.99 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.486 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.9 mt -66.57 -43.7 84.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.87 0.367 . . . . 0.0 110.998 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.1 m -60.85 -51.51 68.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.308 -178.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 90.9 t -71.76 -32.33 44.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.143 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.3 tp -66.48 -56.27 11.71 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.712 -178.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.0 mm -69.1 -41.78 81.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.298 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.94 -40.98 77.44 Favored 'General case' 0 N--CA 1.46 0.056 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.651 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.12 79.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.04 -54.04 49.69 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.698 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.441 ' CG2' ' N ' ' A' ' 28' ' ' TYR . 3.5 m -68.1 -43.57 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.722 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.441 ' N ' ' CG2' ' A' ' 27' ' ' VAL . 69.7 t80 -58.72 -48.66 80.39 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.168 -178.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.2 t80 . . . . . 0 C--N 1.328 -0.336 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.195 -179.35 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.732 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 15.0 p -62.53 -48.52 87.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.466 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 1.8 mm? -51.68 -47.49 63.83 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.7 -33.87 70.67 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-O 121.841 0.829 . . . . 0.0 108.883 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.86 -33.79 88.19 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -72.83 -36.19 51.52 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 119.267 -0.397 . . . . 0.0 111.275 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.6 m -68.18 -40.93 83.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 118.886 -1.125 . . . . 0.0 110.517 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 p -64.57 -38.68 83.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 118.747 -1.181 . . . . 0.0 108.42 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.35 -28.93 73.74 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.486 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 7.8 t0 -65.42 -48.03 74.21 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.2 mt -59.79 -42.26 92.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.688 179.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 95.0 t -69.0 -24.5 28.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.181 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.3 tt -71.97 -53.57 12.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.085 0.469 . . . . 0.0 110.222 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 11.5 m -59.48 -46.34 89.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.564 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.5 t -66.18 -43.72 91.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.699 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.7 tp -57.92 -56.57 20.24 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 34.8 mt -65.52 -41.56 91.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.945 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.95 -31.4 64.94 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 121.355 0.598 . . . . 0.0 109.577 178.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.44 -43.53 69.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.346 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.25 -53.61 51.25 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.612 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 18.3 m -59.91 -41.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.726 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -58.96 -40.76 85.7 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.449 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 77.5 t80 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.111 -179.793 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.635 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.44 ' CG1' ' N ' ' A' ' 9' ' ' LEU . 9.7 p -54.37 -46.82 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.159 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.44 ' N ' ' CG1' ' A' ' 8' ' ' VAL . 2.9 mm? -53.2 -50.63 64.27 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.53 -36.07 61.4 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.991 0.901 . . . . 0.0 109.07 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.64 -35.7 92.37 Favored Glycine 0 C--N 1.317 -0.503 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 37.8 mm -66.09 -43.08 92.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.856 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -59.17 -42.07 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 119.111 -1.036 . . . . 0.0 108.715 179.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.5 t -54.92 -41.39 57.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.27 -33.36 87.03 Favored Glycine 0 CA--C 1.53 0.987 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.026 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.431 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 8.9 t0 -61.16 -47.68 85.07 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -61.0 -39.57 90.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.05 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -60.39 -40.44 84.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.64 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.482 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.6 mt -64.4 -44.66 90.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.774 0.321 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 m -58.09 -51.39 69.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.412 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 62.0 t -71.51 -32.73 47.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.845 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.8 tp -66.73 -53.86 28.9 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.676 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 5.0 mm -68.87 -42.14 82.41 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.461 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.12 -41.96 84.74 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.2 -179.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.6 tp -69.09 -38.28 78.89 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.51 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.06 53.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.941 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 16.7 m -69.63 -42.24 80.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.552 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -62.13 -44.89 95.65 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.825 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.7 t80 . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.11 -179.57 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.458 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 9.0 p -60.36 -44.19 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.411 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 3.4 mm? -57.42 -50.29 73.48 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.465 178.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.02 -29.8 60.91 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.777 0.799 . . . . 0.0 109.348 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.53 -38.33 94.63 Favored Glycine 0 C--N 1.316 -0.532 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 178.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -68.05 -44.04 84.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 120.439 -0.504 . . . . 0.0 111.227 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 2.1 m -60.67 -37.27 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.675 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 61.6 t -58.68 -43.64 88.1 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -64.45 -32.76 85.28 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.373 178.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.482 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -61.85 -48.38 80.8 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.996 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.9 mt -60.08 -44.39 94.81 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.819 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.87 -25.89 37.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.03 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.431 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 2.7 tt -70.48 -49.41 48.75 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.0 0.429 . . . . 0.0 110.287 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 18.3 m -61.21 -46.09 91.89 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.618 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.2 t -70.96 -27.5 30.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.925 -179.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -69.98 -53.83 15.98 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.849 -0.34 . . . . 0.0 111.485 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 55.7 mt -70.99 -41.24 76.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.262 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.77 -42.17 96.98 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.503 -0.479 . . . . 0.0 109.748 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.4 tp -70.51 -28.59 65.07 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.78 -53.84 53.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.237 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 8.6 m -70.45 -34.21 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.066 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -59.74 -49.27 78.38 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.665 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 59.0 t80 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.114 -179.879 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.627 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.6 p -65.14 -44.8 95.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.85 179.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -55.23 -48.72 73.52 Favored 'General case' 0 CA--C 1.543 0.696 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.19 -36.9 76.18 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.984 0.897 . . . . 0.0 109.558 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.01 -36.07 92.35 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 39.3 mm -66.72 -43.67 89.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.95 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -56.7 -42.44 76.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 118.513 -1.275 . . . . 0.0 108.651 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.6 t -55.64 -42.54 69.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.33 -32.04 81.42 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -61.61 -47.23 86.4 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -61.04 -38.87 87.68 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.022 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.5 t -62.41 -42.25 94.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.917 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 16.2 mt -65.55 -45.65 82.55 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.751 0.31 . . . . 0.0 110.878 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.0 m -57.26 -51.58 68.78 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.24 -178.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.1 t -71.03 -34.2 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.267 -0.424 . . . . 0.0 112.003 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.7 tp -64.91 -56.46 13.16 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -68.6 -41.73 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 120.03 -0.668 . . . . 0.0 109.252 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.56 -40.42 71.9 Favored 'General case' 0 CA--C 1.523 -0.091 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.566 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.82 80.1 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.52 -53.89 52.12 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.723 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.436 ' CG2' ' N ' ' A' ' 28' ' ' TYR . 2.5 m -66.58 -43.04 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.622 -179.14 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.436 ' N ' ' CG2' ' A' ' 27' ' ' VAL . 81.3 t80 -59.09 -48.66 80.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.403 -179.011 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 83.5 t80 . . . . . 0 C--N 1.33 -0.282 0 C-N-CA 120.916 -0.314 . . . . 0.0 111.114 -179.214 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.268 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.8 p -68.62 -40.83 82.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.601 -0.299 . . . . 0.0 110.367 179.228 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.96 -49.16 66.31 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.989 179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.37 -28.89 68.55 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.838 0.828 . . . . 0.0 109.349 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.17 -33.98 69.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 76.4 mt -72.25 -37.63 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.686 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 3.0 m -69.47 -43.99 80.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.741 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.7 p -61.44 -42.41 93.73 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 118.943 -1.103 . . . . 0.0 109.101 178.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.19 -27.95 73.33 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 47.3 t0 -65.42 -47.0 77.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.282 0.563 . . . . 0.0 109.639 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -59.41 -40.97 88.36 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -67.75 -24.34 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.686 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 tt -71.28 -53.25 14.94 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.095 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 23.8 m -59.67 -46.68 88.32 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.634 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -65.93 -43.73 92.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.739 -179.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.9 tp -58.53 -56.09 26.69 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -178.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 35.7 mt -65.61 -41.7 91.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.959 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -32.9 64.63 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.485 0.66 . . . . 0.0 109.462 178.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -69.23 -42.3 75.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.278 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.98 -53.7 52.31 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.791 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 15.4 m -58.94 -43.28 88.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 C-N-CA 120.171 -0.612 . . . . 0.0 110.487 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.92 -40.97 81.71 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.902 0.382 . . . . 0.0 110.553 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.8 t80 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 -179.732 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.664 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.2 p -63.98 -43.9 97.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.185 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -54.32 -48.75 70.99 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 121.253 0.549 . . . . 0.0 109.64 178.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.73 -39.28 73.67 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.909 0.861 . . . . 0.0 109.275 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.02 -35.02 90.11 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 39.8 mm -66.41 -44.25 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 120.434 -0.507 . . . . 0.0 111.065 -179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -59.41 -41.06 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 118.544 -1.262 . . . . 0.0 109.089 179.774 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.1 t -54.5 -42.09 57.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.65 -33.37 86.49 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.744 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -58.86 -49.74 76.61 Favored 'General case' 0 CA--C 1.52 -0.207 0 CA-C-O 121.025 0.44 . . . . 0.0 109.848 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -61.09 -39.04 88.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.672 179.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -60.62 -42.58 92.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.833 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.411 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 62.3 mt -63.85 -43.73 95.27 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.772 0.32 . . . . 0.0 110.785 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -58.0 -51.87 67.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.85 0.357 . . . . 0.0 111.277 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 52.9 t -71.31 -29.03 34.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.628 -179.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.49 -51.84 21.57 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 5.1 mm -70.23 -38.46 74.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.011 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.18 -44.25 80.15 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.634 -0.427 . . . . 0.0 111.214 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 47.5 tp -70.53 -35.78 73.36 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.377 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.48 -49.78 51.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.865 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.2 m -68.33 -44.59 83.56 Favored 'Isoleucine or valine' 0 C--O 1.23 0.078 0 C-N-CA 120.049 -0.66 . . . . 0.0 111.193 -178.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 58.3 t80 -63.25 -46.89 84.79 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.032 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.5 t80 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.964 -179.544 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.633 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 14.7 p -53.46 -42.14 47.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -51.32 -52.2 47.51 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.37 -35.25 65.06 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.914 0.864 . . . . 0.0 109.302 179.284 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.01 -33.97 88.7 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -71.69 -39.5 69.15 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.923 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 m -63.84 -44.92 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 118.526 -1.269 . . . . 0.0 110.314 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -60.59 -35.76 65.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 C-N-CA 118.277 -1.369 . . . . 0.0 107.702 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.48 -30.14 76.01 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.919 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.411 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 3.3 t0 -64.35 -48.61 74.89 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -59.26 -43.99 92.43 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -67.12 -25.46 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.46 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 2.9 tt -70.47 -50.26 39.95 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 120.981 0.419 . . . . 0.0 110.268 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 69.7 m -62.25 -45.3 93.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -68.79 -31.06 49.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.6 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 28.6 tp -68.5 -52.15 35.42 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.833 -178.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 63.9 mt -71.36 -40.62 73.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.487 -179.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.74 -40.9 97.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.382 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 49.0 tp -72.82 -31.2 64.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.049 0.452 . . . . 0.0 109.99 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.49 -52.51 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.972 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 23.1 m -70.38 -36.33 66.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.815 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -62.16 -48.67 79.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.551 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.8 t80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.78 -179.866 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.699 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.94 -41.8 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 120.577 -0.449 . . . . 0.0 109.928 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -59.17 -49.39 78.04 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.29 -36.96 66.71 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 122.158 0.98 . . . . 0.0 108.82 179.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.12 -37.71 95.37 Favored Glycine 0 CA--C 1.521 0.43 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.43 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.4 mm -64.53 -43.42 96.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.632 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -57.5 -44.64 85.23 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.552 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -54.98 -39.78 50.84 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.186 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.13 -35.11 91.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -58.08 -49.44 76.92 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-O 121.159 0.504 . . . . 0.0 109.693 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -61.0 -39.01 88.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.769 179.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.74 -38.92 81.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.984 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 72.5 mt -67.65 -39.09 84.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.761 0.315 . . . . 0.0 110.633 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.3 m -61.73 -51.85 66.66 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.635 -0.426 . . . . 0.0 111.19 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.5 t -72.76 -29.6 30.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.765 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.2 tp -72.38 -52.25 16.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.441 -178.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.5 mm -68.75 -38.98 79.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.066 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.47 -42.69 78.38 Favored 'General case' 0 C--N 1.333 -0.138 0 C-N-CA 120.755 -0.378 . . . . 0.0 111.262 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.2 tp -70.53 -36.77 73.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.996 0.426 . . . . 0.0 110.331 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.56 -49.38 48.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.824 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -69.04 -41.82 81.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.451 -178.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -64.66 -46.07 84.07 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.73 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.0 t80 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.02 -179.523 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.204 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.429 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 5.6 p -61.68 -42.88 95.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.429 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 2.5 mm? -60.96 -48.5 81.53 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 119.723 -0.791 . . . . 0.0 109.628 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.71 -35.65 56.04 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 122.131 0.967 . . . . 0.0 108.877 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.58 -42.88 99.84 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 114.293 -1.322 . . . . 0.0 110.084 179.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.34 -29.12 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 C-N-CA 120.357 -0.537 . . . . 0.0 109.832 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 61.4 t -64.2 -57.03 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.826 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 p -57.8 -28.14 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.2 -31.9 78.67 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 178.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -65.6 -46.06 80.79 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.456 ' CD1' ' N ' ' B' ' 17' ' ' LEU . 8.0 mp -58.87 -44.3 91.05 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.424 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -68.9 -23.05 26.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.064 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -70.05 -55.47 9.43 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.016 0.436 . . . . 0.0 110.412 -179.353 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 77.2 m -61.56 -43.9 98.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.3 t -67.04 -38.46 81.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.623 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 30.0 tp -63.13 -51.66 65.62 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 47.0 mt -69.34 -39.73 79.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 119.964 -0.695 . . . . 0.0 110.397 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.2 -44.79 96.72 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.583 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -71.73 -27.55 63.07 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.03 -53.78 44.5 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.649 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 33.2 m -71.01 -38.81 73.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.321 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 48.6 t80 -60.75 -48.64 80.87 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.494 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 t80 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.667 -179.921 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.832 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.9 p -56.47 -27.73 25.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.967 0.413 . . . . 0.0 109.952 179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -61.61 -48.74 79.53 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.5 -39.38 83.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 122.258 1.028 . . . . 0.0 109.172 179.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.45 -37.24 92.93 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 114.592 -1.185 . . . . 0.0 110.174 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 4.9 mm -66.14 -43.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.888 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.53 -43.07 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 118.907 -1.117 . . . . 0.0 108.486 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 66.9 t -55.18 -41.49 60.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.46 -30.94 79.1 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.796 178.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -61.4 -49.32 77.38 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -61.8 -40.17 94.27 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.591 179.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -61.51 -43.19 96.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.225 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.0 mt -64.31 -45.83 86.22 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 10.7 m -57.11 -51.86 67.6 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.883 0.373 . . . . 0.0 110.913 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.6 t -71.89 -27.68 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.882 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 42.4 tp -72.09 -52.65 15.81 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 5.1 mm -69.8 -38.77 76.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.317 -0.553 . . . . 0.0 109.885 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.37 -42.94 82.61 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.327 -179.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.2 tp -70.63 -38.01 73.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.901 0.381 . . . . 0.0 110.214 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.49 -49.27 64.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.746 -179.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 18.3 m -70.28 -39.67 77.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.285 -178.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.0 t80 -63.51 -46.52 85.71 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.898 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.5 t80 . . . . . 0 C--N 1.331 -0.215 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.336 -179.316 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.382 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 14.4 p -58.92 -43.46 88.63 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.411 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 0.6 OUTLIER -54.27 -48.52 71.12 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.488 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.59 -38.06 66.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -35.6 91.29 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.166 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -69.47 -38.84 77.78 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 CA-C-O 119.111 -0.471 . . . . 0.0 111.131 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.2 m -65.71 -45.65 91.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.651 -179.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.2 p -60.84 -32.73 52.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 C-N-CA 118.285 -1.366 . . . . 0.0 107.524 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.9 -28.64 72.88 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.703 178.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.0 t0 -65.33 -49.26 70.12 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.6 mp -59.95 -42.28 93.72 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.6 t -67.2 -26.4 36.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.348 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 2.0 tt -70.65 -48.58 54.2 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.938 0.399 . . . . 0.0 110.228 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 12.1 m -62.59 -45.61 92.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.679 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.9 t -70.22 -27.5 32.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.622 -179.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 27.4 tp -70.86 -53.13 16.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.758 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 55.0 mt -71.08 -38.98 73.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -65.77 -41.6 91.84 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.584 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -72.56 -31.68 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.028 0.442 . . . . 0.0 109.979 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.31 -52.35 54.64 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.037 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 28.3 m -70.81 -37.41 68.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.979 -179.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -61.32 -49.31 77.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.619 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 67.6 t80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.788 -179.937 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.783 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.4 p -56.08 -42.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.172 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -56.66 -48.59 77.24 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.81 -37.6 60.12 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-O 122.107 0.956 . . . . 0.0 108.824 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.49 -39.55 97.97 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.6 mm -61.91 -40.2 86.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.687 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -62.92 -42.4 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 C-N-CA 119.257 -0.977 . . . . 0.0 109.276 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.5 t -53.44 -44.59 55.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.1 -32.36 83.81 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.3 179.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.434 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 16.6 t0 -61.8 -51.46 68.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.772 0.32 . . . . 0.0 110.538 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -61.15 -38.3 85.93 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.2 t -64.32 -33.33 62.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.29 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 35.6 mt -72.71 -49.55 30.5 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.134 -179.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.1 m -59.6 -48.62 80.94 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.097 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.0 t -70.74 -38.57 73.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.3 tp -62.53 -54.58 37.68 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.712 -0.395 . . . . 0.0 111.753 -178.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.3 mm -69.04 -41.87 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.82 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.6 -39.51 73.7 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.446 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.9 tp -69.96 -37.05 75.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.3 -53.6 52.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.422 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.4 m -67.84 -40.83 84.3 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.514 -179.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 75.4 t80 -59.68 -46.67 88.35 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.921 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.9 t80 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.972 -179.582 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.41 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.43 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 8.8 p -60.79 -44.6 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.601 -0.44 . . . . 0.0 109.912 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.43 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 2.9 mm? -58.57 -48.52 80.66 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 119.919 -0.713 . . . . 0.0 109.295 179.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.74 -33.36 55.49 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.561 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.37 -39.73 98.11 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.8 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.05 -25.51 27.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.463 -0.368 . . . . 0.0 110.135 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t -68.13 -53.84 26.5 Favored 'Isoleucine or valine' 0 C--O 1.243 0.73 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.554 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.2 p -58.86 -31.26 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.96 -26.12 73.26 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -68.23 -60.9 2.12 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 111.761 0.282 . . . . 0.0 111.761 -178.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.449 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.39 -24.37 62.93 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.57 -179.684 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 17.9 t -68.82 -38.37 78.65 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.434 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 15.6 mt -64.43 -50.16 68.68 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.309 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 13.9 m -58.26 -50.58 73.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.775 -178.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.8 t -71.39 -27.04 27.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 20.9 tp -69.84 -57.09 5.49 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.212 -178.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 14.0 mt -70.82 -39.54 75.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.21 -39.49 90.42 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 109.895 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.1 tp -70.31 -33.21 71.26 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.02 -51.61 68.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.548 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -64.07 -40.71 90.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -59.54 -46.33 89.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.582 -179.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 85.3 t80 . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.806 -179.902 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.721 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.8 p -55.37 -45.94 78.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.164 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -51.7 -48.8 63.39 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.96 -37.73 69.43 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.078 0.942 . . . . 0.0 109.427 179.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.85 -37.99 94.59 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -66.57 -40.87 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.32 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.408 ' H ' HG12 ' A' ' 13' ' ' VAL . 0.8 OUTLIER -57.82 -42.02 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 118.664 -1.214 . . . . 0.0 108.759 179.691 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.6 t -55.54 -43.34 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.2 -33.83 87.18 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.06 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 19.7 t0 -60.02 -51.17 70.81 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 120.949 0.404 . . . . 0.0 110.361 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -60.38 -37.87 82.12 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.5 t -64.01 -33.91 65.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.302 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.7 mt -71.72 -46.97 56.96 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.94 -0.304 . . . . 0.0 111.231 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.7 m -59.59 -49.39 77.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.871 -179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.8 t -70.94 -35.43 59.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.404 -179.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.79 -55.7 18.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.746 -0.381 . . . . 0.0 111.763 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 mm -68.77 -40.96 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.638 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.55 -39.51 76.83 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.621 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.5 tp -69.37 -37.06 77.43 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.55 39.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.579 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.422 ' CG2' ' N ' ' A' ' 28' ' ' TYR . 4.6 m -66.23 -43.9 91.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 C-N-CA 120.413 -0.515 . . . . 0.0 111.696 -179.078 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.422 ' N ' ' CG2' ' A' ' 27' ' ' VAL . 73.1 t80 -59.02 -45.4 90.79 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.78 -179.389 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.4 t80 . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.082 -179.698 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.622 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -63.48 -44.92 98.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.29 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -61.09 -50.16 74.37 Favored 'General case' 0 C--O 1.239 0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 110.233 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.71 -37.42 70.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 122.053 0.93 . . . . 0.0 109.222 179.086 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.98 -36.77 93.35 Favored Glycine 0 CA--C 1.519 0.297 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 89.9 mt -66.04 -42.79 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 120.242 -0.583 . . . . 0.0 111.3 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -60.25 -38.73 78.46 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 118.558 -1.257 . . . . 0.0 108.793 179.25 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.1 t -57.51 -35.98 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 177.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.45 -25.4 75.39 Favored Glycine 0 CA--C 1.533 1.183 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.945 178.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -69.35 -60.95 2.0 Allowed 'General case' 0 C--O 1.237 0.413 0 O-C-N 122.479 -0.424 . . . . 0.0 111.776 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.463 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.12 -24.42 63.19 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 119.039 -1.064 . . . . 0.0 110.382 -179.6 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 7.2 t -66.07 -45.08 91.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 38.1 mt -63.35 -49.43 73.92 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.033 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 10.4 m -56.54 -50.73 71.01 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.507 -0.477 . . . . 0.0 111.293 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 96.5 t -67.57 -43.05 87.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.167 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 36.0 tp -57.9 -57.83 11.05 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -178.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 29.0 mt -64.67 -41.82 93.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.716 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.53 -32.33 62.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.421 0.629 . . . . 0.0 109.601 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.06 -43.4 71.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.426 179.662 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.67 -53.1 59.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.722 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 17.1 m -60.29 -41.83 88.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.647 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -58.64 -42.76 89.03 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.556 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 t80 . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.824 -179.794 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.759 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.1 p -62.99 -43.14 98.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.436 -0.506 . . . . 0.0 109.759 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -57.38 -47.41 81.75 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.44 -38.56 59.48 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.147 0.975 . . . . 0.0 108.482 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -40.07 98.51 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 114.487 -1.233 . . . . 0.0 110.639 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.6 mm -60.61 -41.53 88.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.516 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -61.29 -43.95 97.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.291 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.7 t -52.6 -45.75 48.12 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 178.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.35 80.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -60.54 -48.48 81.61 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.2 mp -61.77 -40.93 96.9 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.282 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.5 t -59.44 -41.88 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.707 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.462 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 57.4 mt -64.5 -44.7 90.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -57.52 -51.64 68.62 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -71.73 -24.19 23.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.781 -179.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 52.9 tp -70.17 -56.44 6.84 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.774 -178.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.3 mm -73.06 -38.09 54.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.552 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.19 -38.51 86.78 Favored 'General case' 0 N--CA 1.457 -0.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.074 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.5 tp -70.59 -36.65 73.67 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.39 -54.41 37.13 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.172 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.8 m -66.31 -42.47 90.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.292 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 83.9 t80 -60.35 -45.15 94.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.797 0.332 . . . . 0.0 110.867 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.2 t80 . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.101 -179.555 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.397 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 7.2 p -58.69 -41.09 81.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.407 ' O ' ' N ' ' B' ' 12' ' ' ILE . 3.5 mm? -56.89 -50.52 72.27 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.17 -30.99 40.4 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.82 -34.47 87.35 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 178.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . 0.407 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.7 mp -74.02 -29.3 25.2 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.448 -0.31 . . . . 0.0 110.902 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -72.0 -45.6 63.02 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.689 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 p -62.09 -39.66 84.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 C-N-CA 119.778 -0.769 . . . . 0.0 108.944 178.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.92 -29.02 71.13 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -66.47 -62.6 1.38 Allowed 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.48 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -63.93 -27.5 69.18 Favored 'General case' 0 C--O 1.232 0.146 0 C-N-CA 119.039 -1.064 . . . . 0.0 109.759 -179.891 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 6.8 t -68.57 -28.86 41.87 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 tt -69.17 -55.46 10.58 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.092 0.472 . . . . 0.0 110.142 179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 7.5 m -57.43 -46.15 83.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.317 -179.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 87.2 t -68.26 -41.98 84.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.831 -178.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.1 tp -59.45 -57.18 14.09 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 54.0 mt -64.74 -42.04 93.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 120.206 -0.598 . . . . 0.0 109.903 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.36 -32.2 56.36 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -69.8 -45.29 68.26 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.522 179.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.81 -52.01 58.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.744 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 16.3 m -63.51 -41.56 93.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.017 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -57.5 -45.75 84.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.34 . . . . 0.0 110.565 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 57.0 t80 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.658 -179.933 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.767 0 N-CA-C 111.998 -0.441 . . . . 0.0 111.998 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.473 ' CG1' ' N ' ' A' ' 9' ' ' LEU . 7.5 p -59.31 -48.91 85.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.831 -179.27 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.473 ' N ' ' CG1' ' A' ' 8' ' ' VAL . 2.8 mm? -51.81 -46.84 64.42 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.078 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.98 -41.61 71.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.851 0.834 . . . . 0.0 108.838 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.33 -29.87 69.91 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 42.5 mm -70.29 -42.71 78.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.51 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.53 -42.31 80.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.145 179.272 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -55.06 -42.76 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.255 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.75 -33.08 83.96 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -58.95 -50.52 73.77 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.047 0.451 . . . . 0.0 109.925 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -61.35 -39.27 89.97 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.907 179.587 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.21 -42.09 85.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.738 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.489 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 35.7 mt -65.72 -45.12 83.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.701 0.286 . . . . 0.0 111.198 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.2 m -56.29 -53.04 61.98 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.088 -178.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 65.9 t -71.9 -27.3 27.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.819 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.8 tp -72.15 -51.4 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -178.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.9 mm -70.37 -37.49 70.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.753 -179.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.46 -43.78 80.22 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.083 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -71.94 -32.92 67.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.089 0.471 . . . . 0.0 110.246 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.41 -50.61 36.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.698 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 22.8 m -68.98 -42.86 82.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.625 -0.43 . . . . 0.0 111.332 -178.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 49.1 t80 -63.07 -47.05 84.59 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.699 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.5 t80 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.187 -179.484 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.644 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -57.86 -43.84 85.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.758 -179.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 13.7 mt -64.83 -35.02 79.77 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 119.002 -1.079 . . . . 0.0 109.651 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.47 -39.81 73.83 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.99 -36.32 92.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 178.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.31 -31.31 46.57 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-O 119.155 -0.45 . . . . 0.0 111.518 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.3 m -73.01 -41.58 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.573 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 p -62.37 -37.48 78.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.547 178.026 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.87 -29.38 73.61 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.763 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.489 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.1 t0 -64.08 -49.07 73.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.114 0.483 . . . . 0.0 109.754 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 1.8 mt -59.63 -44.35 93.5 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.084 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.3 t -64.53 -24.61 36.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.541 179.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 tt -70.67 -48.51 54.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.929 0.395 . . . . 0.0 110.255 -179.473 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.7 m -61.63 -45.84 92.35 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.555 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.8 t -71.0 -26.49 27.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.668 -179.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.2 tp -71.07 -52.88 16.92 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.31 -179.075 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 46.5 mt -69.81 -42.13 79.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.831 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.68 -43.92 97.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.572 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 54.1 tp -72.02 -29.95 64.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.956 0.408 . . . . 0.0 109.988 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.6 -51.66 53.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.046 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 26.5 m -70.62 -38.81 74.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.121 -179.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -62.59 -48.48 79.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.726 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 83.3 t80 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.904 -179.911 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.4 p -66.05 -44.98 91.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -57.64 -47.61 81.76 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.19 -38.27 68.15 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.082 0.944 . . . . 0.0 108.521 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.89 -37.52 93.87 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 44.2 mm -62.76 -43.23 98.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.811 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -60.69 -43.42 94.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.576 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 88.7 t -53.5 -42.39 49.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -34.66 90.54 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 178.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -57.23 -50.31 73.26 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 120.754 0.312 . . . . 0.0 110.177 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -61.39 -40.19 93.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -62.11 -39.57 84.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 46.7 mt -67.04 -44.23 80.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.453 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.1 m -59.76 -51.59 69.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.175 -179.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.3 t -71.83 -27.98 29.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.187 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -68.99 -56.48 7.66 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.716 -178.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -70.47 -39.88 76.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.323 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.99 -39.82 82.97 Favored 'General case' 0 CA--C 1.521 -0.167 0 C-N-CA 120.867 -0.333 . . . . 0.0 110.714 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.9 tp -69.72 -37.48 76.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.59 -53.7 52.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.771 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.416 ' CG2' ' N ' ' A' ' 28' ' ' TYR . 6.4 m -67.53 -43.13 87.42 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.744 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.416 ' N ' ' CG2' ' A' ' 27' ' ' VAL . 62.8 t80 -59.29 -46.97 87.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.083 -179.355 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.3 t80 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.148 -179.306 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 14.3 p -55.13 -43.09 68.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -54.55 -52.47 61.96 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 120.391 -0.524 . . . . 0.0 109.765 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -51.41 -36.33 43.12 Favored 'General case' 0 C--O 1.241 0.658 0 CA-C-O 121.968 0.89 . . . . 0.0 109.11 179.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -37.79 95.12 Favored Glycine 0 CA--C 1.524 0.624 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.123 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.174 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 33.2 t -69.64 -52.82 28.39 Favored 'Isoleucine or valine' 0 C--O 1.246 0.901 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.491 178.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -58.53 -32.38 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.418 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.3 -25.2 75.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -69.79 -61.72 1.67 Allowed 'General case' 0 C--O 1.235 0.334 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.457 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -67.52 -23.47 65.46 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 118.368 -1.333 . . . . 0.0 109.954 -179.557 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 9.4 t -70.32 -38.91 75.82 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.863 177.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 1.9 tt -66.47 -52.07 50.13 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 120.996 0.427 . . . . 0.0 110.531 -179.219 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 9.7 m -58.8 -49.01 79.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.025 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 72.0 t -65.24 -42.01 92.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.609 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 35.6 tp -57.73 -56.51 21.0 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 112.006 0.372 . . . . 0.0 112.006 -178.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 52.7 mt -66.02 -41.71 90.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 120.084 -0.646 . . . . 0.0 110.082 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.45 -31.72 62.17 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.32 0.581 . . . . 0.0 109.484 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.77 -44.56 66.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.25 179.541 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.38 -51.97 56.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.661 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 18.0 m -63.04 -40.67 89.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.742 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.09 -47.93 79.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.83 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 63.9 t80 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.872 -179.914 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.52 -45.29 96.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.147 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -51.32 -49.48 61.28 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.3 -37.5 72.56 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-O 121.968 0.889 . . . . 0.0 109.302 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.13 -38.49 94.46 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -66.26 -44.02 91.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.378 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.19 -42.62 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 118.568 -1.253 . . . . 0.0 108.652 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 95.6 t -55.21 -42.31 65.19 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 178.09 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.56 -32.9 84.88 Favored Glycine 0 CA--C 1.53 1.012 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.131 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -61.24 -49.59 76.47 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.84 0.352 . . . . 0.0 110.179 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.405 ' N ' ' CD1' ' A' ' 17' ' ' LEU . 10.5 mp -61.53 -38.57 87.89 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.402 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 74.6 t -62.57 -41.44 92.09 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.265 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.009 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.484 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 36.6 mt -65.56 -44.61 86.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.749 0.309 . . . . 0.0 111.019 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.3 m -59.16 -51.48 69.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.229 -179.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.7 t -71.92 -30.59 37.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.754 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 35.4 tp -69.0 -52.87 24.24 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.698 -178.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.5 mm -69.9 -42.45 79.79 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.682 0 C-N-CA 119.713 -0.795 . . . . 0.0 109.25 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.88 93.02 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.435 -179.271 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 42.4 tp -70.1 -36.34 74.79 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.601 -179.632 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.19 -51.5 30.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.236 -178.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.2 m -69.37 -41.02 80.71 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 C-N-CA 120.441 -0.503 . . . . 0.0 111.366 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -65.67 -45.9 81.16 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.91 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.5 t80 . . . . . 0 C--N 1.328 -0.366 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.07 -179.47 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . 0.436 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 8.5 p -54.39 -43.89 64.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . 0.436 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 2.3 mm? -53.43 -50.47 65.16 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.67 -33.66 61.1 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 121.781 0.8 . . . . 0.0 109.156 178.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.33 -35.55 92.1 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.172 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -72.72 -33.12 43.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.169 -0.443 . . . . 0.0 111.296 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.9 m -70.32 -41.48 78.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 118.884 -1.127 . . . . 0.0 110.378 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 p -63.27 -38.06 81.11 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 C-N-CA 118.623 -1.231 . . . . 0.0 108.087 178.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.59 -29.43 73.96 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 178.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.484 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 5.3 t0 -64.67 -49.39 71.15 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.198 0.523 . . . . 0.0 109.631 179.816 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -58.82 -43.24 90.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.54 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.77 -24.39 30.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.102 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 2.3 tt -70.54 -51.64 27.29 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 121.07 0.462 . . . . 0.0 110.139 -179.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 7.8 m -60.79 -48.89 79.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.626 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -63.66 -42.54 96.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.286 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 26.7 tp -57.36 -54.02 51.56 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 59.3 mt -64.02 -44.84 97.9 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.494 -178.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.52 -36.78 67.1 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.39 -39.23 88.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -53.6 -55.65 23.96 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.262 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.7 m -63.68 -37.54 79.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 C-N-CA 119.387 -0.925 . . . . 0.0 111.02 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -56.65 -47.36 79.95 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.568 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.3 t80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.784 -179.969 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.573 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.4 p -65.32 -38.98 83.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.282 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.57 -46.27 84.17 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.59 -40.93 84.56 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 122.1 0.952 . . . . 0.0 109.441 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.16 -38.87 93.74 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.0 mm -63.98 -42.76 96.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.653 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.04 -42.67 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 C-N-CA 118.789 -1.164 . . . . 0.0 108.864 179.651 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 57.6 t -54.26 -45.08 67.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 119.485 -0.886 . . . . 0.0 108.769 178.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -33.27 86.78 Favored Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.407 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 15.0 t0 -62.12 -51.98 65.69 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.774 0.321 . . . . 0.0 110.706 -179.425 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.8 mp -60.93 -37.79 83.56 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 64.4 t -64.3 -33.19 61.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.141 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.401 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 27.3 mt -73.43 -46.7 46.94 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.188 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.0 m -60.28 -49.14 78.8 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.073 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -71.93 -37.27 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.9 tp -63.1 -55.18 27.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.408 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.6 mm -67.98 -44.68 84.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.684 -179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.46 -42.18 66.91 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 43.3 tp -66.96 -38.25 85.76 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.961 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.66 -50.87 71.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.243 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.0 t -68.7 -45.88 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 C-N-CA 120.614 -0.435 . . . . 0.0 111.497 -179.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -58.1 -47.82 82.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.42 -178.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 58.8 t80 . . . . . 0 C--N 1.328 -0.35 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.239 -179.295 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.438 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.71 -35.04 53.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -62.47 -46.78 86.96 Favored 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.129 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.0 -32.32 69.6 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.89 -32.93 84.25 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 178.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 12' ' ' ILE . . . . . 0.426 HG21 HD13 ' B' ' 12' ' ' ILE . 88.9 mt -72.77 -34.7 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-O 119.091 -0.48 . . . . 0.0 111.812 -179.706 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 m -69.54 -44.85 79.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 119.025 -1.07 . . . . 0.0 109.95 179.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 14' ' ' VAL . . . . . 0.413 ' O ' ' CG2' ' B' ' 18' ' ' VAL . 3.2 p -60.09 -33.73 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.61 -25.9 74.18 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 178.329 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.401 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 9.3 t70 -69.08 -61.49 1.77 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -178.391 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.468 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -68.15 -25.82 65.46 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.238 -179.724 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . 0.413 ' CG2' ' O ' ' B' ' 14' ' ' VAL . 14.6 t -66.74 -39.2 83.13 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.462 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 14.2 mt -63.29 -47.31 82.86 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.157 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 10.3 m -57.55 -50.26 73.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.561 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -72.31 -28.49 29.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.0 tp -68.51 -56.62 7.74 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.456 -0.498 . . . . 0.0 111.311 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 30.1 mt -69.82 -41.69 79.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.471 -0.491 . . . . 0.0 109.991 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -38.82 77.82 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.127 0.489 . . . . 0.0 109.73 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -69.54 -35.75 75.73 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.675 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.6 -51.76 68.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.518 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 16.4 m -64.99 -38.26 82.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.656 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.9 t80 -57.97 -48.57 79.58 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.472 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 84.6 t80 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.866 -179.983 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 95.7 m . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.583 ' HG ' ' H ' ' A' ' 3' ' ' THR . 35.9 t -164.06 -176.59 4.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.569 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.583 ' H ' ' HG ' ' A' ' 2' ' ' SER . 97.6 m -67.22 -68.58 0.37 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.806 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 89.7 t 56.64 -76.01 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.543 ' N ' ' O ' ' A' ' 3' ' ' THR . 1.4 m 69.26 79.95 0.21 Allowed Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.507 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -79.12 18.13 1.09 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.145 1.897 . . . . 0.0 111.974 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.93 -51.52 34.04 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.7 p -55.6 -39.81 56.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 C-N-CA 120.614 -0.434 . . . . 0.0 109.851 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -52.86 -50.3 64.06 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.96 -38.77 73.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 122.029 0.919 . . . . 0.0 109.028 179.116 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.75 -35.6 90.16 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 42.0 mm -67.44 -43.16 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.792 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.45 -42.69 81.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.516 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -55.85 -43.36 74.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.32 -30.44 76.1 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.56 -48.31 80.04 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.2 mp -60.36 -39.76 88.31 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.0 t -60.66 -40.72 85.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.742 179.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.483 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.0 mt -64.48 -44.44 91.0 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.784 0.326 . . . . 0.0 110.921 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 m -59.81 -52.31 66.0 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.695 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.4 t -72.31 -27.92 27.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -178.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 29.6 tp -69.38 -56.17 8.25 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.498 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.2 mm -70.03 -40.73 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.567 -179.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.86 -39.22 80.7 Favored 'General case' 0 C--O 1.231 0.111 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.171 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.6 tp -69.56 -35.46 75.42 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.48 -56.01 19.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.223 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.406 ' CG2' ' N ' ' A' ' 28' ' ' TYR . 7.6 m -65.41 -43.15 94.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.113 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.68 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.406 ' N ' ' CG2' ' A' ' 27' ' ' VAL . 91.5 t80 -61.01 -45.35 95.17 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.951 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -61.14 -52.85 63.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.198 -179.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 49.6 tp -174.11 78.06 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.723 0.297 . . . . 0.0 110.514 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' A' ' 33' ' ' LEU . . . -59.39 103.55 0.42 Allowed Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.8 mmm-85 -49.53 93.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.838 0.351 . . . . 0.0 110.438 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.427 ' N ' ' O ' ' A' ' 31' ' ' GLY . 12.2 tp . . . . . 0 C--N 1.33 -0.247 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.411 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.504 ' C ' ' H ' ' B' ' 3' ' ' THR . 6.8 p . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.515 ' C ' ' H ' ' B' ' 4' ' ' VAL . 6.8 p 64.51 -2.89 0.58 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.528 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.504 ' H ' ' C ' ' B' ' 1' ' ' CYS . 2.7 m 66.89 -7.18 0.49 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.766 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.515 ' H ' ' C ' ' B' ' 2' ' ' SER . 13.1 m 31.24 49.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.838 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.402 ' N ' ' CD ' ' B' ' 6' ' ' PRO . 50.4 m -156.65 55.95 1.12 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.61 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' B' ' 5' ' ' SER . 58.3 Cg_endo -70.45 68.74 2.07 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.844 2.363 . . . . 0.0 111.867 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -72.05 -52.82 10.32 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 7.6 p -57.78 -48.2 84.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.382 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -51.1 -46.74 61.95 Favored 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.32 -29.7 70.05 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.851 0.834 . . . . 0.0 109.34 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.67 -35.62 86.21 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -70.31 -45.21 76.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 119.298 -0.382 . . . . 0.0 111.218 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 3.0 m -60.94 -40.52 85.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 C-N-CA 118.529 -1.268 . . . . 0.0 109.602 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 71.4 t -55.95 -45.38 80.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -26.12 69.78 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.483 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 10.5 t70 -66.3 -48.73 69.41 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.2 mp -61.52 -39.61 91.67 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -66.89 -29.86 47.7 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.162 179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.5 tt -71.37 -52.57 17.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.982 0.42 . . . . 0.0 110.543 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.8 m -59.14 -46.09 89.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.874 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -69.76 -30.94 46.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.2 tp -68.47 -55.3 12.28 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.368 -178.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 16.9 mt -71.77 -39.97 69.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.439 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -62.1 -36.35 81.44 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.021 0.439 . . . . 0.0 110.024 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 33.6 tp -71.24 -37.51 71.99 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.34 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.783 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 35.7 m -65.87 -36.86 78.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.855 -0.338 . . . . 0.0 110.792 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.3 t80 -60.18 -47.51 85.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -62.68 -45.68 91.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.622 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 72.0 mt -61.9 -40.8 96.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.489 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.01 -34.8 90.11 Favored Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 49.2 80.29 0.07 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.82 0.343 . . . . 0.0 110.588 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.531 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.229 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.7 p . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.0 t -161.01 160.89 31.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.573 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.43 ' OG1' ' N ' ' A' ' 4' ' ' VAL . 81.1 p -62.76 -98.98 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.587 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.43 ' N ' ' OG1' ' A' ' 3' ' ' THR . 2.6 t 48.77 30.85 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.195 0.521 . . . . 0.0 109.94 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 p -73.51 153.28 89.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.932 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.14 72.69 4.0 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.166 1.911 . . . . 0.0 112.102 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -68.62 -57.4 8.13 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.48 ' CG1' ' N ' ' A' ' 9' ' ' LEU . 11.0 p -63.91 -47.14 91.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.48 ' N ' ' CG1' ' A' ' 8' ' ' VAL . 1.5 mm? -55.48 -48.78 74.02 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.603 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.95 -37.93 67.09 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.06 -36.1 92.42 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 43.8 mm -65.15 -45.67 93.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.32 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -58.95 -41.26 82.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.085 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.5 t -55.7 -40.32 59.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -32.6 84.72 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 178.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.51 -48.82 80.16 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -61.19 -39.8 91.55 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.662 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 69.8 t -60.24 -43.47 93.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.713 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 32.8 mt -62.36 -43.69 98.22 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.911 0.386 . . . . 0.0 110.481 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -56.93 -51.41 69.25 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.077 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -69.3 -34.91 65.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 32.6 tp -64.61 -57.62 8.59 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -178.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.5 mm -68.47 -38.35 79.11 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.493 -179.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.65 -39.65 77.5 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.455 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.28 -38.36 78.32 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.41 -53.53 53.55 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.46 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 29.2 m -62.56 -46.03 97.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.612 -179.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 83.9 t80 -61.19 -43.87 98.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.308 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -60.46 -53.71 54.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.157 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 54.0 tp -174.38 78.1 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.135 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -52.85 144.56 22.33 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 51.7 mmt-85 -54.82 101.35 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.757 0.313 . . . . 0.0 110.312 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 22.1 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.389 -179.974 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.474 ' C ' ' H ' ' B' ' 3' ' ' THR . 6.8 t . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.426 ' O ' ' O ' ' B' ' 3' ' ' THR . 9.5 m 46.18 15.4 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.741 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.474 ' H ' ' C ' ' B' ' 1' ' ' CYS . 91.8 m 56.06 160.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.638 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 11.4 t -85.58 117.01 29.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.109 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 5.6 m -156.54 81.1 3.58 Favored Pre-proline 0 CA--C 1.529 0.172 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.784 -179.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -81.06 83.69 2.15 Favored 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.441 2.094 . . . . 0.0 111.594 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -71.19 -40.78 60.96 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 14.7 p -51.83 -38.54 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.573 -0.451 . . . . 0.0 109.875 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -55.19 -51.08 67.66 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.6 -39.56 64.98 Favored 'General case' 0 C--O 1.242 0.663 0 CA-C-O 121.862 0.839 . . . . 0.0 109.506 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.86 -43.02 94.93 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 114.568 -1.196 . . . . 0.0 110.147 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . 0.409 ' O ' ' N ' ' B' ' 15' ' ' GLY . 1.8 mp -62.44 -42.38 95.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.493 0 C-N-CA 120.208 -0.597 . . . . 0.0 109.452 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 44.0 t -49.65 -50.85 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 C-N-CA 119.94 -0.704 . . . . 0.0 109.146 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.02 -33.85 47.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' B' ' 12' ' ' ILE . . . -64.95 -39.91 96.81 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.412 ' C ' ' OD1' ' B' ' 16' ' ' ASP . 8.1 t0 -61.68 -45.47 93.86 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.14 0.495 . . . . 0.0 109.932 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.19 -42.54 98.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.519 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.0 t -71.86 -26.47 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.403 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.0 tt -73.56 -54.14 8.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 18.6 m -60.11 -45.89 91.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.298 179.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 92.3 t -66.29 -44.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.838 -179.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.8 tp -58.97 -57.93 10.91 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 13.4 mt -65.93 -40.44 87.47 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.948 -179.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.22 -33.07 65.01 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -68.68 -43.81 75.35 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.44 -52.91 42.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.676 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.0 m -63.16 -42.07 95.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.809 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -55.39 -46.77 76.52 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.38 . . . . 0.0 110.782 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -61.61 -47.61 84.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.754 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 81.6 mt -63.4 -38.14 89.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.615 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -48.07 -35.35 13.43 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 61.6 ttt85 51.0 86.33 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 110.527 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . . . . . . . . . 13.7 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.476 179.995 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 60.5 m . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.6 m -72.38 109.5 6.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.598 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.457 ' C ' ' H ' ' A' ' 5' ' ' SER . 30.7 p -78.2 126.62 31.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.948 0.404 . . . . 0.0 110.449 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.1 t -58.81 -7.23 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.366 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.457 ' H ' ' C ' ' A' ' 3' ' ' THR . 2.9 m 63.94 60.35 1.7 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.774 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -76.65 14.39 1.24 Allowed 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.765 2.31 . . . . 0.0 111.781 179.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.2 -30.98 79.32 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -49.2 -42.25 15.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.065 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -52.16 -52.48 51.63 Favored 'General case' 0 CA--C 1.537 0.474 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.4 -37.85 62.86 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.09 0.947 . . . . 0.0 109.145 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.89 -37.42 94.33 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.711 -1.132 . . . . 0.0 110.311 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 43.0 mm -65.3 -43.19 95.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.011 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -57.53 -43.15 82.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 C-N-CA 119.016 -1.074 . . . . 0.0 108.601 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.3 t -54.68 -43.79 67.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.19 -32.45 82.58 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -60.57 -48.91 79.69 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -62.08 -38.41 88.71 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.5 t -61.89 -41.81 92.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.99 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.486 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.9 mt -66.57 -43.7 84.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.87 0.367 . . . . 0.0 110.998 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.1 m -60.85 -51.51 68.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.308 -178.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 90.9 t -71.76 -32.33 44.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.143 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.3 tp -66.48 -56.27 11.71 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.712 -178.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.0 mm -69.1 -41.78 81.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.298 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.94 -40.98 77.44 Favored 'General case' 0 N--CA 1.46 0.056 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.651 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.12 79.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.04 -54.04 49.69 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.698 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.441 ' CG2' ' N ' ' A' ' 28' ' ' TYR . 3.5 m -68.1 -43.57 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.722 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.441 ' N ' ' CG2' ' A' ' 27' ' ' VAL . 69.7 t80 -58.72 -48.66 80.39 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.168 -178.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.2 t80 -70.52 -56.56 6.27 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.195 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.7 tp -175.15 78.71 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.104 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -45.37 109.1 0.27 Allowed Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 34.2 mmm-85 -79.85 17.74 0.9 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.826 0.346 . . . . 0.0 110.412 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 20.1 tp . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.342 -179.977 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.418 ' O ' ' OG ' ' B' ' 2' ' ' SER . 19.8 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.418 ' OG ' ' O ' ' B' ' 1' ' ' CYS . 6.3 p 63.81 134.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.621 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 27.9 m -160.09 113.8 2.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.219 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 p -66.04 129.8 30.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.943 0.401 . . . . 0.0 110.492 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.522 ' N ' ' CD ' ' B' ' 6' ' ' PRO . 15.8 t -173.31 48.52 0.08 OUTLIER Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.794 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.522 ' CD ' ' N ' ' B' ' 5' ' ' SER . 46.3 Cg_endo -66.95 88.11 0.3 Allowed 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.852 2.368 . . . . 0.0 112.054 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.32 -60.14 3.14 Favored Glycine 0 CA--C 1.526 0.732 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.267 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 15.0 p -62.53 -48.52 87.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.466 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 1.8 mm? -51.68 -47.49 63.83 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.7 -33.87 70.67 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-O 121.841 0.829 . . . . 0.0 108.883 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.86 -33.79 88.19 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -72.83 -36.19 51.52 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 119.267 -0.397 . . . . 0.0 111.275 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.6 m -68.18 -40.93 83.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 118.886 -1.125 . . . . 0.0 110.517 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 p -64.57 -38.68 83.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 118.747 -1.181 . . . . 0.0 108.42 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.35 -28.93 73.74 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.486 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 7.8 t0 -65.42 -48.03 74.21 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.2 mt -59.79 -42.26 92.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.688 179.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 95.0 t -69.0 -24.5 28.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.181 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.3 tt -71.97 -53.57 12.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.085 0.469 . . . . 0.0 110.222 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 11.5 m -59.48 -46.34 89.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.564 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.5 t -66.18 -43.72 91.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.699 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.7 tp -57.92 -56.57 20.24 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 34.8 mt -65.52 -41.56 91.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.945 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.95 -31.4 64.94 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 121.355 0.598 . . . . 0.0 109.577 178.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.44 -43.53 69.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.346 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.25 -53.61 51.25 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.612 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 18.3 m -59.91 -41.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.726 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -58.96 -40.76 85.7 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.449 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 77.5 t80 -62.69 -44.25 96.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.111 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 95.9 mt -54.11 -42.03 68.98 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.464 -179.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.31 114.6 6.85 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -60.16 87.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.815 0.34 . . . . 0.0 110.53 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.54 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.428 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.492 ' O ' ' SG ' ' A' ' 1' ' ' CYS . 27.9 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.536 ' O ' ' N ' ' A' ' 4' ' ' VAL . 37.4 t -162.17 161.99 28.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.433 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.431 ' OG1' ' O ' ' A' ' 2' ' ' SER . 68.1 p 52.56 -82.07 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.811 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.536 ' N ' ' O ' ' A' ' 2' ' ' SER . 2.8 t 61.53 41.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.013 0.435 . . . . 0.0 110.303 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 44.6 m 39.62 69.51 1.71 Allowed Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.998 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -87.52 -25.81 0.9 Allowed 'Trans proline' 0 C--N 1.306 -1.706 0 C-N-CA 122.863 2.375 . . . . 0.0 111.975 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -66.61 -30.21 76.01 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.44 ' CG1' ' N ' ' A' ' 9' ' ' LEU . 9.7 p -54.37 -46.82 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.159 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.44 ' N ' ' CG1' ' A' ' 8' ' ' VAL . 2.9 mm? -53.2 -50.63 64.27 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.53 -36.07 61.4 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.991 0.901 . . . . 0.0 109.07 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.64 -35.7 92.37 Favored Glycine 0 C--N 1.317 -0.503 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 37.8 mm -66.09 -43.08 92.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.856 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -59.17 -42.07 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 119.111 -1.036 . . . . 0.0 108.715 179.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.5 t -54.92 -41.39 57.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.27 -33.36 87.03 Favored Glycine 0 CA--C 1.53 0.987 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.026 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.431 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 8.9 t0 -61.16 -47.68 85.07 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -61.0 -39.57 90.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.05 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -60.39 -40.44 84.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.64 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.482 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.6 mt -64.4 -44.66 90.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.774 0.321 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 m -58.09 -51.39 69.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.412 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 62.0 t -71.51 -32.73 47.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.845 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.8 tp -66.73 -53.86 28.9 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.676 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 5.0 mm -68.87 -42.14 82.41 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.461 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.12 -41.96 84.74 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.2 -179.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.6 tp -69.09 -38.28 78.89 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.51 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.06 53.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.941 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 16.7 m -69.63 -42.24 80.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.552 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -62.13 -44.89 95.65 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.825 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.7 t80 -68.9 -54.87 13.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.11 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.0 tp -174.48 78.02 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.331 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -51.97 114.05 2.93 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 36.4 mmm-85 -70.98 -25.47 62.72 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.745 0.307 . . . . 0.0 110.477 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.6 tp . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.225 -179.85 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 23.9 t . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.418 ' O ' ' O ' ' B' ' 3' ' ' THR . 24.6 p 47.4 26.48 0.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.617 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.418 ' O ' ' O ' ' B' ' 2' ' ' SER . 6.1 m 59.34 120.78 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.63 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -78.99 131.65 33.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.433 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.491 ' O ' ' N ' ' B' ' 7' ' ' GLY . 5.2 t -172.56 71.99 0.43 Allowed Pre-proline 0 C--N 1.331 -0.198 0 C-N-CA 120.729 -0.389 . . . . 0.0 111.408 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_exo -46.31 86.45 0.02 OUTLIER 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.643 2.229 . . . . 0.0 111.663 178.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.491 ' N ' ' O ' ' B' ' 5' ' ' SER . . . -46.59 -29.83 4.26 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 9.0 p -60.36 -44.19 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.411 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 3.4 mm? -57.42 -50.29 73.48 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.465 178.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.02 -29.8 60.91 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.777 0.799 . . . . 0.0 109.348 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.53 -38.33 94.63 Favored Glycine 0 C--N 1.316 -0.532 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 178.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -68.05 -44.04 84.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 120.439 -0.504 . . . . 0.0 111.227 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 2.1 m -60.67 -37.27 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.675 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 61.6 t -58.68 -43.64 88.1 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -64.45 -32.76 85.28 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.373 178.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.482 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -61.85 -48.38 80.8 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.996 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.9 mt -60.08 -44.39 94.81 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.819 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.87 -25.89 37.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.03 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.431 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 2.7 tt -70.48 -49.41 48.75 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.0 0.429 . . . . 0.0 110.287 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 18.3 m -61.21 -46.09 91.89 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.618 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.2 t -70.96 -27.5 30.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.925 -179.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -69.98 -53.83 15.98 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.849 -0.34 . . . . 0.0 111.485 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 55.7 mt -70.99 -41.24 76.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.262 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.77 -42.17 96.98 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.503 -0.479 . . . . 0.0 109.748 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.4 tp -70.51 -28.59 65.07 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.78 -53.84 53.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.237 -179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . 0.431 ' O ' ' N ' ' B' ' 31' ' ' GLY . 8.6 m -70.45 -34.21 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.066 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -59.74 -49.27 78.38 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.665 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -72.01 -51.7 20.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.114 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 88.9 mt -63.8 -41.54 97.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.563 -179.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' B' ' 27' ' ' VAL . . . -60.03 111.43 3.57 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -79.93 88.39 5.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.775 0.322 . . . . 0.0 110.579 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.538 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.29 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 65.7 m . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.41 ' O ' ' OG1' ' A' ' 3' ' ' THR . 57.5 m -76.59 -74.21 0.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.719 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.439 ' O ' ' O ' ' A' ' 4' ' ' VAL . 90.7 m -167.27 -87.63 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.796 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' A' ' 3' ' ' THR . 39.2 t 41.23 96.8 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.66 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.45 ' H ' ' HG ' ' A' ' 5' ' ' SER . 2.2 p -81.53 153.28 70.83 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.026 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -64.8 69.59 0.25 Allowed 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 122.15 1.9 . . . . 0.0 111.696 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 5' ' ' SER . . . -70.14 -55.54 9.03 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.6 p -65.14 -44.8 95.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.85 179.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -55.23 -48.72 73.52 Favored 'General case' 0 CA--C 1.543 0.696 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.19 -36.9 76.18 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.984 0.897 . . . . 0.0 109.558 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.01 -36.07 92.35 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 39.3 mm -66.72 -43.67 89.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.95 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -56.7 -42.44 76.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 118.513 -1.275 . . . . 0.0 108.651 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.6 t -55.64 -42.54 69.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.33 -32.04 81.42 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -61.61 -47.23 86.4 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -61.04 -38.87 87.68 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.022 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.5 t -62.41 -42.25 94.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.917 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 16.2 mt -65.55 -45.65 82.55 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.751 0.31 . . . . 0.0 110.878 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.0 m -57.26 -51.58 68.78 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.24 -178.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.1 t -71.03 -34.2 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.267 -0.424 . . . . 0.0 112.003 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.7 tp -64.91 -56.46 13.16 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -68.6 -41.73 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 120.03 -0.668 . . . . 0.0 109.252 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.56 -40.42 71.9 Favored 'General case' 0 CA--C 1.523 -0.091 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.566 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.82 80.1 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.52 -53.89 52.12 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.723 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.436 ' CG2' ' N ' ' A' ' 28' ' ' TYR . 2.5 m -66.58 -43.04 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.622 -179.14 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.436 ' N ' ' CG2' ' A' ' 27' ' ' VAL . 81.3 t80 -59.09 -48.66 80.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.403 -179.011 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -67.93 -56.54 8.63 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.916 -0.314 . . . . 0.0 111.114 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 41.7 tp -175.39 78.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.026 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -43.6 149.64 0.68 Allowed Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.059 -0.817 . . . . 0.0 111.059 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 44.5 mmm-85 -59.21 -30.77 68.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.763 0.316 . . . . 0.0 110.267 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 9.9 tp . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.479 179.91 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.529 ' C ' ' H ' ' B' ' 3' ' ' THR . 2.0 p . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.419 ' OG ' ' O ' ' B' ' 1' ' ' CYS . 3.5 p 71.77 -17.34 0.35 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.732 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.529 ' H ' ' C ' ' B' ' 1' ' ' CYS . 4.5 m 44.97 49.98 9.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.617 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 33.5 m 34.2 29.53 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.82 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.522 ' N ' ' O ' ' B' ' 3' ' ' THR . 40.0 m -166.59 72.46 1.13 Allowed Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.843 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -50.0 130.78 28.59 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.317 2.011 . . . . 0.0 111.771 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -46.17 -36.81 7.48 Favored Glycine 0 C--N 1.331 0.276 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.8 p -68.62 -40.83 82.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.601 -0.299 . . . . 0.0 110.367 179.228 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -66.96 -49.16 66.31 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.989 179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.37 -28.89 68.55 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.838 0.828 . . . . 0.0 109.349 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.17 -33.98 69.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 76.4 mt -72.25 -37.63 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.686 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 3.0 m -69.47 -43.99 80.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.741 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.7 p -61.44 -42.41 93.73 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 118.943 -1.103 . . . . 0.0 109.101 178.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.19 -27.95 73.33 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 47.3 t0 -65.42 -47.0 77.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.282 0.563 . . . . 0.0 109.639 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -59.41 -40.97 88.36 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -67.75 -24.34 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.686 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 tt -71.28 -53.25 14.94 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.095 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 23.8 m -59.67 -46.68 88.32 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.634 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -65.93 -43.73 92.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.739 -179.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.9 tp -58.53 -56.09 26.69 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -178.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 35.7 mt -65.61 -41.7 91.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.959 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -32.9 64.63 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.485 0.66 . . . . 0.0 109.462 178.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -69.23 -42.3 75.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.278 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.98 -53.7 52.31 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.791 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 15.4 m -58.94 -43.28 88.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 C-N-CA 120.171 -0.612 . . . . 0.0 110.487 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.92 -40.97 81.71 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.902 0.382 . . . . 0.0 110.553 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.8 t80 -61.81 -44.93 95.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 94.1 mt -56.91 -38.03 72.28 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.461 -179.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.31 125.91 38.75 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 58.5 ttt85 -70.8 92.49 0.9 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.823 0.344 . . . . 0.0 110.55 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.536 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.281 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.1 m . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.6 m -69.45 149.52 48.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.608 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 10.5 m -64.2 -46.09 85.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.755 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.3 t 49.17 55.35 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.141 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.6 p -91.69 148.23 36.8 Favored Pre-proline 0 CA--C 1.532 0.284 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.288 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -74.56 78.98 2.62 Favored 'Trans proline' 0 N--CA 1.496 1.644 0 C-N-CA 122.214 1.942 . . . . 0.0 112.262 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -73.0 -63.11 2.93 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.2 p -63.98 -43.9 97.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.185 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -54.32 -48.75 70.99 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 121.253 0.549 . . . . 0.0 109.64 178.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.73 -39.28 73.67 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.909 0.861 . . . . 0.0 109.275 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.02 -35.02 90.11 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 39.8 mm -66.41 -44.25 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 120.434 -0.507 . . . . 0.0 111.065 -179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -59.41 -41.06 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 118.544 -1.262 . . . . 0.0 109.089 179.774 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.1 t -54.5 -42.09 57.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.65 -33.37 86.49 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.744 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -58.86 -49.74 76.61 Favored 'General case' 0 CA--C 1.52 -0.207 0 CA-C-O 121.025 0.44 . . . . 0.0 109.848 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -61.09 -39.04 88.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.672 179.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -60.62 -42.58 92.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.833 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.411 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 62.3 mt -63.85 -43.73 95.27 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.772 0.32 . . . . 0.0 110.785 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -58.0 -51.87 67.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.85 0.357 . . . . 0.0 111.277 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 52.9 t -71.31 -29.03 34.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.628 -179.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.49 -51.84 21.57 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 5.1 mm -70.23 -38.46 74.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.011 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.18 -44.25 80.15 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.634 -0.427 . . . . 0.0 111.214 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 47.5 tp -70.53 -35.78 73.36 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.377 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.48 -49.78 51.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.865 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.2 m -68.33 -44.59 83.56 Favored 'Isoleucine or valine' 0 C--O 1.23 0.078 0 C-N-CA 120.049 -0.66 . . . . 0.0 111.193 -178.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 58.3 t80 -63.25 -46.89 84.79 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.032 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -61.94 -52.29 64.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.964 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.7 tp -173.71 77.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.177 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.05 129.8 35.27 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.7 mmm-85 -66.04 -39.92 90.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.786 0.327 . . . . 0.0 110.492 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 32.6 tp . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.296 179.941 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.531 ' C ' ' H ' ' B' ' 3' ' ' THR . 7.4 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' B' ' 1' ' ' CYS . 3.1 p 73.65 -30.66 0.21 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.743 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.531 ' H ' ' C ' ' B' ' 1' ' ' CYS . 23.5 m 54.71 99.61 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.449 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 90.3 t -94.91 115.02 32.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.953 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 30.9 t -152.37 90.96 3.67 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.785 -179.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -80.44 81.59 2.71 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.018 1.812 . . . . 0.0 111.68 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -70.68 -37.98 67.36 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 14.7 p -53.46 -42.14 47.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -51.32 -52.2 47.51 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.37 -35.25 65.06 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.914 0.864 . . . . 0.0 109.302 179.284 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.01 -33.97 88.7 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -71.69 -39.5 69.15 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.923 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 m -63.84 -44.92 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 118.526 -1.269 . . . . 0.0 110.314 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -60.59 -35.76 65.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 C-N-CA 118.277 -1.369 . . . . 0.0 107.702 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.48 -30.14 76.01 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.919 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.411 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 3.3 t0 -64.35 -48.61 74.89 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -59.26 -43.99 92.43 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -67.12 -25.46 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.46 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 2.9 tt -70.47 -50.26 39.95 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 120.981 0.419 . . . . 0.0 110.268 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 69.7 m -62.25 -45.3 93.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -68.79 -31.06 49.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.6 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 28.6 tp -68.5 -52.15 35.42 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.833 -178.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 63.9 mt -71.36 -40.62 73.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.487 -179.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.74 -40.9 97.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.382 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 49.0 tp -72.82 -31.2 64.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.049 0.452 . . . . 0.0 109.99 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.49 -52.51 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.972 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 23.1 m -70.38 -36.33 66.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.815 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -62.16 -48.67 79.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.551 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -63.27 -47.66 81.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.78 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 59.8 mt -63.72 -40.75 97.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.54 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -46.29 -24.17 1.47 Allowed Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 73.5 ttp85 50.98 80.13 0.08 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.834 0.349 . . . . 0.0 110.538 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.151 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 15.3 m . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.9 t -151.14 -88.18 0.07 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.395 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 21.7 p -62.84 -144.97 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.511 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 3.2 t 59.34 34.94 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 121.331 0.586 . . . . 0.0 109.636 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.28 159.13 85.74 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.809 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -73.97 59.33 4.34 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 C-N-CA 122.377 2.051 . . . . 0.0 111.759 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.17 -56.75 16.26 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.94 -41.8 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 120.577 -0.449 . . . . 0.0 109.928 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -59.17 -49.39 78.04 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.29 -36.96 66.71 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 122.158 0.98 . . . . 0.0 108.82 179.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.12 -37.71 95.37 Favored Glycine 0 CA--C 1.521 0.43 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.43 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.4 mm -64.53 -43.42 96.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.632 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -57.5 -44.64 85.23 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.552 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -54.98 -39.78 50.84 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.186 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.13 -35.11 91.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -58.08 -49.44 76.92 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-O 121.159 0.504 . . . . 0.0 109.693 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -61.0 -39.01 88.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.769 179.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.74 -38.92 81.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.984 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 72.5 mt -67.65 -39.09 84.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.761 0.315 . . . . 0.0 110.633 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.3 m -61.73 -51.85 66.66 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.635 -0.426 . . . . 0.0 111.19 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.5 t -72.76 -29.6 30.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.765 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.2 tp -72.38 -52.25 16.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.441 -178.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.5 mm -68.75 -38.98 79.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.066 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.47 -42.69 78.38 Favored 'General case' 0 C--N 1.333 -0.138 0 C-N-CA 120.755 -0.378 . . . . 0.0 111.262 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.2 tp -70.53 -36.77 73.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.996 0.426 . . . . 0.0 110.331 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.56 -49.38 48.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.824 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -69.04 -41.82 81.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.451 -178.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -64.66 -46.07 84.07 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.73 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.0 t80 -61.6 -51.1 69.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.02 -179.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 42.5 tp -172.4 76.47 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.309 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -70.24 127.98 18.4 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 31.1 mmm-85 -82.86 100.53 10.41 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.763 0.316 . . . . 0.0 110.432 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 51.5 tp . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.405 -179.983 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 2.1 p . . . . . 0 N--CA 1.489 1.478 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 90.0 p 44.51 24.9 0.11 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.666 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 3.4 m 48.33 41.73 16.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.313 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 3.6 t 39.06 72.34 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.717 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 32.2 t -147.84 77.83 10.05 Favored Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.268 -179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_exo -46.13 101.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.582 2.188 . . . . 0.0 111.816 179.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -46.79 -29.46 4.3 Favored Glycine 0 C--N 1.332 0.342 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.429 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 5.6 p -61.68 -42.88 95.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.429 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 2.5 mm? -60.96 -48.5 81.53 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 119.723 -0.791 . . . . 0.0 109.628 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.71 -35.65 56.04 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 122.131 0.967 . . . . 0.0 108.877 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.58 -42.88 99.84 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 114.293 -1.322 . . . . 0.0 110.084 179.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.34 -29.12 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 C-N-CA 120.357 -0.537 . . . . 0.0 109.832 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 61.4 t -64.2 -57.03 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.826 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 p -57.8 -28.14 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.2 -31.9 78.67 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 178.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -65.6 -46.06 80.79 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.456 ' CD1' ' N ' ' B' ' 17' ' ' LEU . 8.0 mp -58.87 -44.3 91.05 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.424 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -68.9 -23.05 26.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.064 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -70.05 -55.47 9.43 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.016 0.436 . . . . 0.0 110.412 -179.353 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 77.2 m -61.56 -43.9 98.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.3 t -67.04 -38.46 81.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.623 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 30.0 tp -63.13 -51.66 65.62 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 47.0 mt -69.34 -39.73 79.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 119.964 -0.695 . . . . 0.0 110.397 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.2 -44.79 96.72 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.583 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -71.73 -27.55 63.07 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.03 -53.78 44.5 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.649 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 33.2 m -71.01 -38.81 73.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.321 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 48.6 t80 -60.75 -48.64 80.87 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.494 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -62.52 -45.95 90.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.667 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 52.8 mt -61.28 -41.39 96.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.414 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.84 101.9 1.07 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 72.1 ttt180 -64.36 87.11 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.801 0.334 . . . . 0.0 110.467 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.541 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.272 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.6 m . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 72.7 m -68.88 154.28 42.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.551 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 24.3 m -46.5 103.13 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.542 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 23.7 m -75.17 -158.94 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.552 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.2 p -135.47 99.5 11.8 Favored Pre-proline 0 CA--C 1.535 0.376 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.32 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -79.47 27.87 0.52 Allowed 'Trans proline' 0 N--CA 1.488 1.168 0 C-N-CA 121.838 1.692 . . . . 0.0 112.089 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.38 -57.14 4.79 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.9 p -56.47 -27.73 25.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.967 0.413 . . . . 0.0 109.952 179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -61.61 -48.74 79.53 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.5 -39.38 83.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 122.258 1.028 . . . . 0.0 109.172 179.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.45 -37.24 92.93 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 114.592 -1.185 . . . . 0.0 110.174 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 4.9 mm -66.14 -43.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.888 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.53 -43.07 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 118.907 -1.117 . . . . 0.0 108.486 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 66.9 t -55.18 -41.49 60.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.46 -30.94 79.1 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.796 178.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -61.4 -49.32 77.38 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -61.8 -40.17 94.27 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.591 179.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -61.51 -43.19 96.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.225 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.0 mt -64.31 -45.83 86.22 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 10.7 m -57.11 -51.86 67.6 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.883 0.373 . . . . 0.0 110.913 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.6 t -71.89 -27.68 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.882 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 42.4 tp -72.09 -52.65 15.81 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 5.1 mm -69.8 -38.77 76.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.317 -0.553 . . . . 0.0 109.885 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.37 -42.94 82.61 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.327 -179.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.2 tp -70.63 -38.01 73.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.901 0.381 . . . . 0.0 110.214 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.49 -49.27 64.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.746 -179.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 18.3 m -70.28 -39.67 77.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.285 -178.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.0 t80 -63.51 -46.52 85.71 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.898 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -64.69 -53.96 39.23 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.336 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.6 tp -173.89 77.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.88 0.372 . . . . 0.0 110.201 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -57.46 164.91 6.51 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 34.8 mmm-85 -68.0 -8.41 37.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.749 0.309 . . . . 0.0 110.324 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 54.9 tp . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.391 -179.993 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 37.0 t . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 8.3 p 48.05 65.45 1.31 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.471 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 60.3 m 53.23 99.56 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.511 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 20.6 m -65.32 -33.8 66.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.83 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.502 ' O ' ' N ' ' B' ' 7' ' ' GLY . 0.0 OUTLIER -71.24 169.84 13.75 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.243 -179.813 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -42.54 88.22 0.01 OUTLIER 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.33 2.02 . . . . 0.0 112.019 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' B' ' 5' ' ' SER . . . -47.18 -28.26 4.21 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 14.4 p -58.92 -43.46 88.63 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.411 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 0.6 OUTLIER -54.27 -48.52 71.12 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.488 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.59 -38.06 66.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -35.6 91.29 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.166 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -69.47 -38.84 77.78 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 CA-C-O 119.111 -0.471 . . . . 0.0 111.131 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.2 m -65.71 -45.65 91.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.651 -179.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.2 p -60.84 -32.73 52.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 C-N-CA 118.285 -1.366 . . . . 0.0 107.524 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.9 -28.64 72.88 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.703 178.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.0 t0 -65.33 -49.26 70.12 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.6 mp -59.95 -42.28 93.72 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.6 t -67.2 -26.4 36.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.348 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 2.0 tt -70.65 -48.58 54.2 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.938 0.399 . . . . 0.0 110.228 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 12.1 m -62.59 -45.61 92.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.679 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.9 t -70.22 -27.5 32.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.622 -179.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 27.4 tp -70.86 -53.13 16.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.758 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 55.0 mt -71.08 -38.98 73.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -65.77 -41.6 91.84 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.584 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -72.56 -31.68 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.028 0.442 . . . . 0.0 109.979 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.31 -52.35 54.64 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.037 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' B' ' 31' ' ' GLY . 28.3 m -70.81 -37.41 68.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.979 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -61.32 -49.31 77.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.619 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -64.11 -48.66 75.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.788 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 48.3 mt -71.93 -25.79 62.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.387 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' B' ' 27' ' ' VAL . . . -61.57 -148.9 0.01 OUTLIER Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.0 ttt85 -163.88 78.19 0.39 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.781 0.324 . . . . 0.0 110.552 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.534 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.304 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.0 p . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.2 m -154.79 114.92 3.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.525 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 32.9 m -164.9 76.72 0.3 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.631 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 22.2 t -144.47 -22.49 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.292 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.8 m 53.74 63.81 7.44 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.872 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.59 -6.95 18.24 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.644 2.229 . . . . 0.0 112.097 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -62.61 -32.62 84.0 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.4 p -56.08 -42.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.172 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -56.66 -48.59 77.24 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.81 -37.6 60.12 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-O 122.107 0.956 . . . . 0.0 108.824 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.49 -39.55 97.97 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.6 mm -61.91 -40.2 86.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.687 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -62.92 -42.4 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 C-N-CA 119.257 -0.977 . . . . 0.0 109.276 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.5 t -53.44 -44.59 55.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.1 -32.36 83.81 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.3 179.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.434 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 16.6 t0 -61.8 -51.46 68.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.772 0.32 . . . . 0.0 110.538 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -61.15 -38.3 85.93 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.2 t -64.32 -33.33 62.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.29 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 35.6 mt -72.71 -49.55 30.5 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.134 -179.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.1 m -59.6 -48.62 80.94 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.097 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.0 t -70.74 -38.57 73.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.3 tp -62.53 -54.58 37.68 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.712 -0.395 . . . . 0.0 111.753 -178.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.3 mm -69.04 -41.87 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.82 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.6 -39.51 73.7 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.446 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.9 tp -69.96 -37.05 75.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.3 -53.6 52.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.422 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.4 m -67.84 -40.83 84.3 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.514 -179.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 75.4 t80 -59.68 -46.67 88.35 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.921 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.9 t80 -63.42 -52.8 60.0 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.972 -179.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 52.1 tp -174.42 78.11 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.8 0.333 . . . . 0.0 110.494 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.93 160.58 41.85 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -78.68 13.16 1.74 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.784 0.326 . . . . 0.0 110.528 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 12.4 tp . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.404 -179.975 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 25.9 t -157.68 -32.65 0.08 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.524 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 86.9 m 47.17 96.22 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.7 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 14.6 p -92.03 125.13 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.129 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.036 179.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 10.9 t -161.15 60.68 1.28 Allowed Pre-proline 0 C--N 1.332 -0.192 0 C-N-CA 120.893 -0.323 . . . . 0.0 111.287 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -66.78 84.7 0.3 Allowed 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.54 2.16 . . . . 0.0 111.583 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -52.02 -30.84 31.45 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.43 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 8.8 p -60.79 -44.6 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.601 -0.44 . . . . 0.0 109.912 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.43 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 2.9 mm? -58.57 -48.52 80.66 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 119.919 -0.713 . . . . 0.0 109.295 179.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.74 -33.36 55.49 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.561 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.37 -39.73 98.11 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.8 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.05 -25.51 27.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.463 -0.368 . . . . 0.0 110.135 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t -68.13 -53.84 26.5 Favored 'Isoleucine or valine' 0 C--O 1.243 0.73 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.554 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.2 p -58.86 -31.26 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.96 -26.12 73.26 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -68.23 -60.9 2.12 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 111.761 0.282 . . . . 0.0 111.761 -178.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.449 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.39 -24.37 62.93 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.57 -179.684 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 17.9 t -68.82 -38.37 78.65 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.434 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 15.6 mt -64.43 -50.16 68.68 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.309 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 13.9 m -58.26 -50.58 73.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.775 -178.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.8 t -71.39 -27.04 27.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 20.9 tp -69.84 -57.09 5.49 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.212 -178.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 14.0 mt -70.82 -39.54 75.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.21 -39.49 90.42 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 109.895 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.1 tp -70.31 -33.21 71.26 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.02 -51.61 68.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.548 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -64.07 -40.71 90.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -59.54 -46.33 89.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.582 -179.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 85.3 t80 -62.43 -46.8 86.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.806 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 67.4 mt -62.43 -42.04 99.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.517 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.7 77.56 0.1 OUTLIER Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 51.9 ptt85 -65.83 176.29 1.65 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.321 . . . . 0.0 110.668 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.53 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.237 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.59 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 83.9 m . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.7 m -73.42 154.63 39.92 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.58 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 77.6 p -47.53 108.76 0.17 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.531 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.3 t -65.51 -24.38 34.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.409 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.5 m 58.45 59.76 5.88 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.803 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_endo -76.29 12.88 1.44 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.712 2.274 . . . . 0.0 111.503 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -61.82 -36.59 92.99 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.8 p -55.37 -45.94 78.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.164 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -51.7 -48.8 63.39 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.96 -37.73 69.43 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.078 0.942 . . . . 0.0 109.427 179.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.85 -37.99 94.59 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -66.57 -40.87 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.32 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.408 ' H ' HG12 ' A' ' 13' ' ' VAL . 0.8 OUTLIER -57.82 -42.02 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 118.664 -1.214 . . . . 0.0 108.759 179.691 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 89.6 t -55.54 -43.34 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.2 -33.83 87.18 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.06 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 19.7 t0 -60.02 -51.17 70.81 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 120.949 0.404 . . . . 0.0 110.361 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -60.38 -37.87 82.12 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.5 t -64.01 -33.91 65.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.302 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.7 mt -71.72 -46.97 56.96 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.94 -0.304 . . . . 0.0 111.231 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.7 m -59.59 -49.39 77.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.871 -179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.8 t -70.94 -35.43 59.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.404 -179.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.79 -55.7 18.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.746 -0.381 . . . . 0.0 111.763 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 mm -68.77 -40.96 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.638 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.55 -39.51 76.83 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.621 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.5 tp -69.37 -37.06 77.43 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.55 39.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.579 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.422 ' CG2' ' N ' ' A' ' 28' ' ' TYR . 4.6 m -66.23 -43.9 91.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 C-N-CA 120.413 -0.515 . . . . 0.0 111.696 -179.078 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.422 ' N ' ' CG2' ' A' ' 27' ' ' VAL . 73.1 t80 -59.02 -45.4 90.79 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.78 -179.389 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -61.46 -50.91 70.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.082 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 45.8 tp -172.5 76.72 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.416 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -72.33 157.31 52.75 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 92.8 mtt-85 -77.44 144.44 37.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.817 0.341 . . . . 0.0 110.463 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 25.7 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.38 -179.982 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.59 ' SG ' ' N ' ' A' ' 1' ' ' CYS . 36.3 t . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.454 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 14.4 t -61.72 -43.09 99.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.523 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 67.8 m 51.88 96.24 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.485 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 15.5 m -65.5 -168.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.68 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 13.6 t -160.38 62.28 1.73 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.691 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -73.72 54.07 2.91 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.482 2.121 . . . . 0.0 111.57 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.06 -46.69 90.59 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -63.48 -44.92 98.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.29 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -61.09 -50.16 74.37 Favored 'General case' 0 C--O 1.239 0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 110.233 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.71 -37.42 70.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 122.053 0.93 . . . . 0.0 109.222 179.086 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.98 -36.77 93.35 Favored Glycine 0 CA--C 1.519 0.297 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 89.9 mt -66.04 -42.79 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 120.242 -0.583 . . . . 0.0 111.3 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -60.25 -38.73 78.46 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 118.558 -1.257 . . . . 0.0 108.793 179.25 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 95.1 t -57.51 -35.98 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 177.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.45 -25.4 75.39 Favored Glycine 0 CA--C 1.533 1.183 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.945 178.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -69.35 -60.95 2.0 Allowed 'General case' 0 C--O 1.237 0.413 0 O-C-N 122.479 -0.424 . . . . 0.0 111.776 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.463 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.12 -24.42 63.19 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 119.039 -1.064 . . . . 0.0 110.382 -179.6 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 7.2 t -66.07 -45.08 91.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 38.1 mt -63.35 -49.43 73.92 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.033 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 10.4 m -56.54 -50.73 71.01 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.507 -0.477 . . . . 0.0 111.293 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 96.5 t -67.57 -43.05 87.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.167 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 36.0 tp -57.9 -57.83 11.05 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -178.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 29.0 mt -64.67 -41.82 93.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.716 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.53 -32.33 62.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.421 0.629 . . . . 0.0 109.601 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.06 -43.4 71.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.426 179.662 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.67 -53.1 59.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.722 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 17.1 m -60.29 -41.83 88.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.647 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -58.64 -42.76 89.03 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.556 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -61.29 -44.6 96.95 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.824 -179.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 95.3 mt -59.28 -42.33 90.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.512 -179.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -77.28 128.29 8.89 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -70.73 94.88 1.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.734 0.302 . . . . 0.0 110.584 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.533 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.431 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 50.4 m . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 40.8 t -158.24 172.16 18.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.441 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 33.0 m -60.69 122.94 16.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.542 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 10.1 t -90.15 97.92 7.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.394 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.8 p -79.86 148.53 68.78 Favored Pre-proline 0 CA--C 1.534 0.332 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.375 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.93 40.54 0.95 Allowed 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 122.213 1.942 . . . . 0.0 112.312 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -70.4 -60.52 4.69 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.249 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.1 p -62.99 -43.14 98.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.436 -0.506 . . . . 0.0 109.759 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -57.38 -47.41 81.75 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.44 -38.56 59.48 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.147 0.975 . . . . 0.0 108.482 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -40.07 98.51 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 114.487 -1.233 . . . . 0.0 110.639 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.6 mm -60.61 -41.53 88.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.516 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -61.29 -43.95 97.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.291 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.7 t -52.6 -45.75 48.12 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 178.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.35 80.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -60.54 -48.48 81.61 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.2 mp -61.77 -40.93 96.9 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.282 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.5 t -59.44 -41.88 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.707 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.462 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 57.4 mt -64.5 -44.7 90.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -57.52 -51.64 68.62 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -71.73 -24.19 23.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.781 -179.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 52.9 tp -70.17 -56.44 6.84 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.774 -178.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.3 mm -73.06 -38.09 54.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.552 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.19 -38.51 86.78 Favored 'General case' 0 N--CA 1.457 -0.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.074 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.5 tp -70.59 -36.65 73.67 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.39 -54.41 37.13 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.172 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.8 m -66.31 -42.47 90.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.292 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 83.9 t80 -60.35 -45.15 94.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.797 0.332 . . . . 0.0 110.867 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.2 t80 -62.0 -52.87 62.24 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.101 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.8 tp -174.28 78.57 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.739 0.304 . . . . 0.0 110.447 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -58.19 157.26 18.45 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 31.9 mmm-85 -71.56 134.13 46.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.905 0.383 . . . . 0.0 110.515 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.9 tp . . . . . 0 C--N 1.331 -0.21 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.664 179.916 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.422 ' SG ' ' N ' ' B' ' 2' ' ' SER . 26.8 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.422 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 77.1 p -83.18 66.56 8.79 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.61 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 41.9 m -80.18 121.88 26.13 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.395 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 14.5 p -167.08 143.17 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.583 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 177.73 162.71 0.58 Allowed Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.212 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_exo -33.58 92.39 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 123.079 2.519 . . . . 0.0 112.588 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -58.06 -29.41 62.36 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 7.2 p -58.69 -41.09 81.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.407 ' O ' ' N ' ' B' ' 12' ' ' ILE . 3.5 mm? -56.89 -50.52 72.27 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.17 -30.99 40.4 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.82 -34.47 87.35 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 178.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . 0.407 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.7 mp -74.02 -29.3 25.2 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.448 -0.31 . . . . 0.0 110.902 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -72.0 -45.6 63.02 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.689 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 p -62.09 -39.66 84.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 C-N-CA 119.778 -0.769 . . . . 0.0 108.944 178.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.92 -29.02 71.13 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -66.47 -62.6 1.38 Allowed 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.48 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -63.93 -27.5 69.18 Favored 'General case' 0 C--O 1.232 0.146 0 C-N-CA 119.039 -1.064 . . . . 0.0 109.759 -179.891 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 6.8 t -68.57 -28.86 41.87 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 tt -69.17 -55.46 10.58 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.092 0.472 . . . . 0.0 110.142 179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 7.5 m -57.43 -46.15 83.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.317 -179.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 87.2 t -68.26 -41.98 84.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.831 -178.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.1 tp -59.45 -57.18 14.09 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 54.0 mt -64.74 -42.04 93.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 120.206 -0.598 . . . . 0.0 109.903 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.36 -32.2 56.36 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -69.8 -45.29 68.26 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.522 179.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.81 -52.01 58.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.744 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 16.3 m -63.51 -41.56 93.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.017 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -57.5 -45.75 84.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.34 . . . . 0.0 110.565 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 57.0 t80 -62.28 -46.17 89.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.658 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 88.5 mt -61.81 -41.9 98.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.409 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.18 122.86 10.05 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -70.88 93.82 1.01 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 0.0 110.548 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.542 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.281 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.2 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 70.2 m -159.57 -6.58 0.06 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.554 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.403 ' C ' ' H ' ' A' ' 5' ' ' SER . 6.1 m -160.67 -61.31 0.06 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.402 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.8 t 61.71 6.59 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.361 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.403 ' H ' ' C ' ' A' ' 3' ' ' THR . 6.8 m 53.05 79.21 0.36 Allowed Pre-proline 0 N--CA 1.463 0.218 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.382 179.128 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.434 ' CD ' ' H ' ' A' ' 7' ' ' GLY . 44.6 Cg_endo -94.5 -41.81 0.02 OUTLIER 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 123.273 2.649 . . . . 0.0 112.417 179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.434 ' H ' ' CD ' ' A' ' 6' ' ' PRO . . . -63.89 -29.61 75.31 Favored Glycine 0 CA--C 1.526 0.767 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.998 -179.072 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.473 ' CG1' ' N ' ' A' ' 9' ' ' LEU . 7.5 p -59.31 -48.91 85.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.831 -179.27 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.473 ' N ' ' CG1' ' A' ' 8' ' ' VAL . 2.8 mm? -51.81 -46.84 64.42 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.078 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.98 -41.61 71.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.851 0.834 . . . . 0.0 108.838 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.33 -29.87 69.91 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 42.5 mm -70.29 -42.71 78.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.51 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.53 -42.31 80.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.145 179.272 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -55.06 -42.76 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.255 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.75 -33.08 83.96 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -58.95 -50.52 73.77 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.047 0.451 . . . . 0.0 109.925 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -61.35 -39.27 89.97 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.907 179.587 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.21 -42.09 85.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.738 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.489 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 35.7 mt -65.72 -45.12 83.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.701 0.286 . . . . 0.0 111.198 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.2 m -56.29 -53.04 61.98 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.088 -178.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 65.9 t -71.9 -27.3 27.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.819 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.8 tp -72.15 -51.4 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -178.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.9 mm -70.37 -37.49 70.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.753 -179.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.46 -43.78 80.22 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.083 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -71.94 -32.92 67.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.089 0.471 . . . . 0.0 110.246 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.41 -50.61 36.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.698 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 22.8 m -68.98 -42.86 82.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.625 -0.43 . . . . 0.0 111.332 -178.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 49.1 t80 -63.07 -47.05 84.59 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.699 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.5 t80 -64.21 -53.78 43.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.187 -179.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.9 tp -174.75 78.44 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.311 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -59.71 166.2 10.0 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 35.7 mmm-85 -62.12 -40.22 95.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 0.0 110.487 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 13.2 tp . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.35 179.959 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.573 ' SG ' ' N ' ' B' ' 2' ' ' SER . 51.5 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 2' ' ' SER . . . . . 0.573 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 53.5 m -76.26 -1.11 24.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.612 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 4.8 m 63.56 -69.3 0.08 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.462 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . 0.494 ' N ' ' O ' ' B' ' 2' ' ' SER . 21.7 t 44.61 65.32 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.111 0.481 . . . . 0.0 109.928 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 5' ' ' SER . . . . . 0.534 ' O ' ' N ' ' B' ' 7' ' ' GLY . 73.7 m -133.81 57.99 29.13 Favored Pre-proline 0 N--CA 1.465 0.31 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.356 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . 0.406 ' C ' ' O ' ' B' ' 5' ' ' SER . 7.5 Cg_exo -34.45 88.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.49 1.294 0 C-N-CA 122.743 2.296 . . . . 0.0 111.627 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' B' ' 5' ' ' SER . . . -65.2 -43.08 95.97 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.29 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -57.86 -43.84 85.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.758 -179.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 13.7 mt -64.83 -35.02 79.77 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 119.002 -1.079 . . . . 0.0 109.651 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.47 -39.81 73.83 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.99 -36.32 92.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 178.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.31 -31.31 46.57 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-O 119.155 -0.45 . . . . 0.0 111.518 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.3 m -73.01 -41.58 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.573 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 p -62.37 -37.48 78.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.547 178.026 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.87 -29.38 73.61 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.763 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.489 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.1 t0 -64.08 -49.07 73.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.114 0.483 . . . . 0.0 109.754 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 1.8 mt -59.63 -44.35 93.5 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.084 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.3 t -64.53 -24.61 36.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.541 179.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 tt -70.67 -48.51 54.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.929 0.395 . . . . 0.0 110.255 -179.473 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.7 m -61.63 -45.84 92.35 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.555 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.8 t -71.0 -26.49 27.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.668 -179.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.2 tp -71.07 -52.88 16.92 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.31 -179.075 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 46.5 mt -69.81 -42.13 79.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.831 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.68 -43.92 97.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.572 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 54.1 tp -72.02 -29.95 64.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.956 0.408 . . . . 0.0 109.988 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.6 -51.66 53.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.046 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 26.5 m -70.62 -38.81 74.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.121 -179.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -62.59 -48.48 79.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.726 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 83.3 t80 -62.27 -49.77 74.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.904 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 74.7 mt -62.9 -42.06 99.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.42 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.47 107.6 1.57 Allowed Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 72.6 mtp85 -68.38 144.4 54.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.824 0.345 . . . . 0.0 110.6 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.533 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.2 mm? . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.243 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.492 ' C ' ' H ' ' A' ' 3' ' ' THR . 8.5 p . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.3 t -76.08 32.82 0.12 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.627 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.492 ' H ' ' C ' ' A' ' 1' ' ' CYS . 26.5 m -60.85 -45.46 94.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.54 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' A' ' 5' ' ' SER . 98.9 t -78.25 -86.12 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.394 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 4' ' ' VAL . 3.8 p 59.06 150.51 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.143 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.13 69.16 4.86 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.034 1.823 . . . . 0.0 111.984 179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.57 -56.62 10.92 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.4 p -66.05 -44.98 91.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -57.64 -47.61 81.76 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.19 -38.27 68.15 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.082 0.944 . . . . 0.0 108.521 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.89 -37.52 93.87 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 44.2 mm -62.76 -43.23 98.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.811 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -60.69 -43.42 94.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.576 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 88.7 t -53.5 -42.39 49.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -34.66 90.54 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 178.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -57.23 -50.31 73.26 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 120.754 0.312 . . . . 0.0 110.177 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -61.39 -40.19 93.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -62.11 -39.57 84.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 46.7 mt -67.04 -44.23 80.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.453 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.1 m -59.76 -51.59 69.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.175 -179.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.3 t -71.83 -27.98 29.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.187 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -68.99 -56.48 7.66 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.716 -178.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -70.47 -39.88 76.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.323 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.99 -39.82 82.97 Favored 'General case' 0 CA--C 1.521 -0.167 0 C-N-CA 120.867 -0.333 . . . . 0.0 110.714 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.9 tp -69.72 -37.48 76.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.59 -53.7 52.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.771 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.416 ' CG2' ' N ' ' A' ' 28' ' ' TYR . 6.4 m -67.53 -43.13 87.42 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.744 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.416 ' N ' ' CG2' ' A' ' 27' ' ' VAL . 62.8 t80 -59.29 -46.97 87.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.083 -179.355 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -67.09 -55.84 12.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.148 -179.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 48.2 tp -174.56 77.66 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.315 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -50.36 115.74 3.53 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -74.09 133.91 42.89 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.678 0.275 . . . . 0.0 110.579 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.5 tt . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.598 -179.985 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 42.1 t . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 22.3 p -159.2 -22.71 0.07 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.597 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 16.3 m 46.67 81.14 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.559 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 10.5 m -73.42 142.54 14.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.336 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 13.6 t -144.46 60.6 7.83 Favored Pre-proline 0 N--CA 1.465 0.312 0 CA-C-O 120.822 0.344 . . . . 0.0 110.887 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -78.39 75.49 4.89 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.954 2.436 . . . . 0.0 111.529 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -63.19 -34.98 91.44 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 14.3 p -55.13 -43.09 68.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -54.55 -52.47 61.96 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 120.391 -0.524 . . . . 0.0 109.765 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -51.41 -36.33 43.12 Favored 'General case' 0 C--O 1.241 0.658 0 CA-C-O 121.968 0.89 . . . . 0.0 109.11 179.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -37.79 95.12 Favored Glycine 0 CA--C 1.524 0.624 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.123 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.174 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 33.2 t -69.64 -52.82 28.39 Favored 'Isoleucine or valine' 0 C--O 1.246 0.901 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.491 178.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -58.53 -32.38 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.418 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.3 -25.2 75.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -69.79 -61.72 1.67 Allowed 'General case' 0 C--O 1.235 0.334 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.457 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -67.52 -23.47 65.46 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 118.368 -1.333 . . . . 0.0 109.954 -179.557 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 9.4 t -70.32 -38.91 75.82 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.863 177.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 1.9 tt -66.47 -52.07 50.13 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 120.996 0.427 . . . . 0.0 110.531 -179.219 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 9.7 m -58.8 -49.01 79.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.025 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 72.0 t -65.24 -42.01 92.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.609 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 35.6 tp -57.73 -56.51 21.0 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 112.006 0.372 . . . . 0.0 112.006 -178.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 52.7 mt -66.02 -41.71 90.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 120.084 -0.646 . . . . 0.0 110.082 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.45 -31.72 62.17 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.32 0.581 . . . . 0.0 109.484 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -70.77 -44.56 66.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.25 179.541 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.38 -51.97 56.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.661 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 18.0 m -63.04 -40.67 89.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.742 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.09 -47.93 79.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.83 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -62.29 -45.58 92.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.872 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 73.9 mt -61.9 -42.03 98.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.452 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.33 91.64 0.47 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 61.0 ttt85 -47.33 97.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.745 0.307 . . . . 0.0 110.452 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.539 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.391 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.4 m . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.6 m -67.87 141.41 56.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.445 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.547 ' O ' ' N ' ' A' ' 5' ' ' SER . 68.8 p -81.09 -16.39 53.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.599 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 5' ' ' SER . 59.1 t 52.91 -82.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.401 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.547 ' N ' ' O ' ' A' ' 3' ' ' THR . 5.5 m 59.83 143.61 0.05 OUTLIER Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.623 179.499 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -73.55 82.23 1.7 Allowed 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.153 1.902 . . . . 0.0 112.252 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.31 -64.35 2.42 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 179.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.52 -45.29 96.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.147 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -51.32 -49.48 61.28 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.3 -37.5 72.56 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-O 121.968 0.889 . . . . 0.0 109.302 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.13 -38.49 94.46 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -66.26 -44.02 91.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.378 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.19 -42.62 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 118.568 -1.253 . . . . 0.0 108.652 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 95.6 t -55.21 -42.31 65.19 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 178.09 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.56 -32.9 84.88 Favored Glycine 0 CA--C 1.53 1.012 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.131 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -61.24 -49.59 76.47 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.84 0.352 . . . . 0.0 110.179 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.405 ' N ' ' CD1' ' A' ' 17' ' ' LEU . 10.5 mp -61.53 -38.57 87.89 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.402 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 74.6 t -62.57 -41.44 92.09 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.265 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.009 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.484 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 36.6 mt -65.56 -44.61 86.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.749 0.309 . . . . 0.0 111.019 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.3 m -59.16 -51.48 69.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.229 -179.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.7 t -71.92 -30.59 37.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.754 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 35.4 tp -69.0 -52.87 24.24 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.698 -178.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.5 mm -69.9 -42.45 79.79 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.682 0 C-N-CA 119.713 -0.795 . . . . 0.0 109.25 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.88 93.02 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.435 -179.271 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 42.4 tp -70.1 -36.34 74.79 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.601 -179.632 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.19 -51.5 30.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.236 -178.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 14.2 m -69.37 -41.02 80.71 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 C-N-CA 120.441 -0.503 . . . . 0.0 111.366 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -65.67 -45.9 81.16 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.91 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.5 t80 -63.36 -52.54 61.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.07 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 20.5 tp -173.15 77.29 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.111 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.98 151.37 47.8 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 33.6 mmm-85 -71.98 -16.39 62.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.831 0.348 . . . . 0.0 110.55 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 12.1 tp . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.347 -179.941 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . 0.504 ' C ' ' H ' ' B' ' 3' ' ' THR . 27.6 p . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 4.6 p 64.65 -2.12 0.7 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.579 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.504 ' H ' ' C ' ' B' ' 1' ' ' CYS . 20.5 m 46.2 89.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.634 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 46.4 t -105.66 85.75 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 41.4 m -130.19 93.41 33.33 Favored Pre-proline 0 CA--C 1.536 0.41 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.817 -179.213 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -80.71 89.88 1.27 Allowed 'Trans proline' 0 N--CA 1.491 1.376 0 C-N-CA 122.235 1.957 . . . . 0.0 111.732 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.57 -35.65 92.2 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . 0.436 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 8.5 p -54.39 -43.89 64.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . 0.436 ' N ' ' CG1' ' B' ' 8' ' ' VAL . 2.3 mm? -53.43 -50.47 65.16 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.67 -33.66 61.1 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 121.781 0.8 . . . . 0.0 109.156 178.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.33 -35.55 92.1 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.172 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -72.72 -33.12 43.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.169 -0.443 . . . . 0.0 111.296 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.9 m -70.32 -41.48 78.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 118.884 -1.127 . . . . 0.0 110.378 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 p -63.27 -38.06 81.11 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 C-N-CA 118.623 -1.231 . . . . 0.0 108.087 178.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.59 -29.43 73.96 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 178.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.484 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 5.3 t0 -64.67 -49.39 71.15 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.198 0.523 . . . . 0.0 109.631 179.816 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -58.82 -43.24 90.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.54 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.77 -24.39 30.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.102 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 2.3 tt -70.54 -51.64 27.29 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 121.07 0.462 . . . . 0.0 110.139 -179.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 7.8 m -60.79 -48.89 79.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.626 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -63.66 -42.54 96.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.286 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 26.7 tp -57.36 -54.02 51.56 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 59.3 mt -64.02 -44.84 97.9 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.494 -178.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.52 -36.78 67.1 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.39 -39.23 88.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -53.6 -55.65 23.96 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.262 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.7 m -63.68 -37.54 79.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 C-N-CA 119.387 -0.925 . . . . 0.0 111.02 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -56.65 -47.36 79.95 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.568 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -62.6 -47.64 82.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.784 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 74.8 mt -62.67 -41.92 99.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.647 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' B' ' 33' ' ' LEU . . . -61.17 114.53 6.77 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 74.4 ttt180 -62.31 82.61 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.866 0.365 . . . . 0.0 110.475 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.535 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.4 mm? . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.396 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 72.1 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.403 ' O ' ' OG1' ' A' ' 3' ' ' THR . 68.1 m -76.53 -80.08 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.644 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.403 ' OG1' ' O ' ' A' ' 2' ' ' SER . 23.9 m -166.41 -27.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.644 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 47.0 t 52.96 94.17 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.65 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.4 p -78.02 135.18 63.05 Favored Pre-proline 0 CA--C 1.538 0.5 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.255 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -79.07 75.91 4.82 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 121.998 1.799 . . . . 0.0 112.351 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -72.91 -64.8 2.45 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.4 p -65.32 -38.98 83.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.282 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.57 -46.27 84.17 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.59 -40.93 84.56 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 122.1 0.952 . . . . 0.0 109.441 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.16 -38.87 93.74 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.0 mm -63.98 -42.76 96.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.653 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.04 -42.67 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 C-N-CA 118.789 -1.164 . . . . 0.0 108.864 179.651 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 57.6 t -54.26 -45.08 67.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 119.485 -0.886 . . . . 0.0 108.769 178.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -33.27 86.78 Favored Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.407 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 15.0 t0 -62.12 -51.98 65.69 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.774 0.321 . . . . 0.0 110.706 -179.425 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.8 mp -60.93 -37.79 83.56 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 64.4 t -64.3 -33.19 61.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.141 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.401 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 27.3 mt -73.43 -46.7 46.94 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.188 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.0 m -60.28 -49.14 78.8 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.073 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -71.93 -37.27 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.9 tp -63.1 -55.18 27.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.408 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.6 mm -67.98 -44.68 84.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.684 -179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.46 -42.18 66.91 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 43.3 tp -66.96 -38.25 85.76 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.961 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.66 -50.87 71.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.243 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.0 t -68.7 -45.88 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 C-N-CA 120.614 -0.435 . . . . 0.0 111.497 -179.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -58.1 -47.82 82.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.42 -178.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 58.8 t80 -69.52 -56.9 6.06 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.239 -179.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.503 ' O ' ' N ' ' A' ' 32' ' ' ARG . 57.7 tp -177.9 80.34 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -42.2 92.03 0.01 OUTLIER Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.503 ' N ' ' O ' ' A' ' 30' ' ' LEU . 33.5 mmm-85 -61.32 -34.93 76.05 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.684 0.278 . . . . 0.0 110.455 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 9.4 tp . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.53 -179.879 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 21.3 m 57.0 98.5 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.624 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 7.0 m 60.12 121.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.703 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 74.2 t -145.38 113.6 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.242 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -177.96 154.3 0.96 Allowed Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.54 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -59.82 107.96 0.44 Allowed 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.612 2.208 . . . . 0.0 112.116 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.62 -34.55 90.2 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 179.494 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.71 -35.04 53.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -62.47 -46.78 86.96 Favored 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.129 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.0 -32.32 69.6 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.89 -32.93 84.25 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 178.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' ILE . . . . . 0.426 HG21 HD13 ' B' ' 12' ' ' ILE . 88.9 mt -72.77 -34.7 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-O 119.091 -0.48 . . . . 0.0 111.812 -179.706 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 m -69.54 -44.85 79.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 119.025 -1.07 . . . . 0.0 109.95 179.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' VAL . . . . . 0.413 ' O ' ' CG2' ' B' ' 18' ' ' VAL . 3.2 p -60.09 -33.73 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.61 -25.9 74.18 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 178.329 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.401 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 9.3 t70 -69.08 -61.49 1.77 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -178.391 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.468 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 0.0 OUTLIER -68.15 -25.82 65.46 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.238 -179.724 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . 0.413 ' CG2' ' O ' ' B' ' 14' ' ' VAL . 14.6 t -66.74 -39.2 83.13 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.462 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 14.2 mt -63.29 -47.31 82.86 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.157 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 10.3 m -57.55 -50.26 73.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.561 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -72.31 -28.49 29.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.0 tp -68.51 -56.62 7.74 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.456 -0.498 . . . . 0.0 111.311 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 30.1 mt -69.82 -41.69 79.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.471 -0.491 . . . . 0.0 109.991 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -38.82 77.82 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.127 0.489 . . . . 0.0 109.73 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -69.54 -35.75 75.73 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.675 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.6 -51.76 68.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.518 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 16.4 m -64.99 -38.26 82.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.656 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.9 t80 -57.97 -48.57 79.58 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.472 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -62.96 -46.07 89.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.866 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 72.8 mt -62.24 -42.21 99.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.649 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -54.0 95.18 0.02 OUTLIER Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 76.4 ttt180 -72.73 89.97 1.38 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.834 0.35 . . . . 0.0 110.573 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.54 ' N ' ' CD2' ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.306 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.82 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.415 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.7 p -55.6 -39.81 56.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 C-N-CA 120.614 -0.434 . . . . 0.0 109.851 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.571 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.6 mm? -52.86 -50.3 64.06 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.734 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.96 -38.77 73.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 122.029 0.919 . . . . 0.0 109.028 179.116 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.75 -35.6 90.16 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.657 HG21 HG12 ' B' ' 13' ' ' VAL . 42.0 mm -67.44 -43.16 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.792 -179.773 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.45 -42.69 81.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.516 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -55.85 -43.36 74.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.322 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.32 -30.44 76.1 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.56 -48.31 80.04 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.455 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.2 mp -60.36 -39.76 88.31 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.0 t -60.66 -40.72 85.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.742 179.647 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.483 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.0 mt -64.48 -44.44 91.0 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.784 0.326 . . . . 0.0 110.921 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 m -59.81 -52.31 66.0 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.695 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.4 t -72.31 -27.92 27.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -178.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 29.6 tp -69.38 -56.17 8.25 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.498 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.2 mm -70.03 -40.73 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.567 -179.611 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.86 -39.22 80.7 Favored 'General case' 0 C--O 1.231 0.111 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.171 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.6 tp -69.56 -35.46 75.42 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.338 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.48 -56.01 19.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.223 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.508 HG23 ' N ' ' A' ' 28' ' ' TYR . 7.6 m -65.41 -43.15 94.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.113 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.68 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.508 ' N ' HG23 ' A' ' 27' ' ' VAL . 91.5 t80 -61.01 -45.35 95.17 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.951 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.3 t80 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.198 -179.416 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.791 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.535 HG13 ' N ' ' B' ' 9' ' ' LEU . 7.6 p -57.78 -48.2 84.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.382 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.571 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.2 mm? -51.1 -46.74 61.95 Favored 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.243 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.32 -29.7 70.05 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.851 0.834 . . . . 0.0 109.34 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.67 -35.62 86.21 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.133 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -70.31 -45.21 76.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 119.298 -0.382 . . . . 0.0 111.218 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.657 HG12 HG21 ' A' ' 12' ' ' ILE . 3.0 m -60.94 -40.52 85.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 C-N-CA 118.529 -1.268 . . . . 0.0 109.602 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 71.4 t -55.95 -45.38 80.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -26.12 69.78 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.483 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 10.5 t70 -66.3 -48.73 69.41 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.469 ' N ' HD12 ' B' ' 17' ' ' LEU . 11.2 mp -61.52 -39.61 91.67 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -66.89 -29.86 47.7 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.162 179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.421 ' O ' HD23 ' B' ' 19' ' ' LEU . 3.5 tt -71.37 -52.57 17.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.982 0.42 . . . . 0.0 110.543 -179.362 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.478 ' OG1' HD13 ' A' ' 19' ' ' LEU . 19.8 m -59.14 -46.09 89.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.874 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -69.76 -30.94 46.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.2 tp -68.47 -55.3 12.28 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.368 -178.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 16.9 mt -71.77 -39.97 69.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.439 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -62.1 -36.35 81.44 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.021 0.439 . . . . 0.0 110.024 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 33.6 tp -71.24 -37.51 71.99 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.34 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.783 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 35.7 m -65.87 -36.86 78.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.855 -0.338 . . . . 0.0 110.792 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.3 t80 -60.18 -47.51 85.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 70.1 t80 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.622 179.962 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.562 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.577 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.0 p -63.91 -47.14 91.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.324 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.615 ' HB3' HD12 ' B' ' 9' ' ' LEU . 1.5 mm? -55.48 -48.78 74.02 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.603 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.95 -37.93 67.09 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.06 -36.1 92.42 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 43.8 mm -65.15 -45.67 93.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.32 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.5 HG12 HG21 ' B' ' 12' ' ' ILE . 0.9 OUTLIER -58.95 -41.26 82.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.085 179.921 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.5 t -55.7 -40.32 59.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -32.6 84.72 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 178.614 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.51 -48.82 80.16 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.474 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.19 -39.8 91.55 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.662 179.256 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 69.8 t -60.24 -43.47 93.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.713 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.449 HD13 ' OG1' ' B' ' 20' ' ' THR . 32.8 mt -62.36 -43.69 98.22 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.911 0.386 . . . . 0.0 110.481 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -56.93 -51.41 69.25 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.077 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -69.3 -34.91 65.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 32.6 tp -64.61 -57.62 8.59 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -178.239 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.5 mm -68.47 -38.35 79.11 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.493 -179.314 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.65 -39.65 77.5 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.455 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.28 -38.36 78.32 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.41 -53.53 53.55 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.46 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.492 HG23 ' N ' ' A' ' 28' ' ' TYR . 29.2 m -62.56 -46.03 97.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.612 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.492 ' N ' HG23 ' A' ' 27' ' ' VAL . 83.9 t80 -61.19 -43.87 98.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.308 -179.211 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.4 t80 . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.157 -179.247 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.596 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.414 HG13 HD22 ' B' ' 9' ' ' LEU . 14.7 p -51.83 -38.54 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.573 -0.451 . . . . 0.0 109.875 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.615 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.8 mm? -55.19 -51.08 67.66 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.6 -39.56 64.98 Favored 'General case' 0 C--O 1.242 0.663 0 CA-C-O 121.862 0.839 . . . . 0.0 109.506 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.86 -43.02 94.93 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 114.568 -1.196 . . . . 0.0 110.147 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 12' ' ' ILE . . . . . 0.5 HG21 HG12 ' A' ' 13' ' ' VAL . 1.8 mp -62.44 -42.38 95.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.493 0 C-N-CA 120.208 -0.597 . . . . 0.0 109.452 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 44.0 t -49.65 -50.85 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 C-N-CA 119.94 -0.704 . . . . 0.0 109.146 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.02 -33.85 47.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 15' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' B' ' 12' ' ' ILE . . . -64.95 -39.91 96.81 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.412 ' C ' ' OD1' ' B' ' 16' ' ' ASP . 8.1 t0 -61.68 -45.47 93.86 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.14 0.495 . . . . 0.0 109.932 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.43 ' O ' HG23 ' B' ' 21' ' ' VAL . 7.5 mt -61.19 -42.54 98.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.519 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.0 t -71.86 -26.47 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.403 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.0 tt -73.56 -54.14 8.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.449 ' OG1' HD13 ' A' ' 19' ' ' LEU . 18.6 m -60.11 -45.89 91.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.298 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 21' ' ' VAL . . . . . 0.43 HG23 ' O ' ' B' ' 17' ' ' LEU . 92.3 t -66.29 -44.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.838 -179.25 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.8 tp -58.97 -57.93 10.91 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 13.4 mt -65.93 -40.44 87.47 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.948 -179.141 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.22 -33.07 65.01 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.429 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -68.68 -43.81 75.35 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.414 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.44 -52.91 42.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.676 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.0 m -63.16 -42.07 95.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.809 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -55.39 -46.77 76.52 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.38 . . . . 0.0 110.782 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 86.4 t80 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.754 -179.906 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.771 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -49.2 -42.25 15.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.065 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.521 HD12 ' HB3' ' B' ' 9' ' ' LEU . 4.1 mm? -52.16 -52.48 51.63 Favored 'General case' 0 CA--C 1.537 0.474 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.222 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.4 -37.85 62.86 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.09 0.947 . . . . 0.0 109.145 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.89 -37.42 94.33 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.711 -1.132 . . . . 0.0 110.311 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.527 HG21 HG12 ' B' ' 13' ' ' VAL . 43.0 mm -65.3 -43.19 95.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.011 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -57.53 -43.15 82.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 C-N-CA 119.016 -1.074 . . . . 0.0 108.601 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.3 t -54.68 -43.79 67.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.19 -32.45 82.58 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -60.57 -48.91 79.69 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.466 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -62.08 -38.41 88.71 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.217 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.5 t -61.89 -41.81 92.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.99 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.486 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.9 mt -66.57 -43.7 84.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.87 0.367 . . . . 0.0 110.998 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.1 m -60.85 -51.51 68.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.308 -178.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 90.9 t -71.76 -32.33 44.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.143 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.3 tp -66.48 -56.27 11.71 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.712 -178.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.0 mm -69.1 -41.78 81.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.298 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.94 -40.98 77.44 Favored 'General case' 0 N--CA 1.46 0.056 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.651 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.12 79.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.04 -54.04 49.69 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.698 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.494 HG23 ' N ' ' A' ' 28' ' ' TYR . 3.5 m -68.1 -43.57 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.722 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.494 ' N ' HG23 ' A' ' 27' ' ' VAL . 69.7 t80 -58.72 -48.66 80.39 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.168 -178.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.2 t80 . . . . . 0 C--N 1.328 -0.336 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.195 -179.35 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.732 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.593 HG13 ' N ' ' B' ' 9' ' ' LEU . 15.0 p -62.53 -48.52 87.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.593 ' N ' HG13 ' B' ' 8' ' ' VAL . 1.8 mm? -51.68 -47.49 63.83 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.7 -33.87 70.67 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-O 121.841 0.829 . . . . 0.0 108.883 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.86 -33.79 88.19 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.044 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -72.83 -36.19 51.52 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 119.267 -0.397 . . . . 0.0 111.275 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.527 HG12 HG21 ' A' ' 12' ' ' ILE . 1.6 m -68.18 -40.93 83.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 118.886 -1.125 . . . . 0.0 110.517 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 p -64.57 -38.68 83.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 118.747 -1.181 . . . . 0.0 108.42 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.35 -28.93 73.74 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.486 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 7.8 t0 -65.42 -48.03 74.21 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.2 mt -59.79 -42.26 92.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.688 179.102 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 95.0 t -69.0 -24.5 28.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.181 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.3 tt -71.97 -53.57 12.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.085 0.469 . . . . 0.0 110.222 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.435 ' OG1' HD13 ' A' ' 19' ' ' LEU . 11.5 m -59.48 -46.34 89.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.564 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.5 t -66.18 -43.72 91.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.699 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.7 tp -57.92 -56.57 20.24 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 34.8 mt -65.52 -41.56 91.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.945 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.95 -31.4 64.94 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 121.355 0.598 . . . . 0.0 109.577 178.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.493 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.44 -43.53 69.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.346 179.701 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.25 -53.61 51.25 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.612 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.445 ' CG1' HG12 ' A' ' 27' ' ' VAL . 18.3 m -59.91 -41.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.726 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -58.96 -40.76 85.7 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.449 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 77.5 t80 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.111 -179.793 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.635 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.546 HG13 ' N ' ' A' ' 9' ' ' LEU . 9.7 p -54.37 -46.82 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.159 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.572 HD12 ' HB3' ' B' ' 9' ' ' LEU . 2.9 mm? -53.2 -50.63 64.27 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.769 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.415 ' O ' HG22 ' A' ' 13' ' ' VAL . . . -53.53 -36.07 61.4 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.991 0.901 . . . . 0.0 109.07 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.64 -35.7 92.37 Favored Glycine 0 C--N 1.317 -0.503 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.544 HG21 HG12 ' B' ' 13' ' ' VAL . 37.8 mm -66.09 -43.08 92.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.856 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -59.17 -42.07 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 119.111 -1.036 . . . . 0.0 108.715 179.571 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.5 t -54.92 -41.39 57.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.27 -33.36 87.03 Favored Glycine 0 CA--C 1.53 0.987 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.026 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.431 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 8.9 t0 -61.16 -47.68 85.07 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.457 HD12 ' N ' ' A' ' 17' ' ' LEU . 10.9 mp -61.0 -39.57 90.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.05 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -60.39 -40.44 84.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.64 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.482 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.6 mt -64.4 -44.66 90.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.774 0.321 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 m -58.09 -51.39 69.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.412 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 62.0 t -71.51 -32.73 47.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.845 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.8 tp -66.73 -53.86 28.9 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.676 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.449 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.0 mm -68.87 -42.14 82.41 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.461 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.12 -41.96 84.74 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.2 -179.608 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.6 tp -69.09 -38.28 78.89 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.51 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.06 53.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.941 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.505 HG23 ' N ' ' A' ' 28' ' ' TYR . 16.7 m -69.63 -42.24 80.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.552 -179.005 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.505 ' N ' HG23 ' A' ' 27' ' ' VAL . 84.1 t80 -62.13 -44.89 95.65 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.825 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.7 t80 . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.11 -179.57 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.458 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.476 HG13 ' N ' ' B' ' 9' ' ' LEU . 9.0 p -60.36 -44.19 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.572 ' HB3' HD12 ' A' ' 9' ' ' LEU . 3.4 mm? -57.42 -50.29 73.48 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.465 178.759 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.4 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.02 -29.8 60.91 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.777 0.799 . . . . 0.0 109.348 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.53 -38.33 94.63 Favored Glycine 0 C--N 1.316 -0.532 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 178.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -68.05 -44.04 84.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 120.439 -0.504 . . . . 0.0 111.227 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.544 HG12 HG21 ' A' ' 12' ' ' ILE . 2.1 m -60.67 -37.27 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.675 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 61.6 t -58.68 -43.64 88.1 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.669 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -64.45 -32.76 85.28 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.373 178.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.482 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -61.85 -48.38 80.8 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.996 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.9 mt -60.08 -44.39 94.81 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.819 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.87 -25.89 37.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.03 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.431 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 2.7 tt -70.48 -49.41 48.75 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.0 0.429 . . . . 0.0 110.287 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.449 ' OG1' HD13 ' A' ' 19' ' ' LEU . 18.3 m -61.21 -46.09 91.89 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.618 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.2 t -70.96 -27.5 30.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.925 -179.243 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -69.98 -53.83 15.98 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.849 -0.34 . . . . 0.0 111.485 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.418 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 55.7 mt -70.99 -41.24 76.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.262 -179.362 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.77 -42.17 96.98 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.503 -0.479 . . . . 0.0 109.748 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.4 tp -70.51 -28.59 65.07 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -59.78 -53.84 53.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.237 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.453 HG11 ' CG1' ' A' ' 27' ' ' VAL . 8.6 m -70.45 -34.21 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.066 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -59.74 -49.27 78.38 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.665 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 59.0 t80 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.114 -179.879 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.627 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.471 HG13 ' N ' ' A' ' 9' ' ' LEU . 13.6 p -65.14 -44.8 95.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.85 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.573 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.4 mm? -55.23 -48.72 73.52 Favored 'General case' 0 CA--C 1.543 0.696 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.591 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.19 -36.9 76.18 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.984 0.897 . . . . 0.0 109.558 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.01 -36.07 92.35 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.692 HG21 HG12 ' B' ' 13' ' ' VAL . 39.3 mm -66.72 -43.67 89.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.95 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -56.7 -42.44 76.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 118.513 -1.275 . . . . 0.0 108.651 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.6 t -55.64 -42.54 69.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.33 -32.04 81.42 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -61.61 -47.23 86.4 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.448 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.1 mp -61.04 -38.87 87.68 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.022 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.5 t -62.41 -42.25 94.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.917 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.593 HD13 ' OG1' ' B' ' 20' ' ' THR . 16.2 mt -65.55 -45.65 82.55 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.751 0.31 . . . . 0.0 110.878 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.0 m -57.26 -51.58 68.78 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.24 -178.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.1 t -71.03 -34.2 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.267 -0.424 . . . . 0.0 112.003 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.7 tp -64.91 -56.46 13.16 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -68.6 -41.73 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 120.03 -0.668 . . . . 0.0 109.252 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.56 -40.42 71.9 Favored 'General case' 0 CA--C 1.523 -0.091 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.566 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.82 80.1 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.52 -53.89 52.12 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.723 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.505 HG12 ' CG1' ' B' ' 27' ' ' VAL . 2.5 m -66.58 -43.04 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.622 -179.14 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.437 ' N ' HG23 ' A' ' 27' ' ' VAL . 81.3 t80 -59.09 -48.66 80.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.403 -179.011 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 83.5 t80 . . . . . 0 C--N 1.33 -0.282 0 C-N-CA 120.916 -0.314 . . . . 0.0 111.114 -179.214 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.268 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.8 p -68.62 -40.83 82.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.601 -0.299 . . . . 0.0 110.367 179.228 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.573 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.8 mm? -66.96 -49.16 66.31 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.989 179.383 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.37 -28.89 68.55 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.838 0.828 . . . . 0.0 109.349 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.17 -33.98 69.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 76.4 mt -72.25 -37.63 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.686 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.692 HG12 HG21 ' A' ' 12' ' ' ILE . 3.0 m -69.47 -43.99 80.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.741 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.431 HG13 ' N ' ' B' ' 15' ' ' GLY . 5.7 p -61.44 -42.41 93.73 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 118.943 -1.103 . . . . 0.0 109.101 178.85 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 15' ' ' GLY . . . . . 0.431 ' N ' HG13 ' B' ' 14' ' ' VAL . . . -66.19 -27.95 73.33 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.505 ' OD1' HD12 ' A' ' 19' ' ' LEU . 47.3 t0 -65.42 -47.0 77.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.282 0.563 . . . . 0.0 109.639 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -59.41 -40.97 88.36 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.664 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -67.75 -24.34 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.686 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 tt -71.28 -53.25 14.94 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.095 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.593 ' OG1' HD13 ' A' ' 19' ' ' LEU . 23.8 m -59.67 -46.68 88.32 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.634 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -65.93 -43.73 92.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.739 -179.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.9 tp -58.53 -56.09 26.69 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -178.367 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 35.7 mt -65.61 -41.7 91.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.959 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -32.9 64.63 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.485 0.66 . . . . 0.0 109.462 178.287 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.498 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -69.23 -42.3 75.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.278 179.524 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.98 -53.7 52.31 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.791 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.505 ' CG1' HG12 ' A' ' 27' ' ' VAL . 15.4 m -58.94 -43.28 88.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 C-N-CA 120.171 -0.612 . . . . 0.0 110.487 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.92 -40.97 81.71 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.902 0.382 . . . . 0.0 110.553 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.8 t80 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 -179.732 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.664 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.43 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.2 p -63.98 -43.9 97.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.185 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.624 ' HB3' HD12 ' B' ' 9' ' ' LEU . 3.4 mm? -54.32 -48.75 70.99 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 121.253 0.549 . . . . 0.0 109.64 178.442 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.73 -39.28 73.67 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.909 0.861 . . . . 0.0 109.275 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.02 -35.02 90.11 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.626 HG21 HG12 ' B' ' 13' ' ' VAL . 39.8 mm -66.41 -44.25 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 120.434 -0.507 . . . . 0.0 111.065 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.527 HG12 HG21 ' B' ' 12' ' ' ILE . 1.0 OUTLIER -59.41 -41.06 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 118.544 -1.262 . . . . 0.0 109.089 179.774 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.1 t -54.5 -42.09 57.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.65 -33.37 86.49 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.744 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -58.86 -49.74 76.61 Favored 'General case' 0 CA--C 1.52 -0.207 0 CA-C-O 121.025 0.44 . . . . 0.0 109.848 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.494 HD12 ' N ' ' A' ' 17' ' ' LEU . 10.9 mp -61.09 -39.04 88.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.672 179.352 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -60.62 -42.58 92.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.833 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.411 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 62.3 mt -63.85 -43.73 95.27 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.772 0.32 . . . . 0.0 110.785 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -58.0 -51.87 67.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.85 0.357 . . . . 0.0 111.277 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 52.9 t -71.31 -29.03 34.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.628 -179.255 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.49 -51.84 21.57 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.573 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.1 mm -70.23 -38.46 74.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.011 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.18 -44.25 80.15 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.634 -0.427 . . . . 0.0 111.214 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 47.5 tp -70.53 -35.78 73.36 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.377 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.48 -49.78 51.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.865 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 23' ' ' ILE . 21.2 m -68.33 -44.59 83.56 Favored 'Isoleucine or valine' 0 C--O 1.23 0.078 0 C-N-CA 120.049 -0.66 . . . . 0.0 111.193 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.528 ' N ' HG23 ' A' ' 27' ' ' VAL . 58.3 t80 -63.25 -46.89 84.79 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.032 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.5 t80 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.964 -179.544 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.633 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.445 HG13 ' N ' ' B' ' 9' ' ' LEU . 14.7 p -53.46 -42.14 47.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.7 mm? -51.32 -52.2 47.51 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.37 -35.25 65.06 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.914 0.864 . . . . 0.0 109.302 179.284 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.01 -33.97 88.7 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 12' ' ' ILE . . . . . 0.527 HG21 HG12 ' A' ' 13' ' ' VAL . 1.8 mp -71.69 -39.5 69.15 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.923 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.626 HG12 HG21 ' A' ' 12' ' ' ILE . 1.4 m -63.84 -44.92 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 118.526 -1.269 . . . . 0.0 110.314 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -60.59 -35.76 65.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 C-N-CA 118.277 -1.369 . . . . 0.0 107.702 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.48 -30.14 76.01 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.919 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.411 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 3.3 t0 -64.35 -48.61 74.89 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.433 ' N ' HD12 ' B' ' 17' ' ' LEU . 11.1 mp -59.26 -43.99 92.43 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -67.12 -25.46 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.46 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 2.9 tt -70.47 -50.26 39.95 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 120.981 0.419 . . . . 0.0 110.268 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 69.7 m -62.25 -45.3 93.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -68.79 -31.06 49.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.6 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 28.6 tp -68.5 -52.15 35.42 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.833 -178.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 63.9 mt -71.36 -40.62 73.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.487 -179.201 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.74 -40.9 97.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.382 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 49.0 tp -72.82 -31.2 64.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.049 0.452 . . . . 0.0 109.99 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.49 -52.51 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.972 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.404 HG23 ' N ' ' B' ' 28' ' ' TYR . 23.1 m -70.38 -36.33 66.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.815 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 28' ' ' TYR . . . . . 0.404 ' N ' HG23 ' B' ' 27' ' ' VAL . 80.2 t80 -62.16 -48.67 79.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.551 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.8 t80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.78 -179.866 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.699 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.402 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.7 p -64.94 -41.8 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 120.577 -0.449 . . . . 0.0 109.928 179.547 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.489 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.0 mm? -59.17 -49.39 78.04 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.787 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.29 -36.96 66.71 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 122.158 0.98 . . . . 0.0 108.82 179.032 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.12 -37.71 95.37 Favored Glycine 0 CA--C 1.521 0.43 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.43 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.4 mm -64.53 -43.42 96.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.632 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -57.5 -44.64 85.23 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.552 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -54.98 -39.78 50.84 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.186 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.13 -35.11 91.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -58.08 -49.44 76.92 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-O 121.159 0.504 . . . . 0.0 109.693 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.495 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.0 -39.01 88.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.769 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.74 -38.92 81.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.984 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.479 HD22 ' OG1' ' B' ' 20' ' ' THR . 72.5 mt -67.65 -39.09 84.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.761 0.315 . . . . 0.0 110.633 -179.809 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.3 m -61.73 -51.85 66.66 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.635 -0.426 . . . . 0.0 111.19 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.5 t -72.76 -29.6 30.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.765 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.2 tp -72.38 -52.25 16.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.441 -178.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.75 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.5 mm -68.75 -38.98 79.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.066 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.47 -42.69 78.38 Favored 'General case' 0 C--N 1.333 -0.138 0 C-N-CA 120.755 -0.378 . . . . 0.0 111.262 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.2 tp -70.53 -36.77 73.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.996 0.426 . . . . 0.0 110.331 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.56 -49.38 48.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.824 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.75 HG22 ' O ' ' A' ' 23' ' ' ILE . 28.8 m -69.04 -41.82 81.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.451 -178.854 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.451 ' N ' HG23 ' A' ' 27' ' ' VAL . 77.6 t80 -64.66 -46.07 84.07 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.73 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.0 t80 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.02 -179.523 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.204 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.429 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 5.6 p -61.68 -42.88 95.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.489 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.5 mm? -60.96 -48.5 81.53 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 119.723 -0.791 . . . . 0.0 109.628 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.71 -35.65 56.04 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 122.131 0.967 . . . . 0.0 108.877 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.58 -42.88 99.84 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 114.293 -1.322 . . . . 0.0 110.084 179.233 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.34 -29.12 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 C-N-CA 120.357 -0.537 . . . . 0.0 109.832 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 61.4 t -64.2 -57.03 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.826 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 p -57.8 -28.14 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.2 -31.9 78.67 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 178.461 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -65.6 -46.06 80.79 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.468 ' N ' HD12 ' B' ' 17' ' ' LEU . 8.0 mp -58.87 -44.3 91.05 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.424 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -68.9 -23.05 26.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.064 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.484 ' O ' HD13 ' B' ' 19' ' ' LEU . 0.3 OUTLIER -70.05 -55.47 9.43 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.016 0.436 . . . . 0.0 110.412 -179.353 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.479 ' OG1' HD22 ' A' ' 19' ' ' LEU . 77.2 m -61.56 -43.9 98.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.3 t -67.04 -38.46 81.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.623 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 30.0 tp -63.13 -51.66 65.62 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 47.0 mt -69.34 -39.73 79.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 119.964 -0.695 . . . . 0.0 110.397 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.2 -44.79 96.72 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.583 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -71.73 -27.55 63.07 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.03 -53.78 44.5 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.649 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.451 HG11 HG21 ' A' ' 27' ' ' VAL . 33.2 m -71.01 -38.81 73.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.321 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 28' ' ' TYR . . . . . 0.451 ' N ' HG23 ' B' ' 27' ' ' VAL . 48.6 t80 -60.75 -48.64 80.87 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.494 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 t80 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.667 -179.921 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.832 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.402 HG13 HD22 ' A' ' 9' ' ' LEU . 6.9 p -56.47 -27.73 25.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.967 0.413 . . . . 0.0 109.952 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.561 HD13 HG11 ' B' ' 13' ' ' VAL . 3.4 mm? -61.61 -48.74 79.53 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.718 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.5 -39.38 83.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 122.258 1.028 . . . . 0.0 109.172 179.1 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.45 -37.24 92.93 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 114.592 -1.185 . . . . 0.0 110.174 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 4.9 mm -66.14 -43.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.888 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.53 -43.07 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 118.907 -1.117 . . . . 0.0 108.486 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 66.9 t -55.18 -41.49 60.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.006 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.46 -30.94 79.1 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.796 178.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -61.4 -49.32 77.38 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.506 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.8 -40.17 94.27 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.591 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -61.51 -43.19 96.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.225 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.0 mt -64.31 -45.83 86.22 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 10.7 m -57.11 -51.86 67.6 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.883 0.373 . . . . 0.0 110.913 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.6 t -71.89 -27.68 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.882 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 42.4 tp -72.09 -52.65 15.81 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.568 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.1 mm -69.8 -38.77 76.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.317 -0.553 . . . . 0.0 109.885 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.37 -42.94 82.61 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.327 -179.366 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.2 tp -70.63 -38.01 73.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.901 0.381 . . . . 0.0 110.214 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.49 -49.27 64.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.746 -179.131 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' ' 23' ' ' ILE . 18.3 m -70.28 -39.67 77.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.285 -178.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.411 ' N ' HG23 ' A' ' 27' ' ' VAL . 88.0 t80 -63.51 -46.52 85.71 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.898 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.5 t80 . . . . . 0 C--N 1.331 -0.215 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.336 -179.316 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.382 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.548 HG13 ' N ' ' B' ' 9' ' ' LEU . 14.4 p -58.92 -43.46 88.63 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.548 ' N ' HG13 ' B' ' 8' ' ' VAL . 0.6 OUTLIER -54.27 -48.52 71.12 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.488 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.416 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -54.59 -38.06 66.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -35.6 91.29 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.166 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -69.47 -38.84 77.78 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 CA-C-O 119.111 -0.471 . . . . 0.0 111.131 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.561 HG11 HD13 ' A' ' 9' ' ' LEU . 1.2 m -65.71 -45.65 91.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.651 -179.545 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.405 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -60.84 -32.73 52.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 C-N-CA 118.285 -1.366 . . . . 0.0 107.524 178.374 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.9 -28.64 72.88 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.703 178.355 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.0 t0 -65.33 -49.26 70.12 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.475 ' N ' HD12 ' B' ' 17' ' ' LEU . 10.6 mp -59.95 -42.28 93.72 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.14 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.405 HG23 ' O ' ' B' ' 14' ' ' VAL . 96.6 t -67.2 -26.4 36.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.348 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.422 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.0 tt -70.65 -48.58 54.2 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.938 0.399 . . . . 0.0 110.228 -179.478 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 12.1 m -62.59 -45.61 92.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.679 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.9 t -70.22 -27.5 32.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.622 -179.23 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 27.4 tp -70.86 -53.13 16.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.758 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 55.0 mt -71.08 -38.98 73.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -65.77 -41.6 91.84 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.584 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -72.56 -31.68 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.028 0.442 . . . . 0.0 109.979 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.31 -52.35 54.64 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.037 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.426 HG23 ' N ' ' B' ' 28' ' ' TYR . 28.3 m -70.81 -37.41 68.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.979 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 28' ' ' TYR . . . . . 0.426 ' N ' HG23 ' B' ' 27' ' ' VAL . 80.6 t80 -61.32 -49.31 77.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.619 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 67.6 t80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.788 -179.937 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.783 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.415 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.4 p -56.08 -42.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.172 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.504 ' HB3' HD12 ' B' ' 9' ' ' LEU . 3.1 mm? -56.66 -48.59 77.24 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.81 -37.6 60.12 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-O 122.107 0.956 . . . . 0.0 108.824 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.49 -39.55 97.97 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.6 mm -61.91 -40.2 86.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.687 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 13' ' ' VAL . 0.6 OUTLIER -62.92 -42.4 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 C-N-CA 119.257 -0.977 . . . . 0.0 109.276 -179.993 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.432 ' O ' HG23 ' A' ' 18' ' ' VAL . 99.5 t -53.44 -44.59 55.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.197 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.1 -32.36 83.81 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.3 179.135 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.434 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 16.6 t0 -61.8 -51.46 68.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.772 0.32 . . . . 0.0 110.538 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.476 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.1 mp -61.15 -38.3 85.93 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.36 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 78.2 t -64.32 -33.33 62.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.29 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.437 HD22 ' OG1' ' B' ' 20' ' ' THR . 35.6 mt -72.71 -49.55 30.5 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.134 -179.305 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.1 m -59.6 -48.62 80.94 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.097 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.0 t -70.74 -38.57 73.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.3 tp -62.53 -54.58 37.68 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.712 -0.395 . . . . 0.0 111.753 -178.457 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.3 mm -69.04 -41.87 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.82 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.6 -39.51 73.7 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.446 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.9 tp -69.96 -37.05 75.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.3 -53.6 52.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.422 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.45 HG23 ' N ' ' A' ' 28' ' ' TYR . 5.4 m -67.84 -40.83 84.3 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.514 -179.301 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.45 ' N ' HG23 ' A' ' 27' ' ' VAL . 75.4 t80 -59.68 -46.67 88.35 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.921 -179.654 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.9 t80 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.972 -179.582 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.41 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.477 HG13 ' N ' ' B' ' 9' ' ' LEU . 8.8 p -60.79 -44.6 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.601 -0.44 . . . . 0.0 109.912 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.504 HD12 ' HB3' ' A' ' 9' ' ' LEU . 2.9 mm? -58.57 -48.52 80.66 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 119.919 -0.713 . . . . 0.0 109.295 179.062 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.74 -33.36 55.49 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.561 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.37 -39.73 98.11 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.8 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.05 -25.51 27.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.463 -0.368 . . . . 0.0 110.135 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t -68.13 -53.84 26.5 Favored 'Isoleucine or valine' 0 C--O 1.243 0.73 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.554 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.485 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -58.86 -31.26 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 178.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.96 -26.12 73.26 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -68.23 -60.9 2.12 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 111.761 0.282 . . . . 0.0 111.761 -178.633 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.728 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.39 -24.37 62.93 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.57 -179.684 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.485 HG23 ' O ' ' B' ' 14' ' ' VAL . 17.9 t -68.82 -38.37 78.65 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.281 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.434 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 15.6 mt -64.43 -50.16 68.68 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.309 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.437 ' OG1' HD22 ' A' ' 19' ' ' LEU . 13.9 m -58.26 -50.58 73.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.775 -178.622 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.8 t -71.39 -27.04 27.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.757 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 20.9 tp -69.84 -57.09 5.49 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.212 -178.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 14.0 mt -70.82 -39.54 75.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.21 -39.49 90.42 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 109.895 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.1 tp -70.31 -33.21 71.26 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.02 -51.61 68.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.548 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -64.07 -40.71 90.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -59.54 -46.33 89.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.582 -179.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 85.3 t80 . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.806 -179.902 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.721 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.8 p -55.37 -45.94 78.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.164 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.575 HD12 ' HB3' ' B' ' 9' ' ' LEU . 2.9 mm? -51.7 -48.8 63.39 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.424 ' O ' HG22 ' A' ' 13' ' ' VAL . . . -55.96 -37.73 69.43 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.078 0.942 . . . . 0.0 109.427 179.087 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.85 -37.99 94.59 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.652 HG21 HG12 ' B' ' 13' ' ' VAL . 1.9 mp -66.57 -40.87 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.32 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.424 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -57.82 -42.02 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 118.664 -1.214 . . . . 0.0 108.759 179.691 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.409 ' O ' HG23 ' A' ' 18' ' ' VAL . 89.6 t -55.54 -43.34 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.416 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.2 -33.83 87.18 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.06 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 19.7 t0 -60.02 -51.17 70.81 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 120.949 0.404 . . . . 0.0 110.361 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.477 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.1 mp -60.38 -37.87 82.12 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.5 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 14' ' ' VAL . 75.5 t -64.01 -33.91 65.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.302 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.534 HD22 ' OG1' ' B' ' 20' ' ' THR . 51.7 mt -71.72 -46.97 56.96 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.94 -0.304 . . . . 0.0 111.231 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.7 m -59.59 -49.39 77.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.871 -179.451 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.8 t -70.94 -35.43 59.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.404 -179.009 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.79 -55.7 18.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.746 -0.381 . . . . 0.0 111.763 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 mm -68.77 -40.96 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.638 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.55 -39.51 76.83 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.621 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.5 tp -69.37 -37.06 77.43 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.55 39.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.579 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.511 HG23 ' N ' ' A' ' 28' ' ' TYR . 4.6 m -66.23 -43.9 91.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 C-N-CA 120.413 -0.515 . . . . 0.0 111.696 -179.078 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.511 ' N ' HG23 ' A' ' 27' ' ' VAL . 73.1 t80 -59.02 -45.4 90.79 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.78 -179.389 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.4 t80 . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.082 -179.698 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.622 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.438 ' H ' HG12 ' B' ' 8' ' ' VAL . 1.5 p -63.48 -44.92 98.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.29 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.575 ' HB3' HD12 ' A' ' 9' ' ' LEU . 3.7 mm? -61.09 -50.16 74.37 Favored 'General case' 0 C--O 1.239 0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 110.233 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.406 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.71 -37.42 70.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 122.053 0.93 . . . . 0.0 109.222 179.086 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.98 -36.77 93.35 Favored Glycine 0 CA--C 1.519 0.297 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 89.9 mt -66.04 -42.79 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 120.242 -0.583 . . . . 0.0 111.3 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.652 HG12 HG21 ' A' ' 12' ' ' ILE . 1.0 OUTLIER -60.25 -38.73 78.46 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 118.558 -1.257 . . . . 0.0 108.793 179.25 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.466 ' O ' HG23 ' B' ' 18' ' ' VAL . 95.1 t -57.51 -35.98 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 177.174 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.45 -25.4 75.39 Favored Glycine 0 CA--C 1.533 1.183 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.945 178.371 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -69.35 -60.95 2.0 Allowed 'General case' 0 C--O 1.237 0.413 0 O-C-N 122.479 -0.424 . . . . 0.0 111.776 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.736 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.12 -24.42 63.19 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 119.039 -1.064 . . . . 0.0 110.382 -179.6 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.518 ' N ' HD22 ' B' ' 17' ' ' LEU . 7.2 t -66.07 -45.08 91.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.381 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 38.1 mt -63.35 -49.43 73.92 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.033 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.534 ' OG1' HD22 ' A' ' 19' ' ' LEU . 10.4 m -56.54 -50.73 71.01 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.507 -0.477 . . . . 0.0 111.293 -178.666 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 96.5 t -67.57 -43.05 87.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.167 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 36.0 tp -57.9 -57.83 11.05 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -178.216 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 29.0 mt -64.67 -41.82 93.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.716 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.53 -32.33 62.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.421 0.629 . . . . 0.0 109.601 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.485 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.06 -43.4 71.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.426 179.662 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.67 -53.1 59.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.722 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.436 ' CG1' HG12 ' A' ' 27' ' ' VAL . 17.1 m -60.29 -41.83 88.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.647 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -58.64 -42.76 89.03 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.556 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 t80 . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.824 -179.794 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.759 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.449 HG13 ' N ' ' A' ' 9' ' ' LEU . 8.1 p -62.99 -43.14 98.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.436 -0.506 . . . . 0.0 109.759 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.506 ' HB3' HD12 ' B' ' 9' ' ' LEU . 2.7 mm? -57.38 -47.41 81.75 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.681 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.44 -38.56 59.48 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.147 0.975 . . . . 0.0 108.482 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -40.07 98.51 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 114.487 -1.233 . . . . 0.0 110.639 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.6 mm -60.61 -41.53 88.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.516 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -61.29 -43.95 97.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.291 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.7 t -52.6 -45.75 48.12 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 178.718 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.35 80.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -60.54 -48.48 81.61 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.459 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.2 mp -61.77 -40.93 96.9 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.5 t -59.44 -41.88 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.707 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.517 HD13 ' OG1' ' B' ' 20' ' ' THR . 57.4 mt -64.5 -44.7 90.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -57.52 -51.64 68.62 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -71.73 -24.19 23.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.781 -179.247 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 52.9 tp -70.17 -56.44 6.84 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.774 -178.692 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.3 mm -73.06 -38.09 54.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.552 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.19 -38.51 86.78 Favored 'General case' 0 N--CA 1.457 -0.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.074 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.5 tp -70.59 -36.65 73.67 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.39 -54.41 37.13 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.172 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.52 HG23 ' N ' ' A' ' 28' ' ' TYR . 17.8 m -66.31 -42.47 90.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.292 -179.499 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.52 ' N ' HG23 ' A' ' 27' ' ' VAL . 83.9 t80 -60.35 -45.15 94.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.797 0.332 . . . . 0.0 110.867 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.2 t80 . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.101 -179.555 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.397 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.438 HG13 ' N ' ' B' ' 9' ' ' LEU . 7.2 p -58.69 -41.09 81.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.506 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.5 mm? -56.89 -50.52 72.27 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.17 -30.99 40.4 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.22 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.82 -34.47 87.35 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 178.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 12' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.7 mp -74.02 -29.3 25.2 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.448 -0.31 . . . . 0.0 110.902 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -72.0 -45.6 63.02 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.689 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.41 ' O ' HD13 ' B' ' 17' ' ' LEU . 3.4 p -62.09 -39.66 84.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 C-N-CA 119.778 -0.769 . . . . 0.0 108.944 178.815 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.92 -29.02 71.13 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -66.47 -62.6 1.38 Allowed 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.757 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -63.93 -27.5 69.18 Favored 'General case' 0 C--O 1.232 0.146 0 C-N-CA 119.039 -1.064 . . . . 0.0 109.759 -179.891 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.526 ' N ' HD22 ' B' ' 17' ' ' LEU . 6.8 t -68.57 -28.86 41.87 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.342 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.529 ' O ' HD23 ' B' ' 19' ' ' LEU . 3.1 tt -69.17 -55.46 10.58 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.092 0.472 . . . . 0.0 110.142 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.517 ' OG1' HD13 ' A' ' 19' ' ' LEU . 7.5 m -57.43 -46.15 83.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.317 -179.514 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 87.2 t -68.26 -41.98 84.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.831 -178.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.1 tp -59.45 -57.18 14.09 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 54.0 mt -64.74 -42.04 93.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 120.206 -0.598 . . . . 0.0 109.903 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.36 -32.2 56.36 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.496 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -69.8 -45.29 68.26 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.522 179.327 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.81 -52.01 58.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.744 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 16.3 m -63.51 -41.56 93.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.017 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -57.5 -45.75 84.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.34 . . . . 0.0 110.565 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 57.0 t80 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.658 -179.933 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.767 0 N-CA-C 111.998 -0.441 . . . . 0.0 111.998 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.557 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.5 p -59.31 -48.91 85.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.831 -179.27 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.557 ' N ' HG13 ' A' ' 8' ' ' VAL . 2.8 mm? -51.81 -46.84 64.42 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.078 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.98 -41.61 71.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.851 0.834 . . . . 0.0 108.838 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.33 -29.87 69.91 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.591 HG21 HG12 ' B' ' 13' ' ' VAL . 42.5 mm -70.29 -42.71 78.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.51 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.53 -42.31 80.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.145 179.272 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -55.06 -42.76 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.255 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.75 -33.08 83.96 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.803 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -58.95 -50.52 73.77 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.047 0.451 . . . . 0.0 109.925 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.505 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.35 -39.27 89.97 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.907 179.587 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.21 -42.09 85.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.738 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.489 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 35.7 mt -65.72 -45.12 83.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.701 0.286 . . . . 0.0 111.198 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.2 m -56.29 -53.04 61.98 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.088 -178.775 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 65.9 t -71.9 -27.3 27.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.819 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.8 tp -72.15 -51.4 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -178.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.593 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.9 mm -70.37 -37.49 70.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.753 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.46 -43.78 80.22 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.083 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -71.94 -32.92 67.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.089 0.471 . . . . 0.0 110.246 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.41 -50.61 36.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.698 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.593 HG22 ' O ' ' A' ' 23' ' ' ILE . 22.8 m -68.98 -42.86 82.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.625 -0.43 . . . . 0.0 111.332 -178.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.505 ' N ' HG23 ' A' ' 27' ' ' VAL . 49.1 t80 -63.07 -47.05 84.59 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.699 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.5 t80 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.187 -179.484 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.644 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -57.86 -43.84 85.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.758 -179.475 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 13.7 mt -64.83 -35.02 79.77 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 119.002 -1.079 . . . . 0.0 109.651 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.45 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.47 -39.81 73.83 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.718 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.99 -36.32 92.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 178.369 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.31 -31.31 46.57 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-O 119.155 -0.45 . . . . 0.0 111.518 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.591 HG12 HG21 ' A' ' 12' ' ' ILE . 1.3 m -73.01 -41.58 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.573 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 p -62.37 -37.48 78.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.547 178.026 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.87 -29.38 73.61 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.763 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.489 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.1 t0 -64.08 -49.07 73.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.114 0.483 . . . . 0.0 109.754 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 1.8 mt -59.63 -44.35 93.5 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.084 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.3 t -64.53 -24.61 36.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.541 179.213 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 tt -70.67 -48.51 54.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.929 0.395 . . . . 0.0 110.255 -179.473 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.7 m -61.63 -45.84 92.35 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.555 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.8 t -71.0 -26.49 27.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.668 -179.328 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.2 tp -71.07 -52.88 16.92 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.31 -179.075 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 46.5 mt -69.81 -42.13 79.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.831 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.68 -43.92 97.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.572 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 54.1 tp -72.02 -29.95 64.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.956 0.408 . . . . 0.0 109.988 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.6 -51.66 53.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.046 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.445 HG23 ' N ' ' B' ' 28' ' ' TYR . 26.5 m -70.62 -38.81 74.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.121 -179.387 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 28' ' ' TYR . . . . . 0.445 ' N ' HG23 ' B' ' 27' ' ' VAL . 78.5 t80 -62.59 -48.48 79.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.726 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 83.3 t80 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.904 -179.911 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.495 HG13 ' N ' ' A' ' 9' ' ' LEU . 8.4 p -66.05 -44.98 91.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.309 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.501 ' HB3' HD12 ' B' ' 9' ' ' LEU . 2.1 mm? -57.64 -47.61 81.76 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.19 -38.27 68.15 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.082 0.944 . . . . 0.0 108.521 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.89 -37.52 93.87 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.119 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 44.2 mm -62.76 -43.23 98.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.811 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -60.69 -43.42 94.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.576 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 18' ' ' VAL . 88.7 t -53.5 -42.39 49.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.335 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -34.66 90.54 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 178.465 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -57.23 -50.31 73.26 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 120.754 0.312 . . . . 0.0 110.177 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.503 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.39 -40.19 93.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.487 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 14' ' ' VAL . 78.7 t -62.11 -39.57 84.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.524 HD13 ' OG1' ' B' ' 20' ' ' THR . 46.7 mt -67.04 -44.23 80.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.453 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.1 m -59.76 -51.59 69.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.175 -179.077 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.3 t -71.83 -27.98 29.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.187 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -68.99 -56.48 7.66 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.716 -178.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -70.47 -39.88 76.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.323 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.99 -39.82 82.97 Favored 'General case' 0 CA--C 1.521 -0.167 0 C-N-CA 120.867 -0.333 . . . . 0.0 110.714 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.9 tp -69.72 -37.48 76.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.59 -53.7 52.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.771 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.519 HG23 ' N ' ' A' ' 28' ' ' TYR . 6.4 m -67.53 -43.13 87.42 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.744 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.519 ' N ' HG23 ' A' ' 27' ' ' VAL . 62.8 t80 -59.29 -46.97 87.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.083 -179.355 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.3 t80 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.148 -179.306 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.48 HG13 HD22 ' B' ' 9' ' ' LEU . 14.3 p -55.13 -43.09 68.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.501 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.8 mm? -54.55 -52.47 61.96 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 120.391 -0.524 . . . . 0.0 109.765 179.239 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -51.41 -36.33 43.12 Favored 'General case' 0 C--O 1.241 0.658 0 CA-C-O 121.968 0.89 . . . . 0.0 109.11 179.201 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -37.79 95.12 Favored Glycine 0 CA--C 1.524 0.624 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.123 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.174 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 33.2 t -69.64 -52.82 28.39 Favored 'Isoleucine or valine' 0 C--O 1.246 0.901 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.491 178.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -58.53 -32.38 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.418 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.344 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.3 -25.2 75.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -69.79 -61.72 1.67 Allowed 'General case' 0 C--O 1.235 0.334 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.503 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.737 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -67.52 -23.47 65.46 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 118.368 -1.333 . . . . 0.0 109.954 -179.557 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.494 ' N ' HD22 ' B' ' 17' ' ' LEU . 9.4 t -70.32 -38.91 75.82 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.863 177.497 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.476 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.9 tt -66.47 -52.07 50.13 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 120.996 0.427 . . . . 0.0 110.531 -179.219 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.524 ' OG1' HD13 ' A' ' 19' ' ' LEU . 9.7 m -58.8 -49.01 79.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.025 -179.398 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 72.0 t -65.24 -42.01 92.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.609 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 35.6 tp -57.73 -56.51 21.0 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 112.006 0.372 . . . . 0.0 112.006 -178.394 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 52.7 mt -66.02 -41.71 90.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 120.084 -0.646 . . . . 0.0 110.082 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.45 -31.72 62.17 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.32 0.581 . . . . 0.0 109.484 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.457 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.77 -44.56 66.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.25 179.541 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.38 -51.97 56.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.661 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.436 ' CG1' HG12 ' A' ' 27' ' ' VAL . 18.0 m -63.04 -40.67 89.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.742 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.09 -47.93 79.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.83 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 63.9 t80 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.872 -179.914 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.428 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.7 p -64.52 -45.29 96.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.147 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.602 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.8 mm? -51.32 -49.48 61.28 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.339 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.3 -37.5 72.56 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-O 121.968 0.889 . . . . 0.0 109.302 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.13 -38.49 94.46 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.641 HG21 HG12 ' B' ' 13' ' ' VAL . 1.8 mp -66.26 -44.02 91.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.378 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.19 -42.62 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 118.568 -1.253 . . . . 0.0 108.652 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.405 ' O ' HG23 ' A' ' 18' ' ' VAL . 95.6 t -55.21 -42.31 65.19 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 178.09 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.56 -32.9 84.88 Favored Glycine 0 CA--C 1.53 1.012 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.131 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -61.24 -49.59 76.47 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.84 0.352 . . . . 0.0 110.179 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.483 HD12 ' N ' ' A' ' 17' ' ' LEU . 10.5 mp -61.53 -38.57 87.89 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.402 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.405 HG23 ' O ' ' A' ' 14' ' ' VAL . 74.6 t -62.57 -41.44 92.09 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.265 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.009 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.484 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 36.6 mt -65.56 -44.61 86.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.749 0.309 . . . . 0.0 111.019 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.3 m -59.16 -51.48 69.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.229 -179.122 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.7 t -71.92 -30.59 37.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.754 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 35.4 tp -69.0 -52.87 24.24 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.698 -178.652 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.472 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.5 mm -69.9 -42.45 79.79 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.682 0 C-N-CA 119.713 -0.795 . . . . 0.0 109.25 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.88 93.02 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.435 -179.271 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 42.4 tp -70.1 -36.34 74.79 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.601 -179.632 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.19 -51.5 30.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.236 -178.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.472 HG22 ' O ' ' A' ' 23' ' ' ILE . 14.2 m -69.37 -41.02 80.71 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 C-N-CA 120.441 -0.503 . . . . 0.0 111.366 -178.722 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.443 ' N ' HG23 ' A' ' 27' ' ' VAL . 89.4 t80 -65.67 -45.9 81.16 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.91 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.5 t80 . . . . . 0 C--N 1.328 -0.366 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.07 -179.47 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 8' ' ' VAL . . . . . 0.521 HG13 ' N ' ' B' ' 9' ' ' LEU . 8.5 p -54.39 -43.89 64.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.602 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.3 mm? -53.43 -50.47 65.16 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.432 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -54.67 -33.66 61.1 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 121.781 0.8 . . . . 0.0 109.156 178.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.33 -35.55 92.1 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.172 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -72.72 -33.12 43.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.169 -0.443 . . . . 0.0 111.296 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.641 HG12 HG21 ' A' ' 12' ' ' ILE . 1.9 m -70.32 -41.48 78.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 118.884 -1.127 . . . . 0.0 110.378 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 p -63.27 -38.06 81.11 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 C-N-CA 118.623 -1.231 . . . . 0.0 108.087 178.073 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.59 -29.43 73.96 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 178.635 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.484 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 5.3 t0 -64.67 -49.39 71.15 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.198 0.523 . . . . 0.0 109.631 179.816 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -58.82 -43.24 90.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.54 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.77 -24.39 30.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.102 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.418 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.3 tt -70.54 -51.64 27.29 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 121.07 0.462 . . . . 0.0 110.139 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 20' ' ' THR . . . . . 0.467 ' OG1' HD13 ' A' ' 19' ' ' LEU . 7.8 m -60.79 -48.89 79.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.626 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -63.66 -42.54 96.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.286 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 26.7 tp -57.36 -54.02 51.56 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 23' ' ' ILE . . . . . 0.405 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 59.3 mt -64.02 -44.84 97.9 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.494 -178.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.52 -36.78 67.1 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 25' ' ' LEU . . . . . 0.492 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -66.39 -39.23 88.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.268 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 26' ' ' ALA . . . . . 0.405 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -53.6 -55.65 23.96 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.262 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.415 HG11 ' CG1' ' A' ' 27' ' ' VAL . 12.7 m -63.68 -37.54 79.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 C-N-CA 119.387 -0.925 . . . . 0.0 111.02 179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -56.65 -47.36 79.95 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.568 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.3 t80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.784 -179.969 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.573 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.4 p -65.32 -38.98 83.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.282 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.621 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.9 mm? -57.57 -46.27 84.17 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.337 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.416 ' O ' HG22 ' A' ' 13' ' ' VAL . . . -58.59 -40.93 84.56 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 122.1 0.952 . . . . 0.0 109.441 179.257 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.16 -38.87 93.74 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.596 HG21 HG12 ' B' ' 13' ' ' VAL . 36.0 mm -63.98 -42.76 96.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.653 -179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.416 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -57.04 -42.67 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 C-N-CA 118.789 -1.164 . . . . 0.0 108.864 179.651 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.433 ' O ' HG23 ' A' ' 18' ' ' VAL . 57.6 t -54.26 -45.08 67.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 119.485 -0.886 . . . . 0.0 108.769 178.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -33.27 86.78 Favored Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.407 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 15.0 t0 -62.12 -51.98 65.69 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.774 0.321 . . . . 0.0 110.706 -179.425 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.455 HD12 ' N ' ' A' ' 17' ' ' LEU . 10.8 mp -60.93 -37.79 83.56 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.571 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 14' ' ' VAL . 64.4 t -64.3 -33.19 61.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.141 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.401 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 27.3 mt -73.43 -46.7 46.94 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.188 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.0 m -60.28 -49.14 78.8 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.073 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -71.93 -37.27 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.9 tp -63.1 -55.18 27.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.408 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.426 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.6 mm -67.98 -44.68 84.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.684 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.46 -42.18 66.91 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 43.3 tp -66.96 -38.25 85.76 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.961 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.66 -50.87 71.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.243 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.434 HG22 HG11 ' B' ' 27' ' ' VAL . 3.0 t -68.7 -45.88 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 C-N-CA 120.614 -0.435 . . . . 0.0 111.497 -179.371 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -58.1 -47.82 82.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.42 -178.844 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 58.8 t80 . . . . . 0 C--N 1.328 -0.35 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.239 -179.295 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.438 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.71 -35.04 53.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 9' ' ' LEU . . . . . 0.621 ' HB3' HD12 ' A' ' 9' ' ' LEU . 1.6 mm? -62.47 -46.78 86.96 Favored 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.129 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.0 -32.32 69.6 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.89 -32.93 84.25 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 178.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 88.9 mt -72.77 -34.7 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-O 119.091 -0.48 . . . . 0.0 111.812 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.596 HG12 HG21 ' A' ' 12' ' ' ILE . 1.4 m -69.54 -44.85 79.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 119.025 -1.07 . . . . 0.0 109.95 179.266 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 14' ' ' VAL . . . . . 0.512 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -60.09 -33.73 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.61 -25.9 74.18 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 178.329 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.401 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 9.3 t70 -69.08 -61.49 1.77 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -178.391 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.747 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -68.15 -25.82 65.46 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.238 -179.724 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.512 HG23 ' O ' ' B' ' 14' ' ' VAL . 14.6 t -66.74 -39.2 83.13 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.462 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 14.2 mt -63.29 -47.31 82.86 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.157 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 10.3 m -57.55 -50.26 73.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.561 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -72.31 -28.49 29.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.0 tp -68.51 -56.62 7.74 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.456 -0.498 . . . . 0.0 111.311 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 30.1 mt -69.82 -41.69 79.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.471 -0.491 . . . . 0.0 109.991 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -38.82 77.82 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.127 0.489 . . . . 0.0 109.73 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -69.54 -35.75 75.73 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.675 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.6 -51.76 68.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.518 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.434 HG11 HG22 ' A' ' 27' ' ' VAL . 16.4 m -64.99 -38.26 82.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.656 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.9 t80 -57.97 -48.57 79.58 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.472 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 84.6 t80 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.866 -179.983 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 95.7 m . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.9 t -164.06 -176.59 4.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.569 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.543 ' O ' ' N ' ' A' ' 5' ' ' SER . 97.6 m -67.22 -68.58 0.37 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.806 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 89.7 t 56.64 -76.01 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.543 ' N ' ' O ' ' A' ' 3' ' ' THR . 1.4 m 69.26 79.95 0.21 Allowed Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.507 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -79.12 18.13 1.09 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.145 1.897 . . . . 0.0 111.974 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.93 -51.52 34.04 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.415 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.7 p -55.6 -39.81 56.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 C-N-CA 120.614 -0.434 . . . . 0.0 109.851 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.571 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.6 mm? -52.86 -50.3 64.06 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.96 -38.77 73.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 122.029 0.919 . . . . 0.0 109.028 179.116 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.75 -35.6 90.16 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.657 HG21 HG12 ' B' ' 13' ' ' VAL . 42.0 mm -67.44 -43.16 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.792 -179.773 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.45 -42.69 81.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.516 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -55.85 -43.36 74.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.322 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.32 -30.44 76.1 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.56 -48.31 80.04 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.455 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.2 mp -60.36 -39.76 88.31 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.0 t -60.66 -40.72 85.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.742 179.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.483 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.0 mt -64.48 -44.44 91.0 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.784 0.326 . . . . 0.0 110.921 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 m -59.81 -52.31 66.0 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.695 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.4 t -72.31 -27.92 27.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -178.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 29.6 tp -69.38 -56.17 8.25 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.498 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.2 mm -70.03 -40.73 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.567 -179.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.86 -39.22 80.7 Favored 'General case' 0 C--O 1.231 0.111 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.171 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.6 tp -69.56 -35.46 75.42 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.48 -56.01 19.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.223 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.508 HG23 ' N ' ' A' ' 28' ' ' TYR . 7.6 m -65.41 -43.15 94.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.113 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.68 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.508 ' N ' HG23 ' A' ' 27' ' ' VAL . 91.5 t80 -61.01 -45.35 95.17 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.951 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -61.14 -52.85 63.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.198 -179.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 49.6 tp -174.11 78.06 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.723 0.297 . . . . 0.0 110.514 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' A' ' 33' ' ' LEU . . . -59.39 103.55 0.42 Allowed Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.8 mmm-85 -49.53 93.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.838 0.351 . . . . 0.0 110.438 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.427 ' N ' ' O ' ' A' ' 31' ' ' GLY . 12.2 tp . . . . . 0 C--N 1.33 -0.247 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.411 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.471 ' C ' ' H ' ' B' ' 3' ' ' THR . 6.8 p . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.489 ' C ' ' H ' ' B' ' 4' ' ' VAL . 6.8 p 64.51 -2.89 0.58 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.528 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.471 ' H ' ' C ' ' B' ' 1' ' ' CYS . 2.7 m 66.89 -7.18 0.49 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.766 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.489 ' H ' ' C ' ' B' ' 2' ' ' SER . 13.1 m 31.24 49.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.838 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.402 ' N ' ' CD ' ' B' ' 6' ' ' PRO . 50.4 m -156.65 55.95 1.12 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.61 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' B' ' 5' ' ' SER . 58.3 Cg_endo -70.45 68.74 2.07 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.844 2.363 . . . . 0.0 111.867 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -72.05 -52.82 10.32 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.535 HG13 ' N ' ' B' ' 9' ' ' LEU . 7.6 p -57.78 -48.2 84.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.382 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.571 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.2 mm? -51.1 -46.74 61.95 Favored 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.243 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.32 -29.7 70.05 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.851 0.834 . . . . 0.0 109.34 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.67 -35.62 86.21 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.133 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -70.31 -45.21 76.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 119.298 -0.382 . . . . 0.0 111.218 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.657 HG12 HG21 ' A' ' 12' ' ' ILE . 3.0 m -60.94 -40.52 85.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 C-N-CA 118.529 -1.268 . . . . 0.0 109.602 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 71.4 t -55.95 -45.38 80.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -26.12 69.78 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.483 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 10.5 t70 -66.3 -48.73 69.41 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.469 ' N ' HD12 ' B' ' 17' ' ' LEU . 11.2 mp -61.52 -39.61 91.67 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -66.89 -29.86 47.7 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.162 179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.421 HD23 ' O ' ' B' ' 19' ' ' LEU . 3.5 tt -71.37 -52.57 17.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.982 0.42 . . . . 0.0 110.543 -179.362 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.478 ' OG1' HD13 ' A' ' 19' ' ' LEU . 19.8 m -59.14 -46.09 89.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.874 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -69.76 -30.94 46.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.2 tp -68.47 -55.3 12.28 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.368 -178.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 16.9 mt -71.77 -39.97 69.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.439 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -62.1 -36.35 81.44 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.021 0.439 . . . . 0.0 110.024 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 33.6 tp -71.24 -37.51 71.99 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.34 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.783 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 35.7 m -65.87 -36.86 78.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.855 -0.338 . . . . 0.0 110.792 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.3 t80 -60.18 -47.51 85.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -62.68 -45.68 91.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.622 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 72.0 mt -61.9 -40.8 96.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.489 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.01 -34.8 90.11 Favored Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 49.2 80.29 0.07 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.82 0.343 . . . . 0.0 110.588 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.608 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.229 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.7 p . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.0 t -161.01 160.89 31.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.573 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.462 ' OG1' ' N ' ' A' ' 4' ' ' VAL . 81.1 p -62.76 -98.98 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.587 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.47 ' O ' HG11 ' B' ' 4' ' ' VAL . 2.6 t 48.77 30.85 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.195 0.521 . . . . 0.0 109.94 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 p -73.51 153.28 89.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.932 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.14 72.69 4.0 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.166 1.911 . . . . 0.0 112.102 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -68.62 -57.4 8.13 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.577 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.0 p -63.91 -47.14 91.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.324 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.615 ' HB3' HD12 ' B' ' 9' ' ' LEU . 1.5 mm? -55.48 -48.78 74.02 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.603 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.95 -37.93 67.09 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.06 -36.1 92.42 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 43.8 mm -65.15 -45.67 93.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.32 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.5 HG12 HG21 ' B' ' 12' ' ' ILE . 0.9 OUTLIER -58.95 -41.26 82.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.085 179.921 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.5 t -55.7 -40.32 59.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -32.6 84.72 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 178.614 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.51 -48.82 80.16 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.474 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.0 mp -61.19 -39.8 91.55 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.662 179.256 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 69.8 t -60.24 -43.47 93.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.713 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.449 HD13 ' OG1' ' B' ' 20' ' ' THR . 32.8 mt -62.36 -43.69 98.22 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.911 0.386 . . . . 0.0 110.481 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -56.93 -51.41 69.25 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.077 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -69.3 -34.91 65.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 32.6 tp -64.61 -57.62 8.59 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -178.239 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.5 mm -68.47 -38.35 79.11 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.493 -179.314 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.65 -39.65 77.5 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.455 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.28 -38.36 78.32 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.41 -53.53 53.55 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.46 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.492 HG23 ' N ' ' A' ' 28' ' ' TYR . 29.2 m -62.56 -46.03 97.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.612 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.492 ' N ' HG23 ' A' ' 27' ' ' VAL . 83.9 t80 -61.19 -43.87 98.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.308 -179.211 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -60.46 -53.71 54.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.157 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 54.0 tp -174.38 78.1 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.135 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -52.85 144.56 22.33 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 51.7 mmt-85 -54.82 101.35 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.757 0.313 . . . . 0.0 110.312 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 22.1 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.389 -179.974 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.474 ' O ' ' N ' ' B' ' 3' ' ' THR . 6.8 t . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.426 ' O ' ' O ' ' B' ' 3' ' ' THR . 9.5 m 46.18 15.4 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.741 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.532 HG22 ' N ' ' B' ' 4' ' ' VAL . 91.8 m 56.06 160.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.638 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.532 ' N ' HG22 ' B' ' 3' ' ' THR . 11.4 t -85.58 117.01 29.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.109 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 5.6 m -156.54 81.1 3.58 Favored Pre-proline 0 CA--C 1.529 0.172 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.784 -179.478 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -81.06 83.69 2.15 Favored 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.441 2.094 . . . . 0.0 111.594 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -71.19 -40.78 60.96 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.795 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.414 HG13 HD22 ' B' ' 9' ' ' LEU . 14.7 p -51.83 -38.54 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.573 -0.451 . . . . 0.0 109.875 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.615 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.8 mm? -55.19 -51.08 67.66 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.6 -39.56 64.98 Favored 'General case' 0 C--O 1.242 0.663 0 CA-C-O 121.862 0.839 . . . . 0.0 109.506 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.86 -43.02 94.93 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 114.568 -1.196 . . . . 0.0 110.147 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 12' ' ' ILE . . . . . 0.5 HG21 HG12 ' A' ' 13' ' ' VAL . 1.8 mp -62.44 -42.38 95.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.493 0 C-N-CA 120.208 -0.597 . . . . 0.0 109.452 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 44.0 t -49.65 -50.85 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 C-N-CA 119.94 -0.704 . . . . 0.0 109.146 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.02 -33.85 47.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' B' ' 12' ' ' ILE . . . -64.95 -39.91 96.81 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.412 ' C ' ' OD1' ' B' ' 16' ' ' ASP . 8.1 t0 -61.68 -45.47 93.86 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.14 0.495 . . . . 0.0 109.932 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.43 ' O ' HG23 ' B' ' 21' ' ' VAL . 7.5 mt -61.19 -42.54 98.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.519 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.0 t -71.86 -26.47 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.403 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.0 tt -73.56 -54.14 8.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.449 ' OG1' HD13 ' A' ' 19' ' ' LEU . 18.6 m -60.11 -45.89 91.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.298 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 21' ' ' VAL . . . . . 0.43 HG23 ' O ' ' B' ' 17' ' ' LEU . 92.3 t -66.29 -44.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.838 -179.25 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.8 tp -58.97 -57.93 10.91 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 13.4 mt -65.93 -40.44 87.47 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.948 -179.141 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.22 -33.07 65.01 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.429 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -68.68 -43.81 75.35 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.414 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.44 -52.91 42.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.676 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.0 m -63.16 -42.07 95.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.809 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -55.39 -46.77 76.52 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.38 . . . . 0.0 110.782 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -61.61 -47.61 84.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.754 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 81.6 mt -63.4 -38.14 89.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.615 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -48.07 -35.35 13.43 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 61.6 ttt85 51.0 86.33 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 110.527 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 33' ' ' LEU . . . . . . . . . . . . . 13.7 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.476 179.995 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 60.5 m . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.6 m -72.38 109.5 6.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.598 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.412 ' C ' ' H ' ' A' ' 5' ' ' SER . 30.7 p -78.2 126.62 31.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.948 0.404 . . . . 0.0 110.449 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.451 ' H ' HG23 ' A' ' 4' ' ' VAL . 2.1 t -58.81 -7.23 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.366 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.412 ' H ' ' C ' ' A' ' 3' ' ' THR . 2.9 m 63.94 60.35 1.7 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.774 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -76.65 14.39 1.24 Allowed 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.765 2.31 . . . . 0.0 111.781 179.816 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.2 -30.98 79.32 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -49.2 -42.25 15.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.065 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.521 HD12 ' HB3' ' B' ' 9' ' ' LEU . 4.1 mm? -52.16 -52.48 51.63 Favored 'General case' 0 CA--C 1.537 0.474 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.222 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.4 -37.85 62.86 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.09 0.947 . . . . 0.0 109.145 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.89 -37.42 94.33 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.711 -1.132 . . . . 0.0 110.311 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.527 HG21 HG12 ' B' ' 13' ' ' VAL . 43.0 mm -65.3 -43.19 95.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.011 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -57.53 -43.15 82.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 C-N-CA 119.016 -1.074 . . . . 0.0 108.601 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.3 t -54.68 -43.79 67.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.19 -32.45 82.58 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -60.57 -48.91 79.69 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.466 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.0 mp -62.08 -38.41 88.71 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.217 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.5 t -61.89 -41.81 92.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.99 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.486 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.9 mt -66.57 -43.7 84.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.87 0.367 . . . . 0.0 110.998 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.1 m -60.85 -51.51 68.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.308 -178.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 90.9 t -71.76 -32.33 44.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.143 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.3 tp -66.48 -56.27 11.71 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.712 -178.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.0 mm -69.1 -41.78 81.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.298 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.94 -40.98 77.44 Favored 'General case' 0 N--CA 1.46 0.056 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.651 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.12 79.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.04 -54.04 49.69 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.698 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.494 HG23 ' N ' ' A' ' 28' ' ' TYR . 3.5 m -68.1 -43.57 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.722 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.494 ' N ' HG23 ' A' ' 27' ' ' VAL . 69.7 t80 -58.72 -48.66 80.39 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.168 -178.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.2 t80 -70.52 -56.56 6.27 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.195 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.7 tp -175.15 78.71 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.104 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -45.37 109.1 0.27 Allowed Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 34.2 mmm-85 -79.85 17.74 0.9 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.826 0.346 . . . . 0.0 110.412 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 20.1 tp . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.342 -179.977 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 19.8 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 6.3 p 63.81 134.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.621 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 27.9 m -160.09 113.8 2.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.219 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 p -66.04 129.8 30.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.943 0.401 . . . . 0.0 110.492 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.522 ' N ' ' CD ' ' B' ' 6' ' ' PRO . 15.8 t -173.31 48.52 0.08 OUTLIER Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.794 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.522 ' CD ' ' N ' ' B' ' 5' ' ' SER . 46.3 Cg_endo -66.95 88.11 0.3 Allowed 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.852 2.368 . . . . 0.0 112.054 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.32 -60.14 3.14 Favored Glycine 0 CA--C 1.526 0.732 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.267 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.593 HG13 ' N ' ' B' ' 9' ' ' LEU . 15.0 p -62.53 -48.52 87.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.593 ' N ' HG13 ' B' ' 8' ' ' VAL . 1.8 mm? -51.68 -47.49 63.83 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.7 -33.87 70.67 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-O 121.841 0.829 . . . . 0.0 108.883 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.86 -33.79 88.19 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.044 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -72.83 -36.19 51.52 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 119.267 -0.397 . . . . 0.0 111.275 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.527 HG12 HG21 ' A' ' 12' ' ' ILE . 1.6 m -68.18 -40.93 83.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 118.886 -1.125 . . . . 0.0 110.517 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 p -64.57 -38.68 83.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 118.747 -1.181 . . . . 0.0 108.42 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.35 -28.93 73.74 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.486 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 7.8 t0 -65.42 -48.03 74.21 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.2 mt -59.79 -42.26 92.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.688 179.102 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 95.0 t -69.0 -24.5 28.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.181 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.3 tt -71.97 -53.57 12.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.085 0.469 . . . . 0.0 110.222 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.435 ' OG1' HD13 ' A' ' 19' ' ' LEU . 11.5 m -59.48 -46.34 89.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.564 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.5 t -66.18 -43.72 91.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.699 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.7 tp -57.92 -56.57 20.24 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 34.8 mt -65.52 -41.56 91.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.945 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.95 -31.4 64.94 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 121.355 0.598 . . . . 0.0 109.577 178.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.493 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.44 -43.53 69.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.346 179.701 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.25 -53.61 51.25 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.612 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.445 ' CG1' HG12 ' A' ' 27' ' ' VAL . 18.3 m -59.91 -41.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.726 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -58.96 -40.76 85.7 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.449 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 77.5 t80 -62.69 -44.25 96.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.111 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 95.9 mt -54.11 -42.03 68.98 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.464 -179.623 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.31 114.6 6.85 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -60.16 87.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.815 0.34 . . . . 0.0 110.53 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.601 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.428 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.492 ' O ' ' SG ' ' A' ' 1' ' ' CYS . 27.9 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.536 ' O ' ' N ' ' A' ' 4' ' ' VAL . 37.4 t -162.17 161.99 28.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.433 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.534 ' HG1' ' C ' ' A' ' 2' ' ' SER . 68.1 p 52.56 -82.07 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.811 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.536 ' N ' ' O ' ' A' ' 2' ' ' SER . 2.8 t 61.53 41.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.013 0.435 . . . . 0.0 110.303 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.503 ' O ' HG12 ' A' ' 8' ' ' VAL . 44.6 m 39.62 69.51 1.71 Allowed Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.998 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -87.52 -25.81 0.9 Allowed 'Trans proline' 0 C--N 1.306 -1.706 0 C-N-CA 122.863 2.375 . . . . 0.0 111.975 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -66.61 -30.21 76.01 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.546 HG13 ' N ' ' A' ' 9' ' ' LEU . 9.7 p -54.37 -46.82 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.159 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.572 HD12 ' HB3' ' B' ' 9' ' ' LEU . 2.9 mm? -53.2 -50.63 64.27 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.769 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.415 ' O ' HG22 ' A' ' 13' ' ' VAL . . . -53.53 -36.07 61.4 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.991 0.901 . . . . 0.0 109.07 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.64 -35.7 92.37 Favored Glycine 0 C--N 1.317 -0.503 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.544 HG21 HG12 ' B' ' 13' ' ' VAL . 37.8 mm -66.09 -43.08 92.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.856 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -59.17 -42.07 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 119.111 -1.036 . . . . 0.0 108.715 179.571 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.5 t -54.92 -41.39 57.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.27 -33.36 87.03 Favored Glycine 0 CA--C 1.53 0.987 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.026 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.431 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 8.9 t0 -61.16 -47.68 85.07 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.457 ' N ' HD12 ' A' ' 17' ' ' LEU . 10.9 mp -61.0 -39.57 90.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.05 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -60.39 -40.44 84.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.64 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.482 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.6 mt -64.4 -44.66 90.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.774 0.321 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 m -58.09 -51.39 69.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.412 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 62.0 t -71.51 -32.73 47.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.845 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.8 tp -66.73 -53.86 28.9 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.676 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.449 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.0 mm -68.87 -42.14 82.41 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.461 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.12 -41.96 84.74 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.2 -179.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.6 tp -69.09 -38.28 78.89 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.51 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.06 53.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.941 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.505 HG23 ' N ' ' A' ' 28' ' ' TYR . 16.7 m -69.63 -42.24 80.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.552 -179.005 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.505 ' N ' HG23 ' A' ' 27' ' ' VAL . 84.1 t80 -62.13 -44.89 95.65 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.825 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.7 t80 -68.9 -54.87 13.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.11 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.0 tp -174.48 78.02 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.331 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -51.97 114.05 2.93 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 36.4 mmm-85 -70.98 -25.47 62.72 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.745 0.307 . . . . 0.0 110.477 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.6 tp . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.225 -179.85 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 23.9 t . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.418 ' O ' ' O ' ' B' ' 3' ' ' THR . 24.6 p 47.4 26.48 0.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.617 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.418 ' O ' ' O ' ' B' ' 2' ' ' SER . 6.1 m 59.34 120.78 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.63 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -78.99 131.65 33.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.433 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.491 ' O ' ' N ' ' B' ' 7' ' ' GLY . 5.2 t -172.56 71.99 0.43 Allowed Pre-proline 0 C--N 1.331 -0.198 0 C-N-CA 120.729 -0.389 . . . . 0.0 111.408 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_exo -46.31 86.45 0.02 OUTLIER 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.643 2.229 . . . . 0.0 111.663 178.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.491 ' N ' ' O ' ' B' ' 5' ' ' SER . . . -46.59 -29.83 4.26 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.476 HG13 ' N ' ' B' ' 9' ' ' LEU . 9.0 p -60.36 -44.19 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.572 ' HB3' HD12 ' A' ' 9' ' ' LEU . 3.4 mm? -57.42 -50.29 73.48 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.465 178.759 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.4 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.02 -29.8 60.91 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.777 0.799 . . . . 0.0 109.348 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.53 -38.33 94.63 Favored Glycine 0 C--N 1.316 -0.532 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 178.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -68.05 -44.04 84.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 120.439 -0.504 . . . . 0.0 111.227 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.544 HG12 HG21 ' A' ' 12' ' ' ILE . 2.1 m -60.67 -37.27 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.675 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 61.6 t -58.68 -43.64 88.1 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.669 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -64.45 -32.76 85.28 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.373 178.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.482 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -61.85 -48.38 80.8 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.996 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.9 mt -60.08 -44.39 94.81 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.819 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.87 -25.89 37.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.03 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.431 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 2.7 tt -70.48 -49.41 48.75 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.0 0.429 . . . . 0.0 110.287 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.449 ' OG1' HD13 ' A' ' 19' ' ' LEU . 18.3 m -61.21 -46.09 91.89 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.618 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.2 t -70.96 -27.5 30.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.925 -179.243 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -69.98 -53.83 15.98 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.849 -0.34 . . . . 0.0 111.485 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.418 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 55.7 mt -70.99 -41.24 76.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.262 -179.362 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.77 -42.17 96.98 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.503 -0.479 . . . . 0.0 109.748 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.4 tp -70.51 -28.59 65.07 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -59.78 -53.84 53.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.237 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.453 HG11 ' CG1' ' A' ' 27' ' ' VAL . 8.6 m -70.45 -34.21 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.066 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -59.74 -49.27 78.38 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.665 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -72.01 -51.7 20.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.114 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 88.9 mt -63.8 -41.54 97.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.563 -179.751 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' B' ' 27' ' ' VAL . . . -60.03 111.43 3.57 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -79.93 88.39 5.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.775 0.322 . . . . 0.0 110.579 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.597 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.29 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 65.7 m . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.5 m -76.59 -74.21 0.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.719 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.439 ' O ' ' O ' ' A' ' 4' ' ' VAL . 90.7 m -167.27 -87.63 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.796 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' A' ' 3' ' ' THR . 39.2 t 41.23 96.8 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.66 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.425 ' O ' ' N ' ' A' ' 7' ' ' GLY . 2.2 p -81.53 153.28 70.83 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.026 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -64.8 69.59 0.25 Allowed 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 122.15 1.9 . . . . 0.0 111.696 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 5' ' ' SER . . . -70.14 -55.54 9.03 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.471 HG13 ' N ' ' A' ' 9' ' ' LEU . 13.6 p -65.14 -44.8 95.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.85 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.573 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.4 mm? -55.23 -48.72 73.52 Favored 'General case' 0 CA--C 1.543 0.696 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.591 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.19 -36.9 76.18 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.984 0.897 . . . . 0.0 109.558 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.01 -36.07 92.35 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.692 HG21 HG12 ' B' ' 13' ' ' VAL . 39.3 mm -66.72 -43.67 89.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.95 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -56.7 -42.44 76.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 118.513 -1.275 . . . . 0.0 108.651 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.6 t -55.64 -42.54 69.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.33 -32.04 81.42 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -61.61 -47.23 86.4 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.448 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.1 mp -61.04 -38.87 87.68 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.022 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.5 t -62.41 -42.25 94.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.917 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.593 HD13 ' OG1' ' B' ' 20' ' ' THR . 16.2 mt -65.55 -45.65 82.55 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.751 0.31 . . . . 0.0 110.878 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.0 m -57.26 -51.58 68.78 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.24 -178.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.1 t -71.03 -34.2 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.267 -0.424 . . . . 0.0 112.003 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.7 tp -64.91 -56.46 13.16 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -68.6 -41.73 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 120.03 -0.668 . . . . 0.0 109.252 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.56 -40.42 71.9 Favored 'General case' 0 CA--C 1.523 -0.091 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.566 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.82 80.1 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.52 -53.89 52.12 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.723 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.505 HG12 ' CG1' ' B' ' 27' ' ' VAL . 2.5 m -66.58 -43.04 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.622 -179.14 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.437 ' N ' HG23 ' A' ' 27' ' ' VAL . 81.3 t80 -59.09 -48.66 80.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.403 -179.011 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -67.93 -56.54 8.63 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.916 -0.314 . . . . 0.0 111.114 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 41.7 tp -175.39 78.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.026 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -43.6 149.64 0.68 Allowed Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.059 -0.817 . . . . 0.0 111.059 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 44.5 mmm-85 -59.21 -30.77 68.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.763 0.316 . . . . 0.0 110.267 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 9.9 tp . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.479 179.91 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.504 ' C ' ' H ' ' B' ' 3' ' ' THR . 2.0 p . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.418 ' OG ' ' O ' ' B' ' 1' ' ' CYS . 3.5 p 71.77 -17.34 0.35 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.732 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.522 ' O ' ' N ' ' B' ' 5' ' ' SER . 4.5 m 44.97 49.98 9.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.617 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 33.5 m 34.2 29.53 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.82 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.522 ' N ' ' O ' ' B' ' 3' ' ' THR . 40.0 m -166.59 72.46 1.13 Allowed Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.843 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -50.0 130.78 28.59 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.317 2.011 . . . . 0.0 111.771 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -46.17 -36.81 7.48 Favored Glycine 0 C--N 1.331 0.276 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.8 p -68.62 -40.83 82.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.601 -0.299 . . . . 0.0 110.367 179.228 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.573 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.8 mm? -66.96 -49.16 66.31 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.989 179.383 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.37 -28.89 68.55 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.838 0.828 . . . . 0.0 109.349 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.17 -33.98 69.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 76.4 mt -72.25 -37.63 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.686 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.692 HG12 HG21 ' A' ' 12' ' ' ILE . 3.0 m -69.47 -43.99 80.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.741 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.431 HG13 ' N ' ' B' ' 15' ' ' GLY . 5.7 p -61.44 -42.41 93.73 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 118.943 -1.103 . . . . 0.0 109.101 178.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 15' ' ' GLY . . . . . 0.431 ' N ' HG13 ' B' ' 14' ' ' VAL . . . -66.19 -27.95 73.33 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.505 ' OD1' HD12 ' A' ' 19' ' ' LEU . 47.3 t0 -65.42 -47.0 77.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.282 0.563 . . . . 0.0 109.639 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -59.41 -40.97 88.36 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.664 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -67.75 -24.34 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.686 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 tt -71.28 -53.25 14.94 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.095 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.593 ' OG1' HD13 ' A' ' 19' ' ' LEU . 23.8 m -59.67 -46.68 88.32 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.634 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -65.93 -43.73 92.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.739 -179.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.9 tp -58.53 -56.09 26.69 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -178.367 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 35.7 mt -65.61 -41.7 91.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.959 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -32.9 64.63 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.485 0.66 . . . . 0.0 109.462 178.287 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.498 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -69.23 -42.3 75.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.278 179.524 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.98 -53.7 52.31 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.791 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.505 ' CG1' HG12 ' A' ' 27' ' ' VAL . 15.4 m -58.94 -43.28 88.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 C-N-CA 120.171 -0.612 . . . . 0.0 110.487 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.92 -40.97 81.71 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.902 0.382 . . . . 0.0 110.553 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.8 t80 -61.81 -44.93 95.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 94.1 mt -56.91 -38.03 72.28 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.461 -179.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.31 125.91 38.75 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 58.5 ttt85 -70.8 92.49 0.9 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.823 0.344 . . . . 0.0 110.55 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.607 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.281 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.1 m . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.6 m -69.45 149.52 48.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.608 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 10.5 m -64.2 -46.09 85.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.755 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.425 ' O ' HG11 ' B' ' 4' ' ' VAL . 9.3 t 49.17 55.35 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.141 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.6 p -91.69 148.23 36.8 Favored Pre-proline 0 CA--C 1.532 0.284 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.288 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.448 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 72.3 Cg_endo -74.56 78.98 2.62 Favored 'Trans proline' 0 N--CA 1.496 1.644 0 C-N-CA 122.214 1.942 . . . . 0.0 112.262 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -73.0 -63.11 2.93 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.43 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.2 p -63.98 -43.9 97.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.185 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.624 ' HB3' HD12 ' B' ' 9' ' ' LEU . 3.4 mm? -54.32 -48.75 70.99 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 121.253 0.549 . . . . 0.0 109.64 178.442 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.448 ' HB2' ' O ' ' A' ' 6' ' ' PRO . . . -56.73 -39.28 73.67 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.909 0.861 . . . . 0.0 109.275 179.475 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.02 -35.02 90.11 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.626 HG21 HG12 ' B' ' 13' ' ' VAL . 39.8 mm -66.41 -44.25 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 120.434 -0.507 . . . . 0.0 111.065 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.527 HG12 HG21 ' B' ' 12' ' ' ILE . 1.0 OUTLIER -59.41 -41.06 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 118.544 -1.262 . . . . 0.0 109.089 179.774 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.1 t -54.5 -42.09 57.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.65 -33.37 86.49 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.744 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -58.86 -49.74 76.61 Favored 'General case' 0 CA--C 1.52 -0.207 0 CA-C-O 121.025 0.44 . . . . 0.0 109.848 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.494 HD12 ' N ' ' A' ' 17' ' ' LEU . 10.9 mp -61.09 -39.04 88.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.672 179.352 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -60.62 -42.58 92.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.833 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.411 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 62.3 mt -63.85 -43.73 95.27 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.772 0.32 . . . . 0.0 110.785 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -58.0 -51.87 67.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.85 0.357 . . . . 0.0 111.277 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 52.9 t -71.31 -29.03 34.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.628 -179.255 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.49 -51.84 21.57 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.573 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.1 mm -70.23 -38.46 74.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.011 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.18 -44.25 80.15 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.634 -0.427 . . . . 0.0 111.214 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 47.5 tp -70.53 -35.78 73.36 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.377 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.48 -49.78 51.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.865 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 23' ' ' ILE . 21.2 m -68.33 -44.59 83.56 Favored 'Isoleucine or valine' 0 C--O 1.23 0.078 0 C-N-CA 120.049 -0.66 . . . . 0.0 111.193 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.528 ' N ' HG23 ' A' ' 27' ' ' VAL . 58.3 t80 -63.25 -46.89 84.79 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.032 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -61.94 -52.29 64.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.964 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.7 tp -173.71 77.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.177 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.05 129.8 35.27 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.7 mmm-85 -66.04 -39.92 90.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.786 0.327 . . . . 0.0 110.492 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 32.6 tp . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.296 179.941 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.489 ' C ' ' H ' ' B' ' 3' ' ' THR . 7.4 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 3.1 p 73.65 -30.66 0.21 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.743 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.489 ' H ' ' C ' ' B' ' 1' ' ' CYS . 23.5 m 54.71 99.61 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.449 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.425 HG11 ' O ' ' A' ' 4' ' ' VAL . 90.3 t -94.91 115.02 32.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.953 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 30.9 t -152.37 90.96 3.67 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.785 -179.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -80.44 81.59 2.71 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.018 1.812 . . . . 0.0 111.68 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -70.68 -37.98 67.36 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.445 HG13 ' N ' ' B' ' 9' ' ' LEU . 14.7 p -53.46 -42.14 47.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.7 mm? -51.32 -52.2 47.51 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.37 -35.25 65.06 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.914 0.864 . . . . 0.0 109.302 179.284 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.01 -33.97 88.7 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' ILE . . . . . 0.527 HG21 HG12 ' A' ' 13' ' ' VAL . 1.8 mp -71.69 -39.5 69.15 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.923 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.626 HG12 HG21 ' A' ' 12' ' ' ILE . 1.4 m -63.84 -44.92 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 118.526 -1.269 . . . . 0.0 110.314 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -60.59 -35.76 65.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 C-N-CA 118.277 -1.369 . . . . 0.0 107.702 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.48 -30.14 76.01 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.919 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.411 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 3.3 t0 -64.35 -48.61 74.89 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.433 ' N ' HD12 ' B' ' 17' ' ' LEU . 11.1 mp -59.26 -43.99 92.43 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -67.12 -25.46 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.46 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 2.9 tt -70.47 -50.26 39.95 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 120.981 0.419 . . . . 0.0 110.268 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 69.7 m -62.25 -45.3 93.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -68.79 -31.06 49.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.6 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 28.6 tp -68.5 -52.15 35.42 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.833 -178.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 63.9 mt -71.36 -40.62 73.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.487 -179.201 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.74 -40.9 97.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.382 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 49.0 tp -72.82 -31.2 64.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.049 0.452 . . . . 0.0 109.99 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.49 -52.51 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.972 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.404 HG23 ' N ' ' B' ' 28' ' ' TYR . 23.1 m -70.38 -36.33 66.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.815 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 28' ' ' TYR . . . . . 0.404 ' N ' HG23 ' B' ' 27' ' ' VAL . 80.2 t80 -62.16 -48.67 79.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.551 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -63.27 -47.66 81.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.78 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 59.8 mt -63.72 -40.75 97.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.54 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -46.29 -24.17 1.47 Allowed Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 73.5 ttp85 50.98 80.13 0.08 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.834 0.349 . . . . 0.0 110.538 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 33' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.151 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 15.3 m . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.9 t -151.14 -88.18 0.07 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.395 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.402 ' H ' HG23 ' A' ' 3' ' ' THR . 21.7 p -62.84 -144.97 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.511 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 3.2 t 59.34 34.94 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 121.331 0.586 . . . . 0.0 109.636 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.28 159.13 85.74 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.809 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -73.97 59.33 4.34 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 C-N-CA 122.377 2.051 . . . . 0.0 111.759 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.17 -56.75 16.26 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.402 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.7 p -64.94 -41.8 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 120.577 -0.449 . . . . 0.0 109.928 179.547 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.489 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.0 mm? -59.17 -49.39 78.04 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.787 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.29 -36.96 66.71 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 122.158 0.98 . . . . 0.0 108.82 179.032 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.12 -37.71 95.37 Favored Glycine 0 CA--C 1.521 0.43 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.43 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.4 mm -64.53 -43.42 96.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.632 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -57.5 -44.64 85.23 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.552 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -54.98 -39.78 50.84 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.186 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.13 -35.11 91.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -58.08 -49.44 76.92 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-O 121.159 0.504 . . . . 0.0 109.693 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.495 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.0 -39.01 88.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.769 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.74 -38.92 81.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.984 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.479 HD22 ' OG1' ' B' ' 20' ' ' THR . 72.5 mt -67.65 -39.09 84.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.761 0.315 . . . . 0.0 110.633 -179.809 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.3 m -61.73 -51.85 66.66 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.635 -0.426 . . . . 0.0 111.19 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.5 t -72.76 -29.6 30.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.765 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.2 tp -72.38 -52.25 16.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.441 -178.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.75 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.5 mm -68.75 -38.98 79.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.066 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.47 -42.69 78.38 Favored 'General case' 0 C--N 1.333 -0.138 0 C-N-CA 120.755 -0.378 . . . . 0.0 111.262 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.2 tp -70.53 -36.77 73.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.996 0.426 . . . . 0.0 110.331 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.56 -49.38 48.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.824 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.75 HG22 ' O ' ' A' ' 23' ' ' ILE . 28.8 m -69.04 -41.82 81.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.451 -178.854 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.451 ' N ' HG23 ' A' ' 27' ' ' VAL . 77.6 t80 -64.66 -46.07 84.07 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.73 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.0 t80 -61.6 -51.1 69.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.02 -179.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 42.5 tp -172.4 76.47 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.309 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -70.24 127.98 18.4 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 31.1 mmm-85 -82.86 100.53 10.41 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.763 0.316 . . . . 0.0 110.432 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 51.5 tp . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.405 -179.983 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 2.1 p . . . . . 0 N--CA 1.489 1.478 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 90.0 p 44.51 24.9 0.11 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.666 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 3.4 m 48.33 41.73 16.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.313 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 3.6 t 39.06 72.34 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.717 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 32.2 t -147.84 77.83 10.05 Favored Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.268 -179.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_exo -46.13 101.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.582 2.188 . . . . 0.0 111.816 179.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -46.79 -29.46 4.3 Favored Glycine 0 C--N 1.332 0.342 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.429 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 5.6 p -61.68 -42.88 95.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.489 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.5 mm? -60.96 -48.5 81.53 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 119.723 -0.791 . . . . 0.0 109.628 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.71 -35.65 56.04 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 122.131 0.967 . . . . 0.0 108.877 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.58 -42.88 99.84 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 114.293 -1.322 . . . . 0.0 110.084 179.233 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.34 -29.12 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 C-N-CA 120.357 -0.537 . . . . 0.0 109.832 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 61.4 t -64.2 -57.03 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.826 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 p -57.8 -28.14 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.2 -31.9 78.67 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 178.461 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -65.6 -46.06 80.79 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.468 ' N ' HD12 ' B' ' 17' ' ' LEU . 8.0 mp -58.87 -44.3 91.05 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.424 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -68.9 -23.05 26.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.064 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.484 ' O ' HD13 ' B' ' 19' ' ' LEU . 0.3 OUTLIER -70.05 -55.47 9.43 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.016 0.436 . . . . 0.0 110.412 -179.353 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.479 ' OG1' HD22 ' A' ' 19' ' ' LEU . 77.2 m -61.56 -43.9 98.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.3 t -67.04 -38.46 81.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.623 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 30.0 tp -63.13 -51.66 65.62 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 47.0 mt -69.34 -39.73 79.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 119.964 -0.695 . . . . 0.0 110.397 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.2 -44.79 96.72 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.583 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -71.73 -27.55 63.07 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.03 -53.78 44.5 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.649 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.451 HG11 HG21 ' A' ' 27' ' ' VAL . 33.2 m -71.01 -38.81 73.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.321 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 28' ' ' TYR . . . . . 0.451 ' N ' HG23 ' B' ' 27' ' ' VAL . 48.6 t80 -60.75 -48.64 80.87 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.494 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -62.52 -45.95 90.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.667 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 52.8 mt -61.28 -41.39 96.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.414 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.84 101.9 1.07 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 72.1 ttt180 -64.36 87.11 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.801 0.334 . . . . 0.0 110.467 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.607 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.272 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.6 m . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 72.7 m -68.88 154.28 42.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.551 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 24.3 m -46.5 103.13 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.542 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 23.7 m -75.17 -158.94 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.552 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.2 p -135.47 99.5 11.8 Favored Pre-proline 0 CA--C 1.535 0.376 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.32 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -79.47 27.87 0.52 Allowed 'Trans proline' 0 N--CA 1.488 1.168 0 C-N-CA 121.838 1.692 . . . . 0.0 112.089 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.38 -57.14 4.79 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.402 HG13 HD22 ' A' ' 9' ' ' LEU . 6.9 p -56.47 -27.73 25.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.967 0.413 . . . . 0.0 109.952 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.561 HD13 HG11 ' B' ' 13' ' ' VAL . 3.4 mm? -61.61 -48.74 79.53 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.718 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.5 -39.38 83.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 122.258 1.028 . . . . 0.0 109.172 179.1 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.45 -37.24 92.93 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 114.592 -1.185 . . . . 0.0 110.174 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 4.9 mm -66.14 -43.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.888 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.53 -43.07 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 118.907 -1.117 . . . . 0.0 108.486 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 66.9 t -55.18 -41.49 60.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.006 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.46 -30.94 79.1 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.796 178.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -61.4 -49.32 77.38 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.506 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.0 mp -61.8 -40.17 94.27 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.591 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -61.51 -43.19 96.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.225 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.0 mt -64.31 -45.83 86.22 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 10.7 m -57.11 -51.86 67.6 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.883 0.373 . . . . 0.0 110.913 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.6 t -71.89 -27.68 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.882 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 42.4 tp -72.09 -52.65 15.81 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.568 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.1 mm -69.8 -38.77 76.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.317 -0.553 . . . . 0.0 109.885 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.37 -42.94 82.61 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.327 -179.366 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.2 tp -70.63 -38.01 73.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.901 0.381 . . . . 0.0 110.214 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.49 -49.27 64.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.746 -179.131 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' ' 23' ' ' ILE . 18.3 m -70.28 -39.67 77.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.285 -178.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.411 ' N ' HG23 ' A' ' 27' ' ' VAL . 88.0 t80 -63.51 -46.52 85.71 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.898 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -64.69 -53.96 39.23 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.336 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.6 tp -173.89 77.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.88 0.372 . . . . 0.0 110.201 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -57.46 164.91 6.51 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 34.8 mmm-85 -68.0 -8.41 37.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.749 0.309 . . . . 0.0 110.324 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 54.9 tp . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.391 -179.993 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 37.0 t . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 8.3 p 48.05 65.45 1.31 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.471 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 60.3 m 53.23 99.56 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.511 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 20.6 m -65.32 -33.8 66.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.83 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.502 ' O ' ' N ' ' B' ' 7' ' ' GLY . 0.0 OUTLIER -71.24 169.84 13.75 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.243 -179.813 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -42.54 88.22 0.01 OUTLIER 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.33 2.02 . . . . 0.0 112.019 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' B' ' 5' ' ' SER . . . -47.18 -28.26 4.21 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.548 HG13 ' N ' ' B' ' 9' ' ' LEU . 14.4 p -58.92 -43.46 88.63 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.548 ' N ' HG13 ' B' ' 8' ' ' VAL . 0.6 OUTLIER -54.27 -48.52 71.12 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.488 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.416 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -54.59 -38.06 66.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -35.6 91.29 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.166 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -69.47 -38.84 77.78 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 CA-C-O 119.111 -0.471 . . . . 0.0 111.131 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.561 HG11 HD13 ' A' ' 9' ' ' LEU . 1.2 m -65.71 -45.65 91.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.651 -179.545 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.405 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -60.84 -32.73 52.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 C-N-CA 118.285 -1.366 . . . . 0.0 107.524 178.374 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.9 -28.64 72.88 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.703 178.355 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.0 t0 -65.33 -49.26 70.12 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.475 ' N ' HD12 ' B' ' 17' ' ' LEU . 10.6 mp -59.95 -42.28 93.72 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.14 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.405 HG23 ' O ' ' B' ' 14' ' ' VAL . 96.6 t -67.2 -26.4 36.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.348 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.422 HD23 ' O ' ' B' ' 19' ' ' LEU . 2.0 tt -70.65 -48.58 54.2 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.938 0.399 . . . . 0.0 110.228 -179.478 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 12.1 m -62.59 -45.61 92.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.679 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.9 t -70.22 -27.5 32.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.622 -179.23 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 27.4 tp -70.86 -53.13 16.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.758 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 55.0 mt -71.08 -38.98 73.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -65.77 -41.6 91.84 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.584 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -72.56 -31.68 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.028 0.442 . . . . 0.0 109.979 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.31 -52.35 54.64 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.037 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' B' ' 31' ' ' GLY . 28.3 m -70.81 -37.41 68.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.979 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 28' ' ' TYR . . . . . 0.426 ' N ' HG23 ' B' ' 27' ' ' VAL . 80.6 t80 -61.32 -49.31 77.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.619 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -64.11 -48.66 75.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.788 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 48.3 mt -71.93 -25.79 62.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.387 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' B' ' 27' ' ' VAL . . . -61.57 -148.9 0.01 OUTLIER Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.0 ttt85 -163.88 78.19 0.39 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.781 0.324 . . . . 0.0 110.552 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.589 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.304 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.0 p . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.2 m -154.79 114.92 3.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.525 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 32.9 m -164.9 76.72 0.3 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.631 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 22.2 t -144.47 -22.49 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.292 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.435 ' O ' HG12 ' A' ' 8' ' ' VAL . 50.8 m 53.74 63.81 7.44 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.872 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.59 -6.95 18.24 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.644 2.229 . . . . 0.0 112.097 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -62.61 -32.62 84.0 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 5' ' ' SER . 7.4 p -56.08 -42.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.172 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.504 ' HB3' HD12 ' B' ' 9' ' ' LEU . 3.1 mm? -56.66 -48.59 77.24 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.81 -37.6 60.12 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-O 122.107 0.956 . . . . 0.0 108.824 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.49 -39.55 97.97 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.6 mm -61.91 -40.2 86.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.687 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 13' ' ' VAL . 0.6 OUTLIER -62.92 -42.4 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 C-N-CA 119.257 -0.977 . . . . 0.0 109.276 -179.993 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.432 ' O ' HG23 ' A' ' 18' ' ' VAL . 99.5 t -53.44 -44.59 55.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.197 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.1 -32.36 83.81 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.3 179.135 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.434 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 16.6 t0 -61.8 -51.46 68.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.772 0.32 . . . . 0.0 110.538 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.476 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.1 mp -61.15 -38.3 85.93 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.36 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 78.2 t -64.32 -33.33 62.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.29 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.437 HD22 ' OG1' ' B' ' 20' ' ' THR . 35.6 mt -72.71 -49.55 30.5 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.134 -179.305 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.1 m -59.6 -48.62 80.94 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.097 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.0 t -70.74 -38.57 73.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.3 tp -62.53 -54.58 37.68 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.712 -0.395 . . . . 0.0 111.753 -178.457 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.3 mm -69.04 -41.87 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.82 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.6 -39.51 73.7 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.446 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.9 tp -69.96 -37.05 75.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.3 -53.6 52.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.422 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.45 HG23 ' N ' ' A' ' 28' ' ' TYR . 5.4 m -67.84 -40.83 84.3 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.514 -179.301 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.45 ' N ' HG23 ' A' ' 27' ' ' VAL . 75.4 t80 -59.68 -46.67 88.35 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.921 -179.654 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.9 t80 -63.42 -52.8 60.0 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.972 -179.582 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 52.1 tp -174.42 78.11 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.8 0.333 . . . . 0.0 110.494 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.93 160.58 41.85 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -78.68 13.16 1.74 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.784 0.326 . . . . 0.0 110.528 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 12.4 tp . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.404 -179.975 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 25.9 t -157.68 -32.65 0.08 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.524 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 86.9 m 47.17 96.22 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.7 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.493 HG13 ' O ' ' B' ' 4' ' ' VAL . 14.6 p -92.03 125.13 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.129 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.036 179.773 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 10.9 t -161.15 60.68 1.28 Allowed Pre-proline 0 C--N 1.332 -0.192 0 C-N-CA 120.893 -0.323 . . . . 0.0 111.287 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -66.78 84.7 0.3 Allowed 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.54 2.16 . . . . 0.0 111.583 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -52.02 -30.84 31.45 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.477 HG13 ' N ' ' B' ' 9' ' ' LEU . 8.8 p -60.79 -44.6 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.601 -0.44 . . . . 0.0 109.912 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.504 HD12 ' HB3' ' A' ' 9' ' ' LEU . 2.9 mm? -58.57 -48.52 80.66 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 119.919 -0.713 . . . . 0.0 109.295 179.062 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.74 -33.36 55.49 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.561 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.37 -39.73 98.11 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.8 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.05 -25.51 27.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.463 -0.368 . . . . 0.0 110.135 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t -68.13 -53.84 26.5 Favored 'Isoleucine or valine' 0 C--O 1.243 0.73 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.554 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.485 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -58.86 -31.26 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 178.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.96 -26.12 73.26 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -68.23 -60.9 2.12 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 111.761 0.282 . . . . 0.0 111.761 -178.633 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.728 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.39 -24.37 62.93 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.57 -179.684 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.485 HG23 ' O ' ' B' ' 14' ' ' VAL . 17.9 t -68.82 -38.37 78.65 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.281 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.434 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 15.6 mt -64.43 -50.16 68.68 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.309 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.437 ' OG1' HD22 ' A' ' 19' ' ' LEU . 13.9 m -58.26 -50.58 73.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.775 -178.622 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.8 t -71.39 -27.04 27.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.757 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 20.9 tp -69.84 -57.09 5.49 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.212 -178.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 14.0 mt -70.82 -39.54 75.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.21 -39.49 90.42 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 109.895 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.1 tp -70.31 -33.21 71.26 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.02 -51.61 68.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.548 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -64.07 -40.71 90.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -59.54 -46.33 89.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.582 -179.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 85.3 t80 -62.43 -46.8 86.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.806 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 67.4 mt -62.43 -42.04 99.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.517 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.7 77.56 0.1 OUTLIER Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 51.9 ptt85 -65.83 176.29 1.65 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.321 . . . . 0.0 110.668 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.601 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.237 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.53 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 83.9 m . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.7 m -73.42 154.63 39.92 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.58 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 77.6 p -47.53 108.76 0.17 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.531 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.3 t -65.51 -24.38 34.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.409 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.5 m 58.45 59.76 5.88 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.803 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_endo -76.29 12.88 1.44 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.712 2.274 . . . . 0.0 111.503 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -61.82 -36.59 92.99 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.8 p -55.37 -45.94 78.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.164 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.575 HD12 ' HB3' ' B' ' 9' ' ' LEU . 2.9 mm? -51.7 -48.8 63.39 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.424 ' O ' HG22 ' A' ' 13' ' ' VAL . . . -55.96 -37.73 69.43 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.078 0.942 . . . . 0.0 109.427 179.087 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.85 -37.99 94.59 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.652 HG21 HG12 ' B' ' 13' ' ' VAL . 1.9 mp -66.57 -40.87 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.32 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.424 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -57.82 -42.02 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 118.664 -1.214 . . . . 0.0 108.759 179.691 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.409 ' O ' HG23 ' A' ' 18' ' ' VAL . 89.6 t -55.54 -43.34 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.416 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.2 -33.83 87.18 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.06 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 19.7 t0 -60.02 -51.17 70.81 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 120.949 0.404 . . . . 0.0 110.361 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.477 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.1 mp -60.38 -37.87 82.12 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.5 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 14' ' ' VAL . 75.5 t -64.01 -33.91 65.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.302 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.534 HD22 ' OG1' ' B' ' 20' ' ' THR . 51.7 mt -71.72 -46.97 56.96 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.94 -0.304 . . . . 0.0 111.231 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.7 m -59.59 -49.39 77.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.871 -179.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.8 t -70.94 -35.43 59.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.404 -179.009 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.79 -55.7 18.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.746 -0.381 . . . . 0.0 111.763 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 mm -68.77 -40.96 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.638 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.55 -39.51 76.83 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.621 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.5 tp -69.37 -37.06 77.43 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.55 39.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.579 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.511 HG23 ' N ' ' A' ' 28' ' ' TYR . 4.6 m -66.23 -43.9 91.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 C-N-CA 120.413 -0.515 . . . . 0.0 111.696 -179.078 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.511 ' N ' HG23 ' A' ' 27' ' ' VAL . 73.1 t80 -59.02 -45.4 90.79 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.78 -179.389 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -61.46 -50.91 70.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.082 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 45.8 tp -172.5 76.72 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.416 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -72.33 157.31 52.75 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 92.8 mtt-85 -77.44 144.44 37.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.817 0.341 . . . . 0.0 110.463 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 25.7 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.38 -179.982 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.53 ' SG ' ' N ' ' A' ' 1' ' ' CYS . 36.3 t . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.454 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 14.4 t -61.72 -43.09 99.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.523 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 67.8 m 51.88 96.24 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.485 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 15.5 m -65.5 -168.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.68 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 13.6 t -160.38 62.28 1.73 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.691 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -73.72 54.07 2.91 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.482 2.121 . . . . 0.0 111.57 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.06 -46.69 90.59 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.438 ' H ' HG12 ' B' ' 8' ' ' VAL . 1.5 p -63.48 -44.92 98.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.29 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.575 ' HB3' HD12 ' A' ' 9' ' ' LEU . 3.7 mm? -61.09 -50.16 74.37 Favored 'General case' 0 C--O 1.239 0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 110.233 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.406 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.71 -37.42 70.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 122.053 0.93 . . . . 0.0 109.222 179.086 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.98 -36.77 93.35 Favored Glycine 0 CA--C 1.519 0.297 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 89.9 mt -66.04 -42.79 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 120.242 -0.583 . . . . 0.0 111.3 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.652 HG12 HG21 ' A' ' 12' ' ' ILE . 1.0 OUTLIER -60.25 -38.73 78.46 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 118.558 -1.257 . . . . 0.0 108.793 179.25 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.466 ' O ' HG23 ' B' ' 18' ' ' VAL . 95.1 t -57.51 -35.98 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 177.174 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.45 -25.4 75.39 Favored Glycine 0 CA--C 1.533 1.183 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.945 178.371 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -69.35 -60.95 2.0 Allowed 'General case' 0 C--O 1.237 0.413 0 O-C-N 122.479 -0.424 . . . . 0.0 111.776 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.736 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.12 -24.42 63.19 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 119.039 -1.064 . . . . 0.0 110.382 -179.6 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.518 ' N ' HD22 ' B' ' 17' ' ' LEU . 7.2 t -66.07 -45.08 91.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.381 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 38.1 mt -63.35 -49.43 73.92 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.033 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.534 ' OG1' HD22 ' A' ' 19' ' ' LEU . 10.4 m -56.54 -50.73 71.01 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.507 -0.477 . . . . 0.0 111.293 -178.666 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 96.5 t -67.57 -43.05 87.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.167 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 36.0 tp -57.9 -57.83 11.05 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -178.216 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 29.0 mt -64.67 -41.82 93.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.716 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.53 -32.33 62.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.421 0.629 . . . . 0.0 109.601 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.485 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.06 -43.4 71.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.426 179.662 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.67 -53.1 59.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.722 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.436 ' CG1' HG12 ' A' ' 27' ' ' VAL . 17.1 m -60.29 -41.83 88.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.647 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -58.64 -42.76 89.03 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.556 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -61.29 -44.6 96.95 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.824 -179.794 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 95.3 mt -59.28 -42.33 90.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.512 -179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -77.28 128.29 8.89 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -70.73 94.88 1.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.734 0.302 . . . . 0.0 110.584 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.585 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.431 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 50.4 m . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 40.8 t -158.24 172.16 18.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.441 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 33.0 m -60.69 122.94 16.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.542 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 10.1 t -90.15 97.92 7.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.394 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.8 p -79.86 148.53 68.78 Favored Pre-proline 0 CA--C 1.534 0.332 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.375 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.93 40.54 0.95 Allowed 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 122.213 1.942 . . . . 0.0 112.312 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -70.4 -60.52 4.69 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.249 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.449 HG13 ' N ' ' A' ' 9' ' ' LEU . 8.1 p -62.99 -43.14 98.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.436 -0.506 . . . . 0.0 109.759 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.506 ' HB3' HD12 ' B' ' 9' ' ' LEU . 2.7 mm? -57.38 -47.41 81.75 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.681 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.44 -38.56 59.48 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.147 0.975 . . . . 0.0 108.482 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -40.07 98.51 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 114.487 -1.233 . . . . 0.0 110.639 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.6 mm -60.61 -41.53 88.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.516 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -61.29 -43.95 97.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.291 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.7 t -52.6 -45.75 48.12 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 178.718 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.35 80.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -60.54 -48.48 81.61 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.459 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.2 mp -61.77 -40.93 96.9 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.5 t -59.44 -41.88 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.707 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.517 HD13 ' OG1' ' B' ' 20' ' ' THR . 57.4 mt -64.5 -44.7 90.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -57.52 -51.64 68.62 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -71.73 -24.19 23.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.781 -179.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 52.9 tp -70.17 -56.44 6.84 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.774 -178.692 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.3 mm -73.06 -38.09 54.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.552 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.19 -38.51 86.78 Favored 'General case' 0 N--CA 1.457 -0.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.074 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.5 tp -70.59 -36.65 73.67 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.39 -54.41 37.13 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.172 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.52 HG23 ' N ' ' A' ' 28' ' ' TYR . 17.8 m -66.31 -42.47 90.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.292 -179.499 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.52 ' N ' HG23 ' A' ' 27' ' ' VAL . 83.9 t80 -60.35 -45.15 94.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.797 0.332 . . . . 0.0 110.867 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.2 t80 -62.0 -52.87 62.24 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.101 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.8 tp -174.28 78.57 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.739 0.304 . . . . 0.0 110.447 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -58.19 157.26 18.45 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 31.9 mmm-85 -71.56 134.13 46.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.905 0.383 . . . . 0.0 110.515 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.9 tp . . . . . 0 C--N 1.331 -0.21 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.664 179.916 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.422 ' SG ' ' N ' ' B' ' 2' ' ' SER . 26.8 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.422 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 77.1 p -83.18 66.56 8.79 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.61 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 41.9 m -80.18 121.88 26.13 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.395 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 14.5 p -167.08 143.17 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.583 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 177.73 162.71 0.58 Allowed Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.212 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_exo -33.58 92.39 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 123.079 2.519 . . . . 0.0 112.588 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -58.06 -29.41 62.36 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.446 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.438 HG13 ' N ' ' B' ' 9' ' ' LEU . 7.2 p -58.69 -41.09 81.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.506 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.5 mm? -56.89 -50.52 72.27 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.17 -30.99 40.4 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.22 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.82 -34.47 87.35 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 178.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 12' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.7 mp -74.02 -29.3 25.2 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.448 -0.31 . . . . 0.0 110.902 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -72.0 -45.6 63.02 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.689 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.41 ' O ' HD13 ' B' ' 17' ' ' LEU . 3.4 p -62.09 -39.66 84.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 C-N-CA 119.778 -0.769 . . . . 0.0 108.944 178.815 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.92 -29.02 71.13 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -66.47 -62.6 1.38 Allowed 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.757 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -63.93 -27.5 69.18 Favored 'General case' 0 C--O 1.232 0.146 0 C-N-CA 119.039 -1.064 . . . . 0.0 109.759 -179.891 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.526 ' N ' HD22 ' B' ' 17' ' ' LEU . 6.8 t -68.57 -28.86 41.87 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.342 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.529 HD23 ' O ' ' B' ' 19' ' ' LEU . 3.1 tt -69.17 -55.46 10.58 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.092 0.472 . . . . 0.0 110.142 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.517 ' OG1' HD13 ' A' ' 19' ' ' LEU . 7.5 m -57.43 -46.15 83.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.317 -179.514 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 87.2 t -68.26 -41.98 84.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.831 -178.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.1 tp -59.45 -57.18 14.09 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 54.0 mt -64.74 -42.04 93.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 120.206 -0.598 . . . . 0.0 109.903 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.36 -32.2 56.36 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.496 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -69.8 -45.29 68.26 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.522 179.327 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.81 -52.01 58.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.744 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 16.3 m -63.51 -41.56 93.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.017 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -57.5 -45.75 84.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.34 . . . . 0.0 110.565 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 57.0 t80 -62.28 -46.17 89.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.658 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 88.5 mt -61.81 -41.9 98.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.409 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.18 122.86 10.05 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -70.88 93.82 1.01 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 0.0 110.548 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.603 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.281 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.2 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 70.2 m -159.57 -6.58 0.06 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.554 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 6.1 m -160.67 -61.31 0.06 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.402 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.8 t 61.71 6.59 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.361 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.8 m 53.05 79.21 0.36 Allowed Pre-proline 0 N--CA 1.463 0.218 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.382 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.406 ' CD ' ' H ' ' A' ' 7' ' ' GLY . 44.6 Cg_endo -94.5 -41.81 0.02 OUTLIER 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 123.273 2.649 . . . . 0.0 112.417 179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.406 ' H ' ' CD ' ' A' ' 6' ' ' PRO . . . -63.89 -29.61 75.31 Favored Glycine 0 CA--C 1.526 0.767 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.998 -179.072 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.557 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.5 p -59.31 -48.91 85.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.831 -179.27 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.557 ' N ' HG13 ' A' ' 8' ' ' VAL . 2.8 mm? -51.81 -46.84 64.42 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.078 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.98 -41.61 71.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.851 0.834 . . . . 0.0 108.838 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.33 -29.87 69.91 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.591 HG21 HG12 ' B' ' 13' ' ' VAL . 42.5 mm -70.29 -42.71 78.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.51 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.53 -42.31 80.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.145 179.272 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -55.06 -42.76 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.255 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.75 -33.08 83.96 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.803 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -58.95 -50.52 73.77 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.047 0.451 . . . . 0.0 109.925 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.505 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.35 -39.27 89.97 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.907 179.587 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.21 -42.09 85.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.738 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.489 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 35.7 mt -65.72 -45.12 83.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.701 0.286 . . . . 0.0 111.198 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.2 m -56.29 -53.04 61.98 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.088 -178.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 65.9 t -71.9 -27.3 27.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.819 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.8 tp -72.15 -51.4 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -178.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.593 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.9 mm -70.37 -37.49 70.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.753 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.46 -43.78 80.22 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.083 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -71.94 -32.92 67.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.089 0.471 . . . . 0.0 110.246 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.41 -50.61 36.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.698 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.593 HG22 ' O ' ' A' ' 23' ' ' ILE . 22.8 m -68.98 -42.86 82.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.625 -0.43 . . . . 0.0 111.332 -178.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.505 ' N ' HG23 ' A' ' 27' ' ' VAL . 49.1 t80 -63.07 -47.05 84.59 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.699 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.5 t80 -64.21 -53.78 43.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.187 -179.484 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.9 tp -174.75 78.44 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.311 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -59.71 166.2 10.0 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 35.7 mmm-85 -62.12 -40.22 95.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 0.0 110.487 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 13.2 tp . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.35 179.959 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.573 ' SG ' ' N ' ' B' ' 2' ' ' SER . 51.5 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 2' ' ' SER . . . . . 0.573 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 53.5 m -76.26 -1.11 24.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.612 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 4.8 m 63.56 -69.3 0.08 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.462 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.494 ' N ' ' O ' ' B' ' 2' ' ' SER . 21.7 t 44.61 65.32 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.111 0.481 . . . . 0.0 109.928 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 5' ' ' SER . . . . . 0.534 ' O ' ' N ' ' B' ' 7' ' ' GLY . 73.7 m -133.81 57.99 29.13 Favored Pre-proline 0 N--CA 1.465 0.31 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.356 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 6' ' ' PRO . . . . . 0.406 ' C ' ' O ' ' B' ' 5' ' ' SER . 7.5 Cg_exo -34.45 88.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.49 1.294 0 C-N-CA 122.743 2.296 . . . . 0.0 111.627 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 7' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' B' ' 5' ' ' SER . . . -65.2 -43.08 95.97 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.29 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -57.86 -43.84 85.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.758 -179.475 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 13.7 mt -64.83 -35.02 79.77 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 119.002 -1.079 . . . . 0.0 109.651 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.45 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.47 -39.81 73.83 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.718 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.99 -36.32 92.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 178.369 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.31 -31.31 46.57 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-O 119.155 -0.45 . . . . 0.0 111.518 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.591 HG12 HG21 ' A' ' 12' ' ' ILE . 1.3 m -73.01 -41.58 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.573 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 p -62.37 -37.48 78.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.547 178.026 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.87 -29.38 73.61 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.763 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.489 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.1 t0 -64.08 -49.07 73.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.114 0.483 . . . . 0.0 109.754 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 1.8 mt -59.63 -44.35 93.5 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.084 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.3 t -64.53 -24.61 36.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.541 179.213 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 tt -70.67 -48.51 54.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.929 0.395 . . . . 0.0 110.255 -179.473 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.7 m -61.63 -45.84 92.35 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.555 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.8 t -71.0 -26.49 27.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.668 -179.328 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.2 tp -71.07 -52.88 16.92 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.31 -179.075 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 46.5 mt -69.81 -42.13 79.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.831 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.68 -43.92 97.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.572 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 54.1 tp -72.02 -29.95 64.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.956 0.408 . . . . 0.0 109.988 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.6 -51.66 53.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.046 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.445 HG23 ' N ' ' B' ' 28' ' ' TYR . 26.5 m -70.62 -38.81 74.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.121 -179.387 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 28' ' ' TYR . . . . . 0.445 ' N ' HG23 ' B' ' 27' ' ' VAL . 78.5 t80 -62.59 -48.48 79.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.726 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 83.3 t80 -62.27 -49.77 74.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.904 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 74.7 mt -62.9 -42.06 99.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.42 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.47 107.6 1.57 Allowed Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 72.6 mtp85 -68.38 144.4 54.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.824 0.345 . . . . 0.0 110.6 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.598 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.2 mm? . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.243 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.46 ' C ' ' H ' ' A' ' 3' ' ' THR . 8.5 p . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.3 t -76.08 32.82 0.12 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.627 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.46 ' H ' ' C ' ' A' ' 1' ' ' CYS . 26.5 m -60.85 -45.46 94.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.54 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' A' ' 5' ' ' SER . 98.9 t -78.25 -86.12 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.394 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 4' ' ' VAL . 3.8 p 59.06 150.51 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.143 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.13 69.16 4.86 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.034 1.823 . . . . 0.0 111.984 179.859 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.57 -56.62 10.92 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.495 HG13 ' N ' ' A' ' 9' ' ' LEU . 8.4 p -66.05 -44.98 91.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.309 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.501 ' HB3' HD12 ' B' ' 9' ' ' LEU . 2.1 mm? -57.64 -47.61 81.76 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.19 -38.27 68.15 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.082 0.944 . . . . 0.0 108.521 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.89 -37.52 93.87 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.119 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 44.2 mm -62.76 -43.23 98.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.811 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -60.69 -43.42 94.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.576 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 18' ' ' VAL . 88.7 t -53.5 -42.39 49.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.335 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -34.66 90.54 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 178.465 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -57.23 -50.31 73.26 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 120.754 0.312 . . . . 0.0 110.177 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.503 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.0 mp -61.39 -40.19 93.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.487 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 14' ' ' VAL . 78.7 t -62.11 -39.57 84.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.524 HD13 ' OG1' ' B' ' 20' ' ' THR . 46.7 mt -67.04 -44.23 80.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.453 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.1 m -59.76 -51.59 69.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.175 -179.077 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.3 t -71.83 -27.98 29.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.187 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -68.99 -56.48 7.66 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.716 -178.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -70.47 -39.88 76.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.323 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.99 -39.82 82.97 Favored 'General case' 0 CA--C 1.521 -0.167 0 C-N-CA 120.867 -0.333 . . . . 0.0 110.714 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.9 tp -69.72 -37.48 76.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.59 -53.7 52.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.771 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.519 HG23 ' N ' ' A' ' 28' ' ' TYR . 6.4 m -67.53 -43.13 87.42 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.744 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.519 ' N ' HG23 ' A' ' 27' ' ' VAL . 62.8 t80 -59.29 -46.97 87.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.083 -179.355 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -67.09 -55.84 12.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.148 -179.306 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 48.2 tp -174.56 77.66 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.315 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -50.36 115.74 3.53 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -74.09 133.91 42.89 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.678 0.275 . . . . 0.0 110.579 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.5 tt . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.598 -179.985 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 42.1 t . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 22.3 p -159.2 -22.71 0.07 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.597 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 16.3 m 46.67 81.14 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.559 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 10.5 m -73.42 142.54 14.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.336 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 13.6 t -144.46 60.6 7.83 Favored Pre-proline 0 N--CA 1.465 0.312 0 CA-C-O 120.822 0.344 . . . . 0.0 110.887 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -78.39 75.49 4.89 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.954 2.436 . . . . 0.0 111.529 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -63.19 -34.98 91.44 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.48 HG13 HD22 ' B' ' 9' ' ' LEU . 14.3 p -55.13 -43.09 68.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.501 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.8 mm? -54.55 -52.47 61.96 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 120.391 -0.524 . . . . 0.0 109.765 179.239 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -51.41 -36.33 43.12 Favored 'General case' 0 C--O 1.241 0.658 0 CA-C-O 121.968 0.89 . . . . 0.0 109.11 179.201 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -37.79 95.12 Favored Glycine 0 CA--C 1.524 0.624 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.123 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.174 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 33.2 t -69.64 -52.82 28.39 Favored 'Isoleucine or valine' 0 C--O 1.246 0.901 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.491 178.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -58.53 -32.38 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.418 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.344 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.3 -25.2 75.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -69.79 -61.72 1.67 Allowed 'General case' 0 C--O 1.235 0.334 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.503 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.737 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -67.52 -23.47 65.46 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 118.368 -1.333 . . . . 0.0 109.954 -179.557 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.494 ' N ' HD22 ' B' ' 17' ' ' LEU . 9.4 t -70.32 -38.91 75.82 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.863 177.497 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.476 HD23 ' O ' ' B' ' 19' ' ' LEU . 1.9 tt -66.47 -52.07 50.13 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 120.996 0.427 . . . . 0.0 110.531 -179.219 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.524 ' OG1' HD13 ' A' ' 19' ' ' LEU . 9.7 m -58.8 -49.01 79.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.025 -179.398 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 72.0 t -65.24 -42.01 92.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.609 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 35.6 tp -57.73 -56.51 21.0 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 112.006 0.372 . . . . 0.0 112.006 -178.394 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 52.7 mt -66.02 -41.71 90.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 120.084 -0.646 . . . . 0.0 110.082 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.45 -31.72 62.17 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.32 0.581 . . . . 0.0 109.484 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.457 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.77 -44.56 66.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.25 179.541 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.38 -51.97 56.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.661 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.436 ' CG1' HG12 ' A' ' 27' ' ' VAL . 18.0 m -63.04 -40.67 89.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.742 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.09 -47.93 79.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.83 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -62.29 -45.58 92.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.872 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 73.9 mt -61.9 -42.03 98.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.452 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.33 91.64 0.47 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 61.0 ttt85 -47.33 97.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.745 0.307 . . . . 0.0 110.452 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.62 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.391 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.404 ' CB ' ' H1 ' ' B' ' 1' ' ' CYS . 4.4 m . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.6 m -67.87 141.41 56.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.445 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.547 ' O ' ' N ' ' A' ' 5' ' ' SER . 68.8 p -81.09 -16.39 53.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.599 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 5' ' ' SER . 59.1 t 52.91 -82.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.401 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.547 ' N ' ' O ' ' A' ' 3' ' ' THR . 5.5 m 59.83 143.61 0.05 OUTLIER Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.623 179.499 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 61.7 Cg_endo -73.55 82.23 1.7 Allowed 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.153 1.902 . . . . 0.0 112.252 179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.31 -64.35 2.42 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 179.388 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.428 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.7 p -64.52 -45.29 96.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.147 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.602 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.8 mm? -51.32 -49.48 61.28 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.339 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.454 ' HB2' ' O ' ' A' ' 6' ' ' PRO . . . -57.3 -37.5 72.56 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-O 121.968 0.889 . . . . 0.0 109.302 179.223 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.13 -38.49 94.46 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.641 HG21 HG12 ' B' ' 13' ' ' VAL . 1.8 mp -66.26 -44.02 91.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.378 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.19 -42.62 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 118.568 -1.253 . . . . 0.0 108.652 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.405 ' O ' HG23 ' A' ' 18' ' ' VAL . 95.6 t -55.21 -42.31 65.19 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 178.09 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.56 -32.9 84.88 Favored Glycine 0 CA--C 1.53 1.012 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.131 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -61.24 -49.59 76.47 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.84 0.352 . . . . 0.0 110.179 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.483 ' N ' HD12 ' A' ' 17' ' ' LEU . 10.5 mp -61.53 -38.57 87.89 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.402 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.405 HG23 ' O ' ' A' ' 14' ' ' VAL . 74.6 t -62.57 -41.44 92.09 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.265 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.009 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.484 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 36.6 mt -65.56 -44.61 86.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.749 0.309 . . . . 0.0 111.019 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.3 m -59.16 -51.48 69.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.229 -179.122 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.7 t -71.92 -30.59 37.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.754 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 35.4 tp -69.0 -52.87 24.24 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.698 -178.652 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.472 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.5 mm -69.9 -42.45 79.79 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.682 0 C-N-CA 119.713 -0.795 . . . . 0.0 109.25 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.88 93.02 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.435 -179.271 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 42.4 tp -70.1 -36.34 74.79 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.601 -179.632 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.19 -51.5 30.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.236 -178.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.472 HG22 ' O ' ' A' ' 23' ' ' ILE . 14.2 m -69.37 -41.02 80.71 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 C-N-CA 120.441 -0.503 . . . . 0.0 111.366 -178.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.443 ' N ' HG23 ' A' ' 27' ' ' VAL . 89.4 t80 -65.67 -45.9 81.16 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.91 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.5 t80 -63.36 -52.54 61.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.07 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 20.5 tp -173.15 77.29 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.111 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.98 151.37 47.8 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 33.6 mmm-85 -71.98 -16.39 62.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.831 0.348 . . . . 0.0 110.55 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 12.1 tp . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.347 -179.941 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 1' ' ' CYS . . . . . 0.467 ' C ' ' H ' ' B' ' 3' ' ' THR . 27.6 p . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 4.6 p 64.65 -2.12 0.7 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.579 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.467 ' H ' ' C ' ' B' ' 1' ' ' CYS . 20.5 m 46.2 89.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.634 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 4' ' ' VAL . . . . . 0.454 HG11 ' H ' ' A' ' 5' ' ' SER . 46.4 t -105.66 85.75 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 41.4 m -130.19 93.41 33.33 Favored Pre-proline 0 CA--C 1.536 0.41 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.817 -179.213 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -80.71 89.88 1.27 Allowed 'Trans proline' 0 N--CA 1.491 1.376 0 C-N-CA 122.235 1.957 . . . . 0.0 111.732 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.57 -35.65 92.2 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 8' ' ' VAL . . . . . 0.521 HG13 ' N ' ' B' ' 9' ' ' LEU . 8.5 p -54.39 -43.89 64.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.602 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.3 mm? -53.43 -50.47 65.16 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.432 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -54.67 -33.66 61.1 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 121.781 0.8 . . . . 0.0 109.156 178.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.33 -35.55 92.1 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.172 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -72.72 -33.12 43.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.169 -0.443 . . . . 0.0 111.296 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.641 HG12 HG21 ' A' ' 12' ' ' ILE . 1.9 m -70.32 -41.48 78.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 118.884 -1.127 . . . . 0.0 110.378 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 p -63.27 -38.06 81.11 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 C-N-CA 118.623 -1.231 . . . . 0.0 108.087 178.073 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.59 -29.43 73.96 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 178.635 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.484 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 5.3 t0 -64.67 -49.39 71.15 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.198 0.523 . . . . 0.0 109.631 179.816 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -58.82 -43.24 90.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.54 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.77 -24.39 30.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.102 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.418 HD23 ' O ' ' B' ' 19' ' ' LEU . 2.3 tt -70.54 -51.64 27.29 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 121.07 0.462 . . . . 0.0 110.139 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 20' ' ' THR . . . . . 0.467 ' OG1' HD13 ' A' ' 19' ' ' LEU . 7.8 m -60.79 -48.89 79.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.626 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -63.66 -42.54 96.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.286 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 26.7 tp -57.36 -54.02 51.56 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 23' ' ' ILE . . . . . 0.405 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 59.3 mt -64.02 -44.84 97.9 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.494 -178.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.52 -36.78 67.1 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 25' ' ' LEU . . . . . 0.492 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -66.39 -39.23 88.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.268 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 26' ' ' ALA . . . . . 0.405 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -53.6 -55.65 23.96 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.262 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.415 HG11 ' CG1' ' A' ' 27' ' ' VAL . 12.7 m -63.68 -37.54 79.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 C-N-CA 119.387 -0.925 . . . . 0.0 111.02 179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -56.65 -47.36 79.95 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.568 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -62.6 -47.64 82.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.784 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 74.8 mt -62.67 -41.92 99.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.647 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' B' ' 33' ' ' LEU . . . -61.17 114.53 6.77 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 74.4 ttt180 -62.31 82.61 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.866 0.365 . . . . 0.0 110.475 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.599 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.4 mm? . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.396 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 72.1 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.401 ' O ' ' OG1' ' A' ' 3' ' ' THR . 68.1 m -76.53 -80.08 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.644 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.401 ' OG1' ' O ' ' A' ' 2' ' ' SER . 23.9 m -166.41 -27.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.644 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 47.0 t 52.96 94.17 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.65 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.4 p -78.02 135.18 63.05 Favored Pre-proline 0 CA--C 1.538 0.5 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.255 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.466 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 91.2 Cg_endo -79.07 75.91 4.82 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 121.998 1.799 . . . . 0.0 112.351 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -72.91 -64.8 2.45 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.4 p -65.32 -38.98 83.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.282 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.621 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.9 mm? -57.57 -46.27 84.17 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.337 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 6' ' ' PRO . . . -58.59 -40.93 84.56 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 122.1 0.952 . . . . 0.0 109.441 179.257 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.16 -38.87 93.74 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.596 HG21 HG12 ' B' ' 13' ' ' VAL . 36.0 mm -63.98 -42.76 96.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.653 -179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.416 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -57.04 -42.67 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 C-N-CA 118.789 -1.164 . . . . 0.0 108.864 179.651 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.433 ' O ' HG23 ' A' ' 18' ' ' VAL . 57.6 t -54.26 -45.08 67.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 119.485 -0.886 . . . . 0.0 108.769 178.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -33.27 86.78 Favored Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.407 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 15.0 t0 -62.12 -51.98 65.69 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.774 0.321 . . . . 0.0 110.706 -179.425 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.455 ' N ' HD12 ' A' ' 17' ' ' LEU . 10.8 mp -60.93 -37.79 83.56 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.571 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 14' ' ' VAL . 64.4 t -64.3 -33.19 61.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.141 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.401 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 27.3 mt -73.43 -46.7 46.94 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.188 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.0 m -60.28 -49.14 78.8 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.073 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -71.93 -37.27 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.9 tp -63.1 -55.18 27.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.408 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.426 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.6 mm -67.98 -44.68 84.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.684 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.46 -42.18 66.91 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 43.3 tp -66.96 -38.25 85.76 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.961 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.66 -50.87 71.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.243 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.434 HG22 HG11 ' B' ' 27' ' ' VAL . 3.0 t -68.7 -45.88 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 C-N-CA 120.614 -0.435 . . . . 0.0 111.497 -179.371 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -58.1 -47.82 82.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.42 -178.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 58.8 t80 -69.52 -56.9 6.06 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.239 -179.295 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.503 ' O ' ' N ' ' A' ' 32' ' ' ARG . 57.7 tp -177.9 80.34 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -42.2 92.03 0.01 OUTLIER Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.503 ' N ' ' O ' ' A' ' 30' ' ' LEU . 33.5 mmm-85 -61.32 -34.93 76.05 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.684 0.278 . . . . 0.0 110.455 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 9.4 tp . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.53 -179.879 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 21.3 m 57.0 98.5 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.624 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 7.0 m 60.12 121.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.703 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 74.2 t -145.38 113.6 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.242 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -177.96 154.3 0.96 Allowed Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.54 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -59.82 107.96 0.44 Allowed 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.612 2.208 . . . . 0.0 112.116 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.62 -34.55 90.2 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 179.494 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.71 -35.04 53.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 9' ' ' LEU . . . . . 0.621 ' HB3' HD12 ' A' ' 9' ' ' LEU . 1.6 mm? -62.47 -46.78 86.96 Favored 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.129 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.0 -32.32 69.6 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.89 -32.93 84.25 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 178.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 88.9 mt -72.77 -34.7 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-O 119.091 -0.48 . . . . 0.0 111.812 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.596 HG12 HG21 ' A' ' 12' ' ' ILE . 1.4 m -69.54 -44.85 79.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 119.025 -1.07 . . . . 0.0 109.95 179.266 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 14' ' ' VAL . . . . . 0.512 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -60.09 -33.73 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.61 -25.9 74.18 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 178.329 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.401 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 9.3 t70 -69.08 -61.49 1.77 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -178.391 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.747 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -68.15 -25.82 65.46 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.238 -179.724 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.512 HG23 ' O ' ' B' ' 14' ' ' VAL . 14.6 t -66.74 -39.2 83.13 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.462 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 14.2 mt -63.29 -47.31 82.86 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.157 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 10.3 m -57.55 -50.26 73.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.561 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -72.31 -28.49 29.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.0 tp -68.51 -56.62 7.74 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.456 -0.498 . . . . 0.0 111.311 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 30.1 mt -69.82 -41.69 79.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.471 -0.491 . . . . 0.0 109.991 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -38.82 77.82 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.127 0.489 . . . . 0.0 109.73 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -69.54 -35.75 75.73 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.675 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.6 -51.76 68.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.518 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.434 HG11 HG22 ' A' ' 27' ' ' VAL . 16.4 m -64.99 -38.26 82.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.656 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.9 t80 -57.97 -48.57 79.58 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.472 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -62.96 -46.07 89.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.866 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 72.8 mt -62.24 -42.21 99.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.649 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -54.0 95.18 0.02 OUTLIER Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 76.4 ttt180 -72.73 89.97 1.38 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.834 0.35 . . . . 0.0 110.573 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.601 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.306 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.82 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.415 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.7 p -55.6 -39.81 56.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 C-N-CA 120.614 -0.434 . . . . 0.0 109.851 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.571 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.6 mm? -52.86 -50.3 64.06 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.96 -38.77 73.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 122.029 0.919 . . . . 0.0 109.028 179.116 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.75 -35.6 90.16 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.657 HG21 HG12 ' B' ' 13' ' ' VAL . 42.0 mm -67.44 -43.16 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.792 -179.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.45 -42.69 81.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.516 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -55.85 -43.36 74.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.32 -30.44 76.1 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.56 -48.31 80.04 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.455 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.2 mp -60.36 -39.76 88.31 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.0 t -60.66 -40.72 85.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.742 179.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.483 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.0 mt -64.48 -44.44 91.0 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.784 0.326 . . . . 0.0 110.921 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 m -59.81 -52.31 66.0 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.695 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.4 t -72.31 -27.92 27.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -178.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 29.6 tp -69.38 -56.17 8.25 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.498 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.2 mm -70.03 -40.73 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.567 -179.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.86 -39.22 80.7 Favored 'General case' 0 C--O 1.231 0.111 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.171 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.6 tp -69.56 -35.46 75.42 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.48 -56.01 19.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.223 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.508 HG23 ' N ' ' A' ' 28' ' ' TYR . 7.6 m -65.41 -43.15 94.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.113 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.68 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.508 ' N ' HG23 ' A' ' 27' ' ' VAL . 91.5 t80 -61.01 -45.35 95.17 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.951 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.3 t80 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.198 -179.416 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.791 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.535 HG13 ' N ' ' B' ' 9' ' ' LEU . 7.6 p -57.78 -48.2 84.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.382 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.571 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.2 mm? -51.1 -46.74 61.95 Favored 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.32 -29.7 70.05 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.851 0.834 . . . . 0.0 109.34 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.67 -35.62 86.21 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -70.31 -45.21 76.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 119.298 -0.382 . . . . 0.0 111.218 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.657 HG12 HG21 ' A' ' 12' ' ' ILE . 3.0 m -60.94 -40.52 85.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 C-N-CA 118.529 -1.268 . . . . 0.0 109.602 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 71.4 t -55.95 -45.38 80.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -26.12 69.78 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.483 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 10.5 t70 -66.3 -48.73 69.41 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.469 ' N ' HD12 ' B' ' 17' ' ' LEU . 11.2 mp -61.52 -39.61 91.67 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -66.89 -29.86 47.7 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.162 179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.421 ' O ' HD23 ' B' ' 19' ' ' LEU . 3.5 tt -71.37 -52.57 17.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.982 0.42 . . . . 0.0 110.543 -179.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.478 ' OG1' HD13 ' A' ' 19' ' ' LEU . 19.8 m -59.14 -46.09 89.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.874 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -69.76 -30.94 46.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.2 tp -68.47 -55.3 12.28 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.368 -178.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 16.9 mt -71.77 -39.97 69.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.439 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -62.1 -36.35 81.44 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.021 0.439 . . . . 0.0 110.024 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 33.6 tp -71.24 -37.51 71.99 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.34 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.783 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 35.7 m -65.87 -36.86 78.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.855 -0.338 . . . . 0.0 110.792 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.3 t80 -60.18 -47.51 85.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 70.1 t80 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.622 179.962 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.562 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.577 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.0 p -63.91 -47.14 91.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.615 ' HB3' HD12 ' B' ' 9' ' ' LEU . 1.5 mm? -55.48 -48.78 74.02 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.603 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.95 -37.93 67.09 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.06 -36.1 92.42 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 43.8 mm -65.15 -45.67 93.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.32 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.5 HG12 HG21 ' B' ' 12' ' ' ILE . 0.9 OUTLIER -58.95 -41.26 82.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.085 179.921 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.5 t -55.7 -40.32 59.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -32.6 84.72 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 178.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.51 -48.82 80.16 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.474 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.19 -39.8 91.55 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.662 179.256 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 69.8 t -60.24 -43.47 93.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.713 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.449 HD13 ' OG1' ' B' ' 20' ' ' THR . 32.8 mt -62.36 -43.69 98.22 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.911 0.386 . . . . 0.0 110.481 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -56.93 -51.41 69.25 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.077 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -69.3 -34.91 65.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 32.6 tp -64.61 -57.62 8.59 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -178.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.5 mm -68.47 -38.35 79.11 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.493 -179.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.65 -39.65 77.5 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.455 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.28 -38.36 78.32 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.41 -53.53 53.55 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.46 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.492 HG23 ' N ' ' A' ' 28' ' ' TYR . 29.2 m -62.56 -46.03 97.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.612 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.492 ' N ' HG23 ' A' ' 27' ' ' VAL . 83.9 t80 -61.19 -43.87 98.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.308 -179.211 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.4 t80 . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.157 -179.247 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.596 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.414 HG13 HD22 ' B' ' 9' ' ' LEU . 14.7 p -51.83 -38.54 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.573 -0.451 . . . . 0.0 109.875 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.615 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.8 mm? -55.19 -51.08 67.66 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.6 -39.56 64.98 Favored 'General case' 0 C--O 1.242 0.663 0 CA-C-O 121.862 0.839 . . . . 0.0 109.506 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.86 -43.02 94.93 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 114.568 -1.196 . . . . 0.0 110.147 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . 0.5 HG21 HG12 ' A' ' 13' ' ' VAL . 1.8 mp -62.44 -42.38 95.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.493 0 C-N-CA 120.208 -0.597 . . . . 0.0 109.452 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 44.0 t -49.65 -50.85 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 C-N-CA 119.94 -0.704 . . . . 0.0 109.146 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.02 -33.85 47.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' B' ' 12' ' ' ILE . . . -64.95 -39.91 96.81 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.412 ' C ' ' OD1' ' B' ' 16' ' ' ASP . 8.1 t0 -61.68 -45.47 93.86 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.14 0.495 . . . . 0.0 109.932 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.43 ' O ' HG23 ' B' ' 21' ' ' VAL . 7.5 mt -61.19 -42.54 98.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.519 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.0 t -71.86 -26.47 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.403 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.0 tt -73.56 -54.14 8.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.449 ' OG1' HD13 ' A' ' 19' ' ' LEU . 18.6 m -60.11 -45.89 91.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.298 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . 0.43 HG23 ' O ' ' B' ' 17' ' ' LEU . 92.3 t -66.29 -44.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.838 -179.25 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.8 tp -58.97 -57.93 10.91 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 13.4 mt -65.93 -40.44 87.47 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.948 -179.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.22 -33.07 65.01 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.429 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -68.68 -43.81 75.35 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.414 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.44 -52.91 42.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.676 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.0 m -63.16 -42.07 95.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.809 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -55.39 -46.77 76.52 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.38 . . . . 0.0 110.782 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 86.4 t80 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.754 -179.906 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.771 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -49.2 -42.25 15.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.065 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.521 HD12 ' HB3' ' B' ' 9' ' ' LEU . 4.1 mm? -52.16 -52.48 51.63 Favored 'General case' 0 CA--C 1.537 0.474 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.222 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.4 -37.85 62.86 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.09 0.947 . . . . 0.0 109.145 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.89 -37.42 94.33 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.711 -1.132 . . . . 0.0 110.311 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.527 HG21 HG12 ' B' ' 13' ' ' VAL . 43.0 mm -65.3 -43.19 95.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.011 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -57.53 -43.15 82.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 C-N-CA 119.016 -1.074 . . . . 0.0 108.601 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.3 t -54.68 -43.79 67.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.19 -32.45 82.58 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -60.57 -48.91 79.69 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.466 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -62.08 -38.41 88.71 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.217 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.5 t -61.89 -41.81 92.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.99 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.486 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.9 mt -66.57 -43.7 84.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.87 0.367 . . . . 0.0 110.998 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.1 m -60.85 -51.51 68.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.308 -178.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 90.9 t -71.76 -32.33 44.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.143 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.3 tp -66.48 -56.27 11.71 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.712 -178.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.0 mm -69.1 -41.78 81.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.298 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.94 -40.98 77.44 Favored 'General case' 0 N--CA 1.46 0.056 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.651 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.12 79.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.04 -54.04 49.69 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.698 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.494 HG23 ' N ' ' A' ' 28' ' ' TYR . 3.5 m -68.1 -43.57 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.722 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.494 ' N ' HG23 ' A' ' 27' ' ' VAL . 69.7 t80 -58.72 -48.66 80.39 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.168 -178.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.2 t80 . . . . . 0 C--N 1.328 -0.336 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.195 -179.35 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.732 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.593 HG13 ' N ' ' B' ' 9' ' ' LEU . 15.0 p -62.53 -48.52 87.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.593 ' N ' HG13 ' B' ' 8' ' ' VAL . 1.8 mm? -51.68 -47.49 63.83 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.7 -33.87 70.67 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-O 121.841 0.829 . . . . 0.0 108.883 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.86 -33.79 88.19 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -72.83 -36.19 51.52 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 119.267 -0.397 . . . . 0.0 111.275 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.527 HG12 HG21 ' A' ' 12' ' ' ILE . 1.6 m -68.18 -40.93 83.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 118.886 -1.125 . . . . 0.0 110.517 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 p -64.57 -38.68 83.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 118.747 -1.181 . . . . 0.0 108.42 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.35 -28.93 73.74 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.486 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 7.8 t0 -65.42 -48.03 74.21 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.2 mt -59.79 -42.26 92.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.688 179.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 95.0 t -69.0 -24.5 28.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.181 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.3 tt -71.97 -53.57 12.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.085 0.469 . . . . 0.0 110.222 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.435 ' OG1' HD13 ' A' ' 19' ' ' LEU . 11.5 m -59.48 -46.34 89.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.564 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.5 t -66.18 -43.72 91.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.699 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.7 tp -57.92 -56.57 20.24 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 34.8 mt -65.52 -41.56 91.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.945 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.95 -31.4 64.94 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 121.355 0.598 . . . . 0.0 109.577 178.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.493 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.44 -43.53 69.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.346 179.701 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.25 -53.61 51.25 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.612 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.445 ' CG1' HG12 ' A' ' 27' ' ' VAL . 18.3 m -59.91 -41.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.726 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -58.96 -40.76 85.7 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.449 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 77.5 t80 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.111 -179.793 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.635 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.546 HG13 ' N ' ' A' ' 9' ' ' LEU . 9.7 p -54.37 -46.82 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.159 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.572 HD12 ' HB3' ' B' ' 9' ' ' LEU . 2.9 mm? -53.2 -50.63 64.27 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.415 ' O ' HG22 ' A' ' 13' ' ' VAL . . . -53.53 -36.07 61.4 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.991 0.901 . . . . 0.0 109.07 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.64 -35.7 92.37 Favored Glycine 0 C--N 1.317 -0.503 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.544 HG21 HG12 ' B' ' 13' ' ' VAL . 37.8 mm -66.09 -43.08 92.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.856 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -59.17 -42.07 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 119.111 -1.036 . . . . 0.0 108.715 179.571 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.5 t -54.92 -41.39 57.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.27 -33.36 87.03 Favored Glycine 0 CA--C 1.53 0.987 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.026 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.431 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 8.9 t0 -61.16 -47.68 85.07 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.457 HD12 ' N ' ' A' ' 17' ' ' LEU . 10.9 mp -61.0 -39.57 90.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -60.39 -40.44 84.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.64 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.482 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.6 mt -64.4 -44.66 90.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.774 0.321 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 m -58.09 -51.39 69.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.412 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 62.0 t -71.51 -32.73 47.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.845 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.8 tp -66.73 -53.86 28.9 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.676 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.449 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.0 mm -68.87 -42.14 82.41 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.461 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.12 -41.96 84.74 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.2 -179.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.6 tp -69.09 -38.28 78.89 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.51 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.06 53.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.941 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.505 HG23 ' N ' ' A' ' 28' ' ' TYR . 16.7 m -69.63 -42.24 80.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.552 -179.005 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.505 ' N ' HG23 ' A' ' 27' ' ' VAL . 84.1 t80 -62.13 -44.89 95.65 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.825 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.7 t80 . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.11 -179.57 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.458 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.476 HG13 ' N ' ' B' ' 9' ' ' LEU . 9.0 p -60.36 -44.19 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.572 ' HB3' HD12 ' A' ' 9' ' ' LEU . 3.4 mm? -57.42 -50.29 73.48 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.465 178.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.4 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.02 -29.8 60.91 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.777 0.799 . . . . 0.0 109.348 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.53 -38.33 94.63 Favored Glycine 0 C--N 1.316 -0.532 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 178.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -68.05 -44.04 84.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 120.439 -0.504 . . . . 0.0 111.227 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.544 HG12 HG21 ' A' ' 12' ' ' ILE . 2.1 m -60.67 -37.27 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.675 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 61.6 t -58.68 -43.64 88.1 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -64.45 -32.76 85.28 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.373 178.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.482 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -61.85 -48.38 80.8 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.996 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.9 mt -60.08 -44.39 94.81 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.819 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.87 -25.89 37.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.03 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.431 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 2.7 tt -70.48 -49.41 48.75 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.0 0.429 . . . . 0.0 110.287 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.449 ' OG1' HD13 ' A' ' 19' ' ' LEU . 18.3 m -61.21 -46.09 91.89 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.618 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.2 t -70.96 -27.5 30.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.925 -179.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -69.98 -53.83 15.98 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.849 -0.34 . . . . 0.0 111.485 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.418 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 55.7 mt -70.99 -41.24 76.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.262 -179.362 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.77 -42.17 96.98 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.503 -0.479 . . . . 0.0 109.748 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.4 tp -70.51 -28.59 65.07 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -59.78 -53.84 53.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.237 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.453 HG11 ' CG1' ' A' ' 27' ' ' VAL . 8.6 m -70.45 -34.21 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.066 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -59.74 -49.27 78.38 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.665 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 59.0 t80 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.114 -179.879 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.627 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.471 HG13 ' N ' ' A' ' 9' ' ' LEU . 13.6 p -65.14 -44.8 95.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.85 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.573 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.4 mm? -55.23 -48.72 73.52 Favored 'General case' 0 CA--C 1.543 0.696 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.19 -36.9 76.18 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.984 0.897 . . . . 0.0 109.558 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.01 -36.07 92.35 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.692 HG21 HG12 ' B' ' 13' ' ' VAL . 39.3 mm -66.72 -43.67 89.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.95 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -56.7 -42.44 76.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 118.513 -1.275 . . . . 0.0 108.651 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.6 t -55.64 -42.54 69.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.33 -32.04 81.42 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -61.61 -47.23 86.4 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.448 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.1 mp -61.04 -38.87 87.68 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.022 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.5 t -62.41 -42.25 94.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.917 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.593 HD13 ' OG1' ' B' ' 20' ' ' THR . 16.2 mt -65.55 -45.65 82.55 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.751 0.31 . . . . 0.0 110.878 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.0 m -57.26 -51.58 68.78 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.24 -178.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.1 t -71.03 -34.2 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.267 -0.424 . . . . 0.0 112.003 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.7 tp -64.91 -56.46 13.16 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -68.6 -41.73 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 120.03 -0.668 . . . . 0.0 109.252 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.56 -40.42 71.9 Favored 'General case' 0 CA--C 1.523 -0.091 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.566 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.82 80.1 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.52 -53.89 52.12 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.723 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.505 HG12 ' CG1' ' B' ' 27' ' ' VAL . 2.5 m -66.58 -43.04 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.622 -179.14 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.437 ' N ' HG23 ' A' ' 27' ' ' VAL . 81.3 t80 -59.09 -48.66 80.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.403 -179.011 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 83.5 t80 . . . . . 0 C--N 1.33 -0.282 0 C-N-CA 120.916 -0.314 . . . . 0.0 111.114 -179.214 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.268 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.8 p -68.62 -40.83 82.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.601 -0.299 . . . . 0.0 110.367 179.228 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.573 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.8 mm? -66.96 -49.16 66.31 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.989 179.383 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.37 -28.89 68.55 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.838 0.828 . . . . 0.0 109.349 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.17 -33.98 69.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 76.4 mt -72.25 -37.63 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.686 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.692 HG12 HG21 ' A' ' 12' ' ' ILE . 3.0 m -69.47 -43.99 80.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.741 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.431 HG13 ' N ' ' B' ' 15' ' ' GLY . 5.7 p -61.44 -42.41 93.73 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 118.943 -1.103 . . . . 0.0 109.101 178.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . 0.431 ' N ' HG13 ' B' ' 14' ' ' VAL . . . -66.19 -27.95 73.33 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.505 ' OD1' HD12 ' A' ' 19' ' ' LEU . 47.3 t0 -65.42 -47.0 77.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.282 0.563 . . . . 0.0 109.639 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -59.41 -40.97 88.36 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -67.75 -24.34 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.686 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 tt -71.28 -53.25 14.94 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.095 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.593 ' OG1' HD13 ' A' ' 19' ' ' LEU . 23.8 m -59.67 -46.68 88.32 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.634 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -65.93 -43.73 92.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.739 -179.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.9 tp -58.53 -56.09 26.69 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -178.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 35.7 mt -65.61 -41.7 91.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.959 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -32.9 64.63 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.485 0.66 . . . . 0.0 109.462 178.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.498 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -69.23 -42.3 75.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.278 179.524 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.98 -53.7 52.31 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.791 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.505 ' CG1' HG12 ' A' ' 27' ' ' VAL . 15.4 m -58.94 -43.28 88.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 C-N-CA 120.171 -0.612 . . . . 0.0 110.487 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.92 -40.97 81.71 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.902 0.382 . . . . 0.0 110.553 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.8 t80 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 -179.732 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.664 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.43 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.2 p -63.98 -43.9 97.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.185 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.624 ' HB3' HD12 ' B' ' 9' ' ' LEU . 3.4 mm? -54.32 -48.75 70.99 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 121.253 0.549 . . . . 0.0 109.64 178.442 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.73 -39.28 73.67 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.909 0.861 . . . . 0.0 109.275 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.02 -35.02 90.11 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.626 HG21 HG12 ' B' ' 13' ' ' VAL . 39.8 mm -66.41 -44.25 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 120.434 -0.507 . . . . 0.0 111.065 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.527 HG12 HG21 ' B' ' 12' ' ' ILE . 1.0 OUTLIER -59.41 -41.06 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 118.544 -1.262 . . . . 0.0 109.089 179.774 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.1 t -54.5 -42.09 57.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.65 -33.37 86.49 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.744 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -58.86 -49.74 76.61 Favored 'General case' 0 CA--C 1.52 -0.207 0 CA-C-O 121.025 0.44 . . . . 0.0 109.848 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.494 HD12 ' N ' ' A' ' 17' ' ' LEU . 10.9 mp -61.09 -39.04 88.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.672 179.352 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -60.62 -42.58 92.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.833 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.411 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 62.3 mt -63.85 -43.73 95.27 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.772 0.32 . . . . 0.0 110.785 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -58.0 -51.87 67.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.85 0.357 . . . . 0.0 111.277 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 52.9 t -71.31 -29.03 34.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.628 -179.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.49 -51.84 21.57 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.573 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.1 mm -70.23 -38.46 74.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.011 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.18 -44.25 80.15 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.634 -0.427 . . . . 0.0 111.214 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 47.5 tp -70.53 -35.78 73.36 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.377 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.48 -49.78 51.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.865 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 23' ' ' ILE . 21.2 m -68.33 -44.59 83.56 Favored 'Isoleucine or valine' 0 C--O 1.23 0.078 0 C-N-CA 120.049 -0.66 . . . . 0.0 111.193 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.528 ' N ' HG23 ' A' ' 27' ' ' VAL . 58.3 t80 -63.25 -46.89 84.79 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.032 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.5 t80 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.964 -179.544 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.633 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.445 HG13 ' N ' ' B' ' 9' ' ' LEU . 14.7 p -53.46 -42.14 47.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.7 mm? -51.32 -52.2 47.51 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.37 -35.25 65.06 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.914 0.864 . . . . 0.0 109.302 179.284 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.01 -33.97 88.7 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . 0.527 HG21 HG12 ' A' ' 13' ' ' VAL . 1.8 mp -71.69 -39.5 69.15 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.923 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.626 HG12 HG21 ' A' ' 12' ' ' ILE . 1.4 m -63.84 -44.92 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 118.526 -1.269 . . . . 0.0 110.314 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -60.59 -35.76 65.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 C-N-CA 118.277 -1.369 . . . . 0.0 107.702 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.48 -30.14 76.01 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.919 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.411 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 3.3 t0 -64.35 -48.61 74.89 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.433 ' N ' HD12 ' B' ' 17' ' ' LEU . 11.1 mp -59.26 -43.99 92.43 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -67.12 -25.46 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.46 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 2.9 tt -70.47 -50.26 39.95 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 120.981 0.419 . . . . 0.0 110.268 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 69.7 m -62.25 -45.3 93.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -68.79 -31.06 49.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.6 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 28.6 tp -68.5 -52.15 35.42 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.833 -178.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 63.9 mt -71.36 -40.62 73.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.487 -179.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.74 -40.9 97.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.382 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 49.0 tp -72.82 -31.2 64.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.049 0.452 . . . . 0.0 109.99 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.49 -52.51 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.972 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.404 HG23 ' N ' ' B' ' 28' ' ' TYR . 23.1 m -70.38 -36.33 66.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.815 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . 0.404 ' N ' HG23 ' B' ' 27' ' ' VAL . 80.2 t80 -62.16 -48.67 79.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.551 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.8 t80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.78 -179.866 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.699 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.402 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.7 p -64.94 -41.8 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 120.577 -0.449 . . . . 0.0 109.928 179.547 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.489 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.0 mm? -59.17 -49.39 78.04 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.29 -36.96 66.71 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 122.158 0.98 . . . . 0.0 108.82 179.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.12 -37.71 95.37 Favored Glycine 0 CA--C 1.521 0.43 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.43 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.4 mm -64.53 -43.42 96.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.632 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -57.5 -44.64 85.23 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.552 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -54.98 -39.78 50.84 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.186 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.13 -35.11 91.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -58.08 -49.44 76.92 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-O 121.159 0.504 . . . . 0.0 109.693 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.495 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.0 -39.01 88.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.769 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.74 -38.92 81.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.984 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.479 HD22 ' OG1' ' B' ' 20' ' ' THR . 72.5 mt -67.65 -39.09 84.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.761 0.315 . . . . 0.0 110.633 -179.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.3 m -61.73 -51.85 66.66 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.635 -0.426 . . . . 0.0 111.19 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.5 t -72.76 -29.6 30.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.765 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.2 tp -72.38 -52.25 16.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.441 -178.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.75 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.5 mm -68.75 -38.98 79.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.066 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.47 -42.69 78.38 Favored 'General case' 0 C--N 1.333 -0.138 0 C-N-CA 120.755 -0.378 . . . . 0.0 111.262 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.2 tp -70.53 -36.77 73.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.996 0.426 . . . . 0.0 110.331 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.56 -49.38 48.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.824 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.75 HG22 ' O ' ' A' ' 23' ' ' ILE . 28.8 m -69.04 -41.82 81.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.451 -178.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.451 ' N ' HG23 ' A' ' 27' ' ' VAL . 77.6 t80 -64.66 -46.07 84.07 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.73 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.0 t80 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.02 -179.523 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.204 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.429 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 5.6 p -61.68 -42.88 95.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.489 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.5 mm? -60.96 -48.5 81.53 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 119.723 -0.791 . . . . 0.0 109.628 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.71 -35.65 56.04 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 122.131 0.967 . . . . 0.0 108.877 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.58 -42.88 99.84 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 114.293 -1.322 . . . . 0.0 110.084 179.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.34 -29.12 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 C-N-CA 120.357 -0.537 . . . . 0.0 109.832 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 61.4 t -64.2 -57.03 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.826 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 p -57.8 -28.14 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.2 -31.9 78.67 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 178.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -65.6 -46.06 80.79 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.468 ' N ' HD12 ' B' ' 17' ' ' LEU . 8.0 mp -58.87 -44.3 91.05 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.424 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -68.9 -23.05 26.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.064 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.484 ' O ' HD13 ' B' ' 19' ' ' LEU . 0.3 OUTLIER -70.05 -55.47 9.43 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.016 0.436 . . . . 0.0 110.412 -179.353 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.479 ' OG1' HD22 ' A' ' 19' ' ' LEU . 77.2 m -61.56 -43.9 98.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.3 t -67.04 -38.46 81.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.623 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 30.0 tp -63.13 -51.66 65.62 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 47.0 mt -69.34 -39.73 79.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 119.964 -0.695 . . . . 0.0 110.397 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.2 -44.79 96.72 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.583 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -71.73 -27.55 63.07 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.03 -53.78 44.5 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.649 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.451 HG11 HG21 ' A' ' 27' ' ' VAL . 33.2 m -71.01 -38.81 73.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.321 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . 0.451 ' N ' HG23 ' B' ' 27' ' ' VAL . 48.6 t80 -60.75 -48.64 80.87 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.494 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 t80 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.667 -179.921 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.832 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.402 HG13 HD22 ' A' ' 9' ' ' LEU . 6.9 p -56.47 -27.73 25.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.967 0.413 . . . . 0.0 109.952 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.561 HD13 HG11 ' B' ' 13' ' ' VAL . 3.4 mm? -61.61 -48.74 79.53 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.5 -39.38 83.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 122.258 1.028 . . . . 0.0 109.172 179.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.45 -37.24 92.93 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 114.592 -1.185 . . . . 0.0 110.174 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 4.9 mm -66.14 -43.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.888 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.53 -43.07 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 118.907 -1.117 . . . . 0.0 108.486 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 66.9 t -55.18 -41.49 60.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.46 -30.94 79.1 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.796 178.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -61.4 -49.32 77.38 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.506 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.8 -40.17 94.27 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.591 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -61.51 -43.19 96.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.225 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.0 mt -64.31 -45.83 86.22 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 10.7 m -57.11 -51.86 67.6 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.883 0.373 . . . . 0.0 110.913 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.6 t -71.89 -27.68 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.882 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 42.4 tp -72.09 -52.65 15.81 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.568 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.1 mm -69.8 -38.77 76.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.317 -0.553 . . . . 0.0 109.885 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.37 -42.94 82.61 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.327 -179.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.2 tp -70.63 -38.01 73.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.901 0.381 . . . . 0.0 110.214 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.49 -49.27 64.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.746 -179.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' ' 23' ' ' ILE . 18.3 m -70.28 -39.67 77.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.285 -178.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.411 ' N ' HG23 ' A' ' 27' ' ' VAL . 88.0 t80 -63.51 -46.52 85.71 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.898 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.5 t80 . . . . . 0 C--N 1.331 -0.215 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.336 -179.316 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.382 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.548 HG13 ' N ' ' B' ' 9' ' ' LEU . 14.4 p -58.92 -43.46 88.63 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.548 ' N ' HG13 ' B' ' 8' ' ' VAL . 0.6 OUTLIER -54.27 -48.52 71.12 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.488 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.416 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -54.59 -38.06 66.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -35.6 91.29 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.166 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -69.47 -38.84 77.78 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 CA-C-O 119.111 -0.471 . . . . 0.0 111.131 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.561 HG11 HD13 ' A' ' 9' ' ' LEU . 1.2 m -65.71 -45.65 91.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.651 -179.545 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.405 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -60.84 -32.73 52.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 C-N-CA 118.285 -1.366 . . . . 0.0 107.524 178.374 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.9 -28.64 72.88 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.703 178.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.0 t0 -65.33 -49.26 70.12 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.475 ' N ' HD12 ' B' ' 17' ' ' LEU . 10.6 mp -59.95 -42.28 93.72 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.405 HG23 ' O ' ' B' ' 14' ' ' VAL . 96.6 t -67.2 -26.4 36.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.348 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.422 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.0 tt -70.65 -48.58 54.2 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.938 0.399 . . . . 0.0 110.228 -179.478 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 12.1 m -62.59 -45.61 92.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.679 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.9 t -70.22 -27.5 32.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.622 -179.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 27.4 tp -70.86 -53.13 16.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.758 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 55.0 mt -71.08 -38.98 73.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -65.77 -41.6 91.84 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.584 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -72.56 -31.68 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.028 0.442 . . . . 0.0 109.979 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.31 -52.35 54.64 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.037 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.426 HG23 ' N ' ' B' ' 28' ' ' TYR . 28.3 m -70.81 -37.41 68.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.979 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . 0.426 ' N ' HG23 ' B' ' 27' ' ' VAL . 80.6 t80 -61.32 -49.31 77.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.619 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 67.6 t80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.788 -179.937 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.783 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.415 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.4 p -56.08 -42.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.172 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.504 ' HB3' HD12 ' B' ' 9' ' ' LEU . 3.1 mm? -56.66 -48.59 77.24 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.81 -37.6 60.12 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-O 122.107 0.956 . . . . 0.0 108.824 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.49 -39.55 97.97 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.6 mm -61.91 -40.2 86.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.687 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 13' ' ' VAL . 0.6 OUTLIER -62.92 -42.4 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 C-N-CA 119.257 -0.977 . . . . 0.0 109.276 -179.993 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.432 ' O ' HG23 ' A' ' 18' ' ' VAL . 99.5 t -53.44 -44.59 55.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.1 -32.36 83.81 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.3 179.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.434 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 16.6 t0 -61.8 -51.46 68.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.772 0.32 . . . . 0.0 110.538 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.476 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.1 mp -61.15 -38.3 85.93 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.36 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 78.2 t -64.32 -33.33 62.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.29 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.437 HD22 ' OG1' ' B' ' 20' ' ' THR . 35.6 mt -72.71 -49.55 30.5 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.134 -179.305 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.1 m -59.6 -48.62 80.94 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.097 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.0 t -70.74 -38.57 73.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.3 tp -62.53 -54.58 37.68 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.712 -0.395 . . . . 0.0 111.753 -178.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.3 mm -69.04 -41.87 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.82 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.6 -39.51 73.7 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.446 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.9 tp -69.96 -37.05 75.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.3 -53.6 52.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.422 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.45 HG23 ' N ' ' A' ' 28' ' ' TYR . 5.4 m -67.84 -40.83 84.3 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.514 -179.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.45 ' N ' HG23 ' A' ' 27' ' ' VAL . 75.4 t80 -59.68 -46.67 88.35 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.921 -179.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.9 t80 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.972 -179.582 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.41 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.477 HG13 ' N ' ' B' ' 9' ' ' LEU . 8.8 p -60.79 -44.6 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.601 -0.44 . . . . 0.0 109.912 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.504 HD12 ' HB3' ' A' ' 9' ' ' LEU . 2.9 mm? -58.57 -48.52 80.66 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 119.919 -0.713 . . . . 0.0 109.295 179.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.74 -33.36 55.49 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.561 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.37 -39.73 98.11 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.8 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.05 -25.51 27.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.463 -0.368 . . . . 0.0 110.135 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t -68.13 -53.84 26.5 Favored 'Isoleucine or valine' 0 C--O 1.243 0.73 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.554 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.485 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -58.86 -31.26 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 178.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.96 -26.12 73.26 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -68.23 -60.9 2.12 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 111.761 0.282 . . . . 0.0 111.761 -178.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.728 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.39 -24.37 62.93 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.57 -179.684 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.485 HG23 ' O ' ' B' ' 14' ' ' VAL . 17.9 t -68.82 -38.37 78.65 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.281 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.434 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 15.6 mt -64.43 -50.16 68.68 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.309 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.437 ' OG1' HD22 ' A' ' 19' ' ' LEU . 13.9 m -58.26 -50.58 73.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.775 -178.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.8 t -71.39 -27.04 27.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 20.9 tp -69.84 -57.09 5.49 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.212 -178.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 14.0 mt -70.82 -39.54 75.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.21 -39.49 90.42 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 109.895 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.1 tp -70.31 -33.21 71.26 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.02 -51.61 68.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.548 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -64.07 -40.71 90.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -59.54 -46.33 89.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.582 -179.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 85.3 t80 . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.806 -179.902 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.721 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.8 p -55.37 -45.94 78.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.164 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.575 HD12 ' HB3' ' B' ' 9' ' ' LEU . 2.9 mm? -51.7 -48.8 63.39 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.424 ' O ' HG22 ' A' ' 13' ' ' VAL . . . -55.96 -37.73 69.43 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.078 0.942 . . . . 0.0 109.427 179.087 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.85 -37.99 94.59 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.652 HG21 HG12 ' B' ' 13' ' ' VAL . 1.9 mp -66.57 -40.87 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.32 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.424 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -57.82 -42.02 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 118.664 -1.214 . . . . 0.0 108.759 179.691 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.409 ' O ' HG23 ' A' ' 18' ' ' VAL . 89.6 t -55.54 -43.34 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.2 -33.83 87.18 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.06 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 19.7 t0 -60.02 -51.17 70.81 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 120.949 0.404 . . . . 0.0 110.361 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.477 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.1 mp -60.38 -37.87 82.12 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 14' ' ' VAL . 75.5 t -64.01 -33.91 65.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.302 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.534 HD22 ' OG1' ' B' ' 20' ' ' THR . 51.7 mt -71.72 -46.97 56.96 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.94 -0.304 . . . . 0.0 111.231 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.7 m -59.59 -49.39 77.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.871 -179.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.8 t -70.94 -35.43 59.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.404 -179.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.79 -55.7 18.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.746 -0.381 . . . . 0.0 111.763 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 mm -68.77 -40.96 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.638 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.55 -39.51 76.83 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.621 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.5 tp -69.37 -37.06 77.43 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.55 39.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.579 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.511 HG23 ' N ' ' A' ' 28' ' ' TYR . 4.6 m -66.23 -43.9 91.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 C-N-CA 120.413 -0.515 . . . . 0.0 111.696 -179.078 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.511 ' N ' HG23 ' A' ' 27' ' ' VAL . 73.1 t80 -59.02 -45.4 90.79 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.78 -179.389 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.4 t80 . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.082 -179.698 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.622 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.438 ' H ' HG12 ' B' ' 8' ' ' VAL . 1.5 p -63.48 -44.92 98.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.29 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.575 ' HB3' HD12 ' A' ' 9' ' ' LEU . 3.7 mm? -61.09 -50.16 74.37 Favored 'General case' 0 C--O 1.239 0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 110.233 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.406 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.71 -37.42 70.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 122.053 0.93 . . . . 0.0 109.222 179.086 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.98 -36.77 93.35 Favored Glycine 0 CA--C 1.519 0.297 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 89.9 mt -66.04 -42.79 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 120.242 -0.583 . . . . 0.0 111.3 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.652 HG12 HG21 ' A' ' 12' ' ' ILE . 1.0 OUTLIER -60.25 -38.73 78.46 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 118.558 -1.257 . . . . 0.0 108.793 179.25 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.466 ' O ' HG23 ' B' ' 18' ' ' VAL . 95.1 t -57.51 -35.98 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 177.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.45 -25.4 75.39 Favored Glycine 0 CA--C 1.533 1.183 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.945 178.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -69.35 -60.95 2.0 Allowed 'General case' 0 C--O 1.237 0.413 0 O-C-N 122.479 -0.424 . . . . 0.0 111.776 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.736 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.12 -24.42 63.19 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 119.039 -1.064 . . . . 0.0 110.382 -179.6 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.518 ' N ' HD22 ' B' ' 17' ' ' LEU . 7.2 t -66.07 -45.08 91.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.381 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 38.1 mt -63.35 -49.43 73.92 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.033 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.534 ' OG1' HD22 ' A' ' 19' ' ' LEU . 10.4 m -56.54 -50.73 71.01 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.507 -0.477 . . . . 0.0 111.293 -178.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 96.5 t -67.57 -43.05 87.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.167 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 36.0 tp -57.9 -57.83 11.05 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -178.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 29.0 mt -64.67 -41.82 93.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.716 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.53 -32.33 62.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.421 0.629 . . . . 0.0 109.601 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.485 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.06 -43.4 71.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.426 179.662 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.67 -53.1 59.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.722 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.436 ' CG1' HG12 ' A' ' 27' ' ' VAL . 17.1 m -60.29 -41.83 88.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.647 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -58.64 -42.76 89.03 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.556 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 t80 . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.824 -179.794 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.759 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.449 HG13 ' N ' ' A' ' 9' ' ' LEU . 8.1 p -62.99 -43.14 98.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.436 -0.506 . . . . 0.0 109.759 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.506 ' HB3' HD12 ' B' ' 9' ' ' LEU . 2.7 mm? -57.38 -47.41 81.75 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.681 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.44 -38.56 59.48 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.147 0.975 . . . . 0.0 108.482 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -40.07 98.51 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 114.487 -1.233 . . . . 0.0 110.639 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.6 mm -60.61 -41.53 88.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.516 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -61.29 -43.95 97.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.291 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.7 t -52.6 -45.75 48.12 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 178.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.35 80.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -60.54 -48.48 81.61 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.459 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.2 mp -61.77 -40.93 96.9 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.5 t -59.44 -41.88 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.707 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.517 HD13 ' OG1' ' B' ' 20' ' ' THR . 57.4 mt -64.5 -44.7 90.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -57.52 -51.64 68.62 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -71.73 -24.19 23.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.781 -179.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 52.9 tp -70.17 -56.44 6.84 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.774 -178.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.3 mm -73.06 -38.09 54.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.552 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.19 -38.51 86.78 Favored 'General case' 0 N--CA 1.457 -0.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.074 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.5 tp -70.59 -36.65 73.67 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.39 -54.41 37.13 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.172 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.52 HG23 ' N ' ' A' ' 28' ' ' TYR . 17.8 m -66.31 -42.47 90.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.292 -179.499 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.52 ' N ' HG23 ' A' ' 27' ' ' VAL . 83.9 t80 -60.35 -45.15 94.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.797 0.332 . . . . 0.0 110.867 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.2 t80 . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.101 -179.555 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.397 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.438 HG13 ' N ' ' B' ' 9' ' ' LEU . 7.2 p -58.69 -41.09 81.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.506 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.5 mm? -56.89 -50.52 72.27 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.17 -30.99 40.4 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.82 -34.47 87.35 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 178.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.7 mp -74.02 -29.3 25.2 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.448 -0.31 . . . . 0.0 110.902 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -72.0 -45.6 63.02 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.689 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.41 ' O ' HD13 ' B' ' 17' ' ' LEU . 3.4 p -62.09 -39.66 84.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 C-N-CA 119.778 -0.769 . . . . 0.0 108.944 178.815 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.92 -29.02 71.13 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -66.47 -62.6 1.38 Allowed 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.757 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -63.93 -27.5 69.18 Favored 'General case' 0 C--O 1.232 0.146 0 C-N-CA 119.039 -1.064 . . . . 0.0 109.759 -179.891 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.526 ' N ' HD22 ' B' ' 17' ' ' LEU . 6.8 t -68.57 -28.86 41.87 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.529 ' O ' HD23 ' B' ' 19' ' ' LEU . 3.1 tt -69.17 -55.46 10.58 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.092 0.472 . . . . 0.0 110.142 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.517 ' OG1' HD13 ' A' ' 19' ' ' LEU . 7.5 m -57.43 -46.15 83.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.317 -179.514 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 87.2 t -68.26 -41.98 84.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.831 -178.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.1 tp -59.45 -57.18 14.09 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 54.0 mt -64.74 -42.04 93.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 120.206 -0.598 . . . . 0.0 109.903 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.36 -32.2 56.36 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.496 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -69.8 -45.29 68.26 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.522 179.327 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.81 -52.01 58.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.744 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 16.3 m -63.51 -41.56 93.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.017 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -57.5 -45.75 84.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.34 . . . . 0.0 110.565 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 57.0 t80 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.658 -179.933 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.767 0 N-CA-C 111.998 -0.441 . . . . 0.0 111.998 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.557 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.5 p -59.31 -48.91 85.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.831 -179.27 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.557 ' N ' HG13 ' A' ' 8' ' ' VAL . 2.8 mm? -51.81 -46.84 64.42 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.078 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.98 -41.61 71.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.851 0.834 . . . . 0.0 108.838 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.33 -29.87 69.91 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.591 HG21 HG12 ' B' ' 13' ' ' VAL . 42.5 mm -70.29 -42.71 78.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.51 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.53 -42.31 80.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.145 179.272 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -55.06 -42.76 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.255 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.75 -33.08 83.96 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -58.95 -50.52 73.77 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.047 0.451 . . . . 0.0 109.925 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.505 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.35 -39.27 89.97 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.907 179.587 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.21 -42.09 85.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.738 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.489 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 35.7 mt -65.72 -45.12 83.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.701 0.286 . . . . 0.0 111.198 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.2 m -56.29 -53.04 61.98 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.088 -178.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 65.9 t -71.9 -27.3 27.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.819 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.8 tp -72.15 -51.4 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -178.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.593 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.9 mm -70.37 -37.49 70.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.753 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.46 -43.78 80.22 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.083 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -71.94 -32.92 67.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.089 0.471 . . . . 0.0 110.246 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.41 -50.61 36.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.698 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.593 HG22 ' O ' ' A' ' 23' ' ' ILE . 22.8 m -68.98 -42.86 82.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.625 -0.43 . . . . 0.0 111.332 -178.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.505 ' N ' HG23 ' A' ' 27' ' ' VAL . 49.1 t80 -63.07 -47.05 84.59 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.699 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.5 t80 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.187 -179.484 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.644 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -57.86 -43.84 85.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.758 -179.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 13.7 mt -64.83 -35.02 79.77 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 119.002 -1.079 . . . . 0.0 109.651 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.45 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.47 -39.81 73.83 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.99 -36.32 92.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 178.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.31 -31.31 46.57 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-O 119.155 -0.45 . . . . 0.0 111.518 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.591 HG12 HG21 ' A' ' 12' ' ' ILE . 1.3 m -73.01 -41.58 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.573 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 p -62.37 -37.48 78.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.547 178.026 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.87 -29.38 73.61 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.763 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.489 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.1 t0 -64.08 -49.07 73.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.114 0.483 . . . . 0.0 109.754 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 1.8 mt -59.63 -44.35 93.5 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.084 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.3 t -64.53 -24.61 36.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.541 179.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 tt -70.67 -48.51 54.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.929 0.395 . . . . 0.0 110.255 -179.473 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.7 m -61.63 -45.84 92.35 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.555 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.8 t -71.0 -26.49 27.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.668 -179.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.2 tp -71.07 -52.88 16.92 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.31 -179.075 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 46.5 mt -69.81 -42.13 79.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.831 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.68 -43.92 97.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.572 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 54.1 tp -72.02 -29.95 64.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.956 0.408 . . . . 0.0 109.988 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.6 -51.66 53.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.046 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.445 HG23 ' N ' ' B' ' 28' ' ' TYR . 26.5 m -70.62 -38.81 74.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.121 -179.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . 0.445 ' N ' HG23 ' B' ' 27' ' ' VAL . 78.5 t80 -62.59 -48.48 79.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.726 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 83.3 t80 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.904 -179.911 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.495 HG13 ' N ' ' A' ' 9' ' ' LEU . 8.4 p -66.05 -44.98 91.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.501 ' HB3' HD12 ' B' ' 9' ' ' LEU . 2.1 mm? -57.64 -47.61 81.76 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.19 -38.27 68.15 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.082 0.944 . . . . 0.0 108.521 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.89 -37.52 93.87 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 44.2 mm -62.76 -43.23 98.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.811 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -60.69 -43.42 94.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.576 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 18' ' ' VAL . 88.7 t -53.5 -42.39 49.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.335 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -34.66 90.54 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 178.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -57.23 -50.31 73.26 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 120.754 0.312 . . . . 0.0 110.177 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.503 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.39 -40.19 93.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.487 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 14' ' ' VAL . 78.7 t -62.11 -39.57 84.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.524 HD13 ' OG1' ' B' ' 20' ' ' THR . 46.7 mt -67.04 -44.23 80.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.453 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.1 m -59.76 -51.59 69.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.175 -179.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.3 t -71.83 -27.98 29.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.187 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -68.99 -56.48 7.66 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.716 -178.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -70.47 -39.88 76.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.323 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.99 -39.82 82.97 Favored 'General case' 0 CA--C 1.521 -0.167 0 C-N-CA 120.867 -0.333 . . . . 0.0 110.714 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.9 tp -69.72 -37.48 76.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.59 -53.7 52.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.771 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.519 HG23 ' N ' ' A' ' 28' ' ' TYR . 6.4 m -67.53 -43.13 87.42 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.744 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.519 ' N ' HG23 ' A' ' 27' ' ' VAL . 62.8 t80 -59.29 -46.97 87.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.083 -179.355 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.3 t80 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.148 -179.306 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.48 HG13 HD22 ' B' ' 9' ' ' LEU . 14.3 p -55.13 -43.09 68.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.501 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.8 mm? -54.55 -52.47 61.96 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 120.391 -0.524 . . . . 0.0 109.765 179.239 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -51.41 -36.33 43.12 Favored 'General case' 0 C--O 1.241 0.658 0 CA-C-O 121.968 0.89 . . . . 0.0 109.11 179.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -37.79 95.12 Favored Glycine 0 CA--C 1.524 0.624 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.123 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.174 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 33.2 t -69.64 -52.82 28.39 Favored 'Isoleucine or valine' 0 C--O 1.246 0.901 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.491 178.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -58.53 -32.38 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.418 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.3 -25.2 75.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -69.79 -61.72 1.67 Allowed 'General case' 0 C--O 1.235 0.334 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.737 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -67.52 -23.47 65.46 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 118.368 -1.333 . . . . 0.0 109.954 -179.557 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.494 ' N ' HD22 ' B' ' 17' ' ' LEU . 9.4 t -70.32 -38.91 75.82 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.863 177.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.476 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.9 tt -66.47 -52.07 50.13 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 120.996 0.427 . . . . 0.0 110.531 -179.219 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.524 ' OG1' HD13 ' A' ' 19' ' ' LEU . 9.7 m -58.8 -49.01 79.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.025 -179.398 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 72.0 t -65.24 -42.01 92.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.609 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 35.6 tp -57.73 -56.51 21.0 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 112.006 0.372 . . . . 0.0 112.006 -178.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 52.7 mt -66.02 -41.71 90.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 120.084 -0.646 . . . . 0.0 110.082 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.45 -31.72 62.17 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.32 0.581 . . . . 0.0 109.484 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.457 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.77 -44.56 66.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.25 179.541 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.38 -51.97 56.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.661 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.436 ' CG1' HG12 ' A' ' 27' ' ' VAL . 18.0 m -63.04 -40.67 89.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.742 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.09 -47.93 79.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.83 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 63.9 t80 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.872 -179.914 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.428 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.7 p -64.52 -45.29 96.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.147 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.602 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.8 mm? -51.32 -49.48 61.28 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.339 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.3 -37.5 72.56 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-O 121.968 0.889 . . . . 0.0 109.302 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.13 -38.49 94.46 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.641 HG21 HG12 ' B' ' 13' ' ' VAL . 1.8 mp -66.26 -44.02 91.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.378 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.19 -42.62 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 118.568 -1.253 . . . . 0.0 108.652 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.405 ' O ' HG23 ' A' ' 18' ' ' VAL . 95.6 t -55.21 -42.31 65.19 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 178.09 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.56 -32.9 84.88 Favored Glycine 0 CA--C 1.53 1.012 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.131 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -61.24 -49.59 76.47 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.84 0.352 . . . . 0.0 110.179 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.483 HD12 ' N ' ' A' ' 17' ' ' LEU . 10.5 mp -61.53 -38.57 87.89 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.402 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.405 HG23 ' O ' ' A' ' 14' ' ' VAL . 74.6 t -62.57 -41.44 92.09 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.265 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.009 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.484 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 36.6 mt -65.56 -44.61 86.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.749 0.309 . . . . 0.0 111.019 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.3 m -59.16 -51.48 69.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.229 -179.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.7 t -71.92 -30.59 37.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.754 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 35.4 tp -69.0 -52.87 24.24 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.698 -178.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.472 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.5 mm -69.9 -42.45 79.79 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.682 0 C-N-CA 119.713 -0.795 . . . . 0.0 109.25 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.88 93.02 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.435 -179.271 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 42.4 tp -70.1 -36.34 74.79 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.601 -179.632 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.19 -51.5 30.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.236 -178.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.472 HG22 ' O ' ' A' ' 23' ' ' ILE . 14.2 m -69.37 -41.02 80.71 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 C-N-CA 120.441 -0.503 . . . . 0.0 111.366 -178.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.443 ' N ' HG23 ' A' ' 27' ' ' VAL . 89.4 t80 -65.67 -45.9 81.16 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.91 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.5 t80 . . . . . 0 C--N 1.328 -0.366 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.07 -179.47 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . 0.521 HG13 ' N ' ' B' ' 9' ' ' LEU . 8.5 p -54.39 -43.89 64.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.602 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.3 mm? -53.43 -50.47 65.16 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.432 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -54.67 -33.66 61.1 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 121.781 0.8 . . . . 0.0 109.156 178.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.33 -35.55 92.1 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.172 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -72.72 -33.12 43.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.169 -0.443 . . . . 0.0 111.296 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.641 HG12 HG21 ' A' ' 12' ' ' ILE . 1.9 m -70.32 -41.48 78.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 118.884 -1.127 . . . . 0.0 110.378 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 p -63.27 -38.06 81.11 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 C-N-CA 118.623 -1.231 . . . . 0.0 108.087 178.073 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.59 -29.43 73.96 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 178.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.484 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 5.3 t0 -64.67 -49.39 71.15 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.198 0.523 . . . . 0.0 109.631 179.816 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -58.82 -43.24 90.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.54 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.77 -24.39 30.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.102 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.418 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.3 tt -70.54 -51.64 27.29 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 121.07 0.462 . . . . 0.0 110.139 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . 0.467 ' OG1' HD13 ' A' ' 19' ' ' LEU . 7.8 m -60.79 -48.89 79.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.626 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -63.66 -42.54 96.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.286 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 26.7 tp -57.36 -54.02 51.56 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . 0.405 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 59.3 mt -64.02 -44.84 97.9 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.494 -178.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.52 -36.78 67.1 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . 0.492 ' O ' HD13 ' B' ' 25' ' ' LEU . 0.2 OUTLIER -66.39 -39.23 88.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.268 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . 0.405 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -53.6 -55.65 23.96 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.262 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.415 HG11 ' CG1' ' A' ' 27' ' ' VAL . 12.7 m -63.68 -37.54 79.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 C-N-CA 119.387 -0.925 . . . . 0.0 111.02 179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -56.65 -47.36 79.95 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.568 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.3 t80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.784 -179.969 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.573 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.4 p -65.32 -38.98 83.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.282 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.621 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.9 mm? -57.57 -46.27 84.17 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.416 ' O ' HG22 ' A' ' 13' ' ' VAL . . . -58.59 -40.93 84.56 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 122.1 0.952 . . . . 0.0 109.441 179.257 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.16 -38.87 93.74 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.596 HG21 HG12 ' B' ' 13' ' ' VAL . 36.0 mm -63.98 -42.76 96.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.653 -179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.416 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -57.04 -42.67 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 C-N-CA 118.789 -1.164 . . . . 0.0 108.864 179.651 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.433 ' O ' HG23 ' A' ' 18' ' ' VAL . 57.6 t -54.26 -45.08 67.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 119.485 -0.886 . . . . 0.0 108.769 178.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -33.27 86.78 Favored Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.407 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 15.0 t0 -62.12 -51.98 65.69 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.774 0.321 . . . . 0.0 110.706 -179.425 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.455 HD12 ' N ' ' A' ' 17' ' ' LEU . 10.8 mp -60.93 -37.79 83.56 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 14' ' ' VAL . 64.4 t -64.3 -33.19 61.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.141 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.401 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 27.3 mt -73.43 -46.7 46.94 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.188 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.0 m -60.28 -49.14 78.8 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.073 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -71.93 -37.27 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.9 tp -63.1 -55.18 27.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.408 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.426 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.6 mm -67.98 -44.68 84.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.684 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.46 -42.18 66.91 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 43.3 tp -66.96 -38.25 85.76 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.961 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.66 -50.87 71.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.243 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.434 HG22 HG11 ' B' ' 27' ' ' VAL . 3.0 t -68.7 -45.88 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 C-N-CA 120.614 -0.435 . . . . 0.0 111.497 -179.371 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -58.1 -47.82 82.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.42 -178.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 58.8 t80 . . . . . 0 C--N 1.328 -0.35 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.239 -179.295 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.438 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.71 -35.04 53.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 9' ' ' LEU . . . . . 0.621 ' HB3' HD12 ' A' ' 9' ' ' LEU . 1.6 mm? -62.47 -46.78 86.96 Favored 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.129 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.0 -32.32 69.6 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.89 -32.93 84.25 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 178.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 88.9 mt -72.77 -34.7 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-O 119.091 -0.48 . . . . 0.0 111.812 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.596 HG12 HG21 ' A' ' 12' ' ' ILE . 1.4 m -69.54 -44.85 79.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 119.025 -1.07 . . . . 0.0 109.95 179.266 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 14' ' ' VAL . . . . . 0.512 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -60.09 -33.73 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.61 -25.9 74.18 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 178.329 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.401 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 9.3 t70 -69.08 -61.49 1.77 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -178.391 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.747 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -68.15 -25.82 65.46 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.238 -179.724 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.512 HG23 ' O ' ' B' ' 14' ' ' VAL . 14.6 t -66.74 -39.2 83.13 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.462 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 14.2 mt -63.29 -47.31 82.86 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.157 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 10.3 m -57.55 -50.26 73.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.561 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -72.31 -28.49 29.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.0 tp -68.51 -56.62 7.74 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.456 -0.498 . . . . 0.0 111.311 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 30.1 mt -69.82 -41.69 79.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.471 -0.491 . . . . 0.0 109.991 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -38.82 77.82 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.127 0.489 . . . . 0.0 109.73 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -69.54 -35.75 75.73 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.675 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.6 -51.76 68.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.518 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.434 HG11 HG22 ' A' ' 27' ' ' VAL . 16.4 m -64.99 -38.26 82.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.656 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.9 t80 -57.97 -48.57 79.58 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.472 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 84.6 t80 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.866 -179.983 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 95.7 m . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.9 t -164.06 -176.59 4.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.569 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.543 ' O ' ' N ' ' A' ' 5' ' ' SER . 97.6 m -67.22 -68.58 0.37 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.806 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 89.7 t 56.64 -76.01 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.543 ' N ' ' O ' ' A' ' 3' ' ' THR . 1.4 m 69.26 79.95 0.21 Allowed Pre-proline 0 C--N 1.33 -0.239 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.507 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -79.12 18.13 1.09 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.145 1.897 . . . . 0.0 111.974 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.93 -51.52 34.04 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.415 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.7 p -55.6 -39.81 56.4 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 C-N-CA 120.614 -0.434 . . . . 0.0 109.851 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.571 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.6 mm? -52.86 -50.3 64.06 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.96 -38.77 73.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 122.029 0.919 . . . . 0.0 109.028 179.116 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.75 -35.6 90.16 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.657 HG21 HG12 ' B' ' 13' ' ' VAL . 42.0 mm -67.44 -43.16 87.71 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.792 -179.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.45 -42.69 81.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 119.061 -1.056 . . . . 0.0 108.516 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 96.9 t -55.85 -43.36 74.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.32 -30.44 76.1 Favored Glycine 0 CA--C 1.527 0.823 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -62.56 -48.31 80.04 Favored 'General case' 0 CA--C 1.52 -0.189 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.455 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.2 mp -60.36 -39.76 88.31 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 82.0 t -60.66 -40.72 85.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.742 179.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.483 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.0 mt -64.48 -44.44 91.0 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.784 0.326 . . . . 0.0 110.921 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.0 m -59.81 -52.31 66.0 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.695 -178.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.4 t -72.31 -27.92 27.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -178.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 29.6 tp -69.38 -56.17 8.25 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.498 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.2 mm -70.03 -40.73 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.443 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.567 -179.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.86 -39.22 80.7 Favored 'General case' 0 C--O 1.231 0.111 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.171 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.6 tp -69.56 -35.46 75.42 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.48 -56.01 19.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.223 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.508 HG23 ' N ' ' A' ' 28' ' ' TYR . 7.6 m -65.41 -43.15 94.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.113 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.68 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.508 ' N ' HG23 ' A' ' 27' ' ' VAL . 91.5 t80 -61.01 -45.35 95.17 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.951 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.3 t80 -61.14 -52.85 63.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.198 -179.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 49.6 tp -174.11 78.06 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.723 0.297 . . . . 0.0 110.514 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' A' ' 33' ' ' LEU . . . -59.39 103.55 0.42 Allowed Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.8 mmm-85 -49.53 93.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.838 0.351 . . . . 0.0 110.438 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.427 ' N ' ' O ' ' A' ' 31' ' ' GLY . 12.2 tp . . . . . 0 C--N 1.33 -0.247 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.411 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.471 ' C ' ' H ' ' B' ' 3' ' ' THR . 6.8 p . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.489 ' C ' ' H ' ' B' ' 4' ' ' VAL . 6.8 p 64.51 -2.89 0.58 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.528 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.471 ' H ' ' C ' ' B' ' 1' ' ' CYS . 2.7 m 66.89 -7.18 0.49 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.766 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.489 ' H ' ' C ' ' B' ' 2' ' ' SER . 13.1 m 31.24 49.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.838 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.402 ' N ' ' CD ' ' B' ' 6' ' ' PRO . 50.4 m -156.65 55.95 1.12 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.61 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' B' ' 5' ' ' SER . 58.3 Cg_endo -70.45 68.74 2.07 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.844 2.363 . . . . 0.0 111.867 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -72.05 -52.82 10.32 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.535 HG13 ' N ' ' B' ' 9' ' ' LEU . 7.6 p -57.78 -48.2 84.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 C-N-CA 120.582 -0.447 . . . . 0.0 110.382 -179.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.571 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.2 mm? -51.1 -46.74 61.95 Favored 'General case' 0 CA--C 1.535 0.382 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.32 -29.7 70.05 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.851 0.834 . . . . 0.0 109.34 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.67 -35.62 86.21 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -70.31 -45.21 76.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-O 119.298 -0.382 . . . . 0.0 111.218 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.657 HG12 HG21 ' A' ' 12' ' ' ILE . 3.0 m -60.94 -40.52 85.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 C-N-CA 118.529 -1.268 . . . . 0.0 109.602 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 71.4 t -55.95 -45.38 80.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -26.12 69.78 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.483 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 10.5 t70 -66.3 -48.73 69.41 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.469 ' N ' HD12 ' B' ' 17' ' ' LEU . 11.2 mp -61.52 -39.61 91.67 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -66.89 -29.86 47.7 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.162 179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.421 HD23 ' O ' ' B' ' 19' ' ' LEU . 3.5 tt -71.37 -52.57 17.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.982 0.42 . . . . 0.0 110.543 -179.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.478 ' OG1' HD13 ' A' ' 19' ' ' LEU . 19.8 m -59.14 -46.09 89.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.874 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -69.76 -30.94 46.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.2 tp -68.47 -55.3 12.28 Favored 'General case' 0 C--N 1.326 -0.425 0 C-N-CA 120.309 -0.556 . . . . 0.0 111.368 -178.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 16.9 mt -71.77 -39.97 69.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.439 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -62.1 -36.35 81.44 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.021 0.439 . . . . 0.0 110.024 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 33.6 tp -71.24 -37.51 71.99 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.34 65.98 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.783 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 35.7 m -65.87 -36.86 78.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.855 -0.338 . . . . 0.0 110.792 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.3 t80 -60.18 -47.51 85.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -62.68 -45.68 91.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.622 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 72.0 mt -61.9 -40.8 96.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.489 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.01 -34.8 90.11 Favored Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 49.2 80.29 0.07 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.82 0.343 . . . . 0.0 110.588 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.608 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.229 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.7 p . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.0 t -161.01 160.89 31.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.573 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.462 ' OG1' ' N ' ' A' ' 4' ' ' VAL . 81.1 p -62.76 -98.98 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.587 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.47 ' O ' HG11 ' B' ' 4' ' ' VAL . 2.6 t 48.77 30.85 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.195 0.521 . . . . 0.0 109.94 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 p -73.51 153.28 89.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.932 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.14 72.69 4.0 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.166 1.911 . . . . 0.0 112.102 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -68.62 -57.4 8.13 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.577 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.0 p -63.91 -47.14 91.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.615 ' HB3' HD12 ' B' ' 9' ' ' LEU . 1.5 mm? -55.48 -48.78 74.02 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.603 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.95 -37.93 67.09 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.06 -36.1 92.42 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 43.8 mm -65.15 -45.67 93.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.32 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.5 HG12 HG21 ' B' ' 12' ' ' ILE . 0.9 OUTLIER -58.95 -41.26 82.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 C-N-CA 118.905 -1.118 . . . . 0.0 109.085 179.921 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 75.5 t -55.7 -40.32 59.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 177.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.85 -32.6 84.72 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 178.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.51 -48.82 80.16 Favored 'General case' 0 C--O 1.233 0.194 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.474 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.0 mp -61.19 -39.8 91.55 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.662 179.256 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 69.8 t -60.24 -43.47 93.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.713 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.449 HD13 ' OG1' ' B' ' 20' ' ' THR . 32.8 mt -62.36 -43.69 98.22 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.911 0.386 . . . . 0.0 110.481 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -56.93 -51.41 69.25 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.077 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 89.0 t -69.3 -34.91 65.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 32.6 tp -64.61 -57.62 8.59 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -178.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.5 mm -68.47 -38.35 79.11 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.493 -179.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.65 -39.65 77.5 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.455 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.1 tp -69.28 -38.36 78.32 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.41 -53.53 53.55 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.46 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.492 HG23 ' N ' ' A' ' 28' ' ' TYR . 29.2 m -62.56 -46.03 97.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.612 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.492 ' N ' HG23 ' A' ' 27' ' ' VAL . 83.9 t80 -61.19 -43.87 98.2 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.308 -179.211 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -60.46 -53.71 54.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.157 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 54.0 tp -174.38 78.1 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.135 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -52.85 144.56 22.33 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 51.7 mmt-85 -54.82 101.35 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.757 0.313 . . . . 0.0 110.312 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 22.1 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.389 -179.974 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.474 ' O ' ' N ' ' B' ' 3' ' ' THR . 6.8 t . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.426 ' O ' ' O ' ' B' ' 3' ' ' THR . 9.5 m 46.18 15.4 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.741 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.532 HG22 ' N ' ' B' ' 4' ' ' VAL . 91.8 m 56.06 160.71 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.638 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.532 ' N ' HG22 ' B' ' 3' ' ' THR . 11.4 t -85.58 117.01 29.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.109 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 5.6 m -156.54 81.1 3.58 Favored Pre-proline 0 CA--C 1.529 0.172 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.784 -179.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -81.06 83.69 2.15 Favored 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.441 2.094 . . . . 0.0 111.594 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -71.19 -40.78 60.96 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.414 HG13 HD22 ' B' ' 9' ' ' LEU . 14.7 p -51.83 -38.54 22.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.573 -0.451 . . . . 0.0 109.875 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.615 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.8 mm? -55.19 -51.08 67.66 Favored 'General case' 0 CA--C 1.536 0.426 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.6 -39.56 64.98 Favored 'General case' 0 C--O 1.242 0.663 0 CA-C-O 121.862 0.839 . . . . 0.0 109.506 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.86 -43.02 94.93 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 114.568 -1.196 . . . . 0.0 110.147 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . 0.5 HG21 HG12 ' A' ' 13' ' ' VAL . 1.8 mp -62.44 -42.38 95.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.493 0 C-N-CA 120.208 -0.597 . . . . 0.0 109.452 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 44.0 t -49.65 -50.85 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 C-N-CA 119.94 -0.704 . . . . 0.0 109.146 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 57.2 t -58.02 -33.85 47.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' B' ' 12' ' ' ILE . . . -64.95 -39.91 96.81 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.412 ' C ' ' OD1' ' B' ' 16' ' ' ASP . 8.1 t0 -61.68 -45.47 93.86 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.14 0.495 . . . . 0.0 109.932 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.43 ' O ' HG23 ' B' ' 21' ' ' VAL . 7.5 mt -61.19 -42.54 98.77 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.519 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.0 t -71.86 -26.47 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.403 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.0 tt -73.56 -54.14 8.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.449 ' OG1' HD13 ' A' ' 19' ' ' LEU . 18.6 m -60.11 -45.89 91.45 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.298 179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . 0.43 HG23 ' O ' ' B' ' 17' ' ' LEU . 92.3 t -66.29 -44.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.838 -179.25 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.8 tp -58.97 -57.93 10.91 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.11 0.411 . . . . 0.0 112.11 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 13.4 mt -65.93 -40.44 87.47 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.948 -179.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.22 -33.07 65.01 Favored 'General case' 0 C--O 1.232 0.147 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.429 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -68.68 -43.81 75.35 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.414 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -51.44 -52.91 42.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.676 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 12.0 m -63.16 -42.07 95.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 C-N-CA 120.139 -0.624 . . . . 0.0 110.809 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -55.39 -46.77 76.52 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.38 . . . . 0.0 110.782 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -61.61 -47.61 84.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.754 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 81.6 mt -63.4 -38.14 89.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.615 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -48.07 -35.35 13.43 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 61.6 ttt85 51.0 86.33 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 110.527 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . . . . . . . . . 13.7 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.476 179.995 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 60.5 m . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.6 m -72.38 109.5 6.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.598 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.412 ' C ' ' H ' ' A' ' 5' ' ' SER . 30.7 p -78.2 126.62 31.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.948 0.404 . . . . 0.0 110.449 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.451 ' H ' HG23 ' A' ' 4' ' ' VAL . 2.1 t -58.81 -7.23 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.366 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.412 ' H ' ' C ' ' A' ' 3' ' ' THR . 2.9 m 63.94 60.35 1.7 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.774 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -76.65 14.39 1.24 Allowed 'Trans proline' 0 C--N 1.307 -1.653 0 C-N-CA 122.765 2.31 . . . . 0.0 111.781 179.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.2 -30.98 79.32 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -49.2 -42.25 15.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.065 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.521 HD12 ' HB3' ' B' ' 9' ' ' LEU . 4.1 mm? -52.16 -52.48 51.63 Favored 'General case' 0 CA--C 1.537 0.474 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.222 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.4 -37.85 62.86 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.09 0.947 . . . . 0.0 109.145 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.89 -37.42 94.33 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 114.711 -1.132 . . . . 0.0 110.311 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.527 HG21 HG12 ' B' ' 13' ' ' VAL . 43.0 mm -65.3 -43.19 95.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.011 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -57.53 -43.15 82.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 C-N-CA 119.016 -1.074 . . . . 0.0 108.601 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 92.3 t -54.68 -43.79 67.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.298 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.19 -32.45 82.58 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -60.57 -48.91 79.69 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.466 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.0 mp -62.08 -38.41 88.71 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.217 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.5 t -61.89 -41.81 92.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.99 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.486 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.9 mt -66.57 -43.7 84.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.87 0.367 . . . . 0.0 110.998 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.1 m -60.85 -51.51 68.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.308 -178.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 90.9 t -71.76 -32.33 44.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.143 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 25.3 tp -66.48 -56.27 11.71 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.712 -178.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.0 mm -69.1 -41.78 81.61 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 C-N-CA 120.058 -0.657 . . . . 0.0 109.298 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.94 -40.98 77.44 Favored 'General case' 0 N--CA 1.46 0.056 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.651 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.12 79.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.04 -54.04 49.69 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.698 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.494 HG23 ' N ' ' A' ' 28' ' ' TYR . 3.5 m -68.1 -43.57 85.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.722 -179.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.494 ' N ' HG23 ' A' ' 27' ' ' VAL . 69.7 t80 -58.72 -48.66 80.39 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.168 -178.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.2 t80 -70.52 -56.56 6.27 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.195 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 55.7 tp -175.15 78.71 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.104 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -45.37 109.1 0.27 Allowed Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 34.2 mmm-85 -79.85 17.74 0.9 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.826 0.346 . . . . 0.0 110.412 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 20.1 tp . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.342 -179.977 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 19.8 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 6.3 p 63.81 134.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.621 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 27.9 m -160.09 113.8 2.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.219 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 p -66.04 129.8 30.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.943 0.401 . . . . 0.0 110.492 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.522 ' N ' ' CD ' ' B' ' 6' ' ' PRO . 15.8 t -173.31 48.52 0.08 OUTLIER Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.794 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.522 ' CD ' ' N ' ' B' ' 5' ' ' SER . 46.3 Cg_endo -66.95 88.11 0.3 Allowed 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.852 2.368 . . . . 0.0 112.054 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.32 -60.14 3.14 Favored Glycine 0 CA--C 1.526 0.732 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.267 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.593 HG13 ' N ' ' B' ' 9' ' ' LEU . 15.0 p -62.53 -48.52 87.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.593 ' N ' HG13 ' B' ' 8' ' ' VAL . 1.8 mm? -51.68 -47.49 63.83 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.078 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.7 -33.87 70.67 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-O 121.841 0.829 . . . . 0.0 108.883 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.86 -33.79 88.19 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -72.83 -36.19 51.52 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 119.267 -0.397 . . . . 0.0 111.275 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.527 HG12 HG21 ' A' ' 12' ' ' ILE . 1.6 m -68.18 -40.93 83.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 118.886 -1.125 . . . . 0.0 110.517 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 p -64.57 -38.68 83.26 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 C-N-CA 118.747 -1.181 . . . . 0.0 108.42 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.35 -28.93 73.74 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.486 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 7.8 t0 -65.42 -48.03 74.21 Favored 'General case' 0 CA--C 1.52 -0.185 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.2 mt -59.79 -42.26 92.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.688 179.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 95.0 t -69.0 -24.5 28.4 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.239 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.181 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.3 tt -71.97 -53.57 12.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.085 0.469 . . . . 0.0 110.222 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.435 ' OG1' HD13 ' A' ' 19' ' ' LEU . 11.5 m -59.48 -46.34 89.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.564 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.5 t -66.18 -43.72 91.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.699 -179.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.7 tp -57.92 -56.57 20.24 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 34.8 mt -65.52 -41.56 91.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.945 -178.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.95 -31.4 64.94 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 121.355 0.598 . . . . 0.0 109.577 178.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.493 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.44 -43.53 69.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.346 179.701 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.25 -53.61 51.25 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.612 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.445 ' CG1' HG12 ' A' ' 27' ' ' VAL . 18.3 m -59.91 -41.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.726 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -58.96 -40.76 85.7 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.449 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 77.5 t80 -62.69 -44.25 96.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.111 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 95.9 mt -54.11 -42.03 68.98 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.464 -179.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.31 114.6 6.85 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -60.16 87.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.815 0.34 . . . . 0.0 110.53 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.601 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.428 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.492 ' O ' ' SG ' ' A' ' 1' ' ' CYS . 27.9 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.536 ' O ' ' N ' ' A' ' 4' ' ' VAL . 37.4 t -162.17 161.99 28.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.433 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.534 ' HG1' ' C ' ' A' ' 2' ' ' SER . 68.1 p 52.56 -82.07 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.811 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.536 ' N ' ' O ' ' A' ' 2' ' ' SER . 2.8 t 61.53 41.64 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.013 0.435 . . . . 0.0 110.303 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.503 ' O ' HG12 ' A' ' 8' ' ' VAL . 44.6 m 39.62 69.51 1.71 Allowed Pre-proline 0 N--CA 1.463 0.217 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.998 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -87.52 -25.81 0.9 Allowed 'Trans proline' 0 C--N 1.306 -1.706 0 C-N-CA 122.863 2.375 . . . . 0.0 111.975 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -66.61 -30.21 76.01 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.546 HG13 ' N ' ' A' ' 9' ' ' LEU . 9.7 p -54.37 -46.82 70.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.159 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.572 HD12 ' HB3' ' B' ' 9' ' ' LEU . 2.9 mm? -53.2 -50.63 64.27 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.415 ' O ' HG22 ' A' ' 13' ' ' VAL . . . -53.53 -36.07 61.4 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.991 0.901 . . . . 0.0 109.07 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.64 -35.7 92.37 Favored Glycine 0 C--N 1.317 -0.503 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.544 HG21 HG12 ' B' ' 13' ' ' VAL . 37.8 mm -66.09 -43.08 92.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.856 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -59.17 -42.07 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 119.111 -1.036 . . . . 0.0 108.715 179.571 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.5 t -54.92 -41.39 57.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.27 -33.36 87.03 Favored Glycine 0 CA--C 1.53 0.987 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.026 179.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.431 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 8.9 t0 -61.16 -47.68 85.07 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.457 ' N ' HD12 ' A' ' 17' ' ' LEU . 10.9 mp -61.0 -39.57 90.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 179.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -60.39 -40.44 84.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.64 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.482 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 22.6 mt -64.4 -44.66 90.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.774 0.321 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 m -58.09 -51.39 69.91 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.412 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 62.0 t -71.51 -32.73 47.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.845 -179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.8 tp -66.73 -53.86 28.9 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.676 -178.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.449 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.0 mm -68.87 -42.14 82.41 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 109.461 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.12 -41.96 84.74 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.2 -179.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.6 tp -69.09 -38.28 78.89 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.51 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.77 -51.06 53.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.941 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.505 HG23 ' N ' ' A' ' 28' ' ' TYR . 16.7 m -69.63 -42.24 80.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.552 -179.005 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.505 ' N ' HG23 ' A' ' 27' ' ' VAL . 84.1 t80 -62.13 -44.89 95.65 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.825 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 57.7 t80 -68.9 -54.87 13.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.11 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.0 tp -174.48 78.02 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.331 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -51.97 114.05 2.93 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 36.4 mmm-85 -70.98 -25.47 62.72 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.745 0.307 . . . . 0.0 110.477 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.6 tp . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.225 -179.85 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 23.9 t . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.418 ' O ' ' O ' ' B' ' 3' ' ' THR . 24.6 p 47.4 26.48 0.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.617 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.418 ' O ' ' O ' ' B' ' 2' ' ' SER . 6.1 m 59.34 120.78 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.63 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -78.99 131.65 33.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.433 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.491 ' O ' ' N ' ' B' ' 7' ' ' GLY . 5.2 t -172.56 71.99 0.43 Allowed Pre-proline 0 C--N 1.331 -0.198 0 C-N-CA 120.729 -0.389 . . . . 0.0 111.408 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_exo -46.31 86.45 0.02 OUTLIER 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.643 2.229 . . . . 0.0 111.663 178.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.491 ' N ' ' O ' ' B' ' 5' ' ' SER . . . -46.59 -29.83 4.26 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.476 HG13 ' N ' ' B' ' 9' ' ' LEU . 9.0 p -60.36 -44.19 95.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.572 ' HB3' HD12 ' A' ' 9' ' ' LEU . 3.4 mm? -57.42 -50.29 73.48 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.465 178.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.4 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.02 -29.8 60.91 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.777 0.799 . . . . 0.0 109.348 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.53 -38.33 94.63 Favored Glycine 0 C--N 1.316 -0.532 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 178.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -68.05 -44.04 84.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 120.439 -0.504 . . . . 0.0 111.227 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.544 HG12 HG21 ' A' ' 12' ' ' ILE . 2.1 m -60.67 -37.27 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.675 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 61.6 t -58.68 -43.64 88.1 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -64.45 -32.76 85.28 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.373 178.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.482 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -61.85 -48.38 80.8 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-O 121.149 0.5 . . . . 0.0 109.996 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.9 mt -60.08 -44.39 94.81 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.819 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -65.87 -25.89 37.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.03 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.431 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 2.7 tt -70.48 -49.41 48.75 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.0 0.429 . . . . 0.0 110.287 -179.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.449 ' OG1' HD13 ' A' ' 19' ' ' LEU . 18.3 m -61.21 -46.09 91.89 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.618 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.2 t -70.96 -27.5 30.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.925 -179.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.8 tp -69.98 -53.83 15.98 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.849 -0.34 . . . . 0.0 111.485 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.418 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 55.7 mt -70.99 -41.24 76.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.262 -179.362 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.77 -42.17 96.98 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.503 -0.479 . . . . 0.0 109.748 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 46.4 tp -70.51 -28.59 65.07 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -59.78 -53.84 53.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.237 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.453 HG11 ' CG1' ' A' ' 27' ' ' VAL . 8.6 m -70.45 -34.21 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.066 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -59.74 -49.27 78.38 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.665 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -72.01 -51.7 20.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.114 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 88.9 mt -63.8 -41.54 97.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.563 -179.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' B' ' 27' ' ' VAL . . . -60.03 111.43 3.57 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -79.93 88.39 5.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.775 0.322 . . . . 0.0 110.579 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.597 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.29 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 65.7 m . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.5 m -76.59 -74.21 0.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.719 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.439 ' O ' ' O ' ' A' ' 4' ' ' VAL . 90.7 m -167.27 -87.63 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.796 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' A' ' 3' ' ' THR . 39.2 t 41.23 96.8 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.66 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.425 ' O ' ' N ' ' A' ' 7' ' ' GLY . 2.2 p -81.53 153.28 70.83 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.026 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -64.8 69.59 0.25 Allowed 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 122.15 1.9 . . . . 0.0 111.696 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 5' ' ' SER . . . -70.14 -55.54 9.03 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.471 HG13 ' N ' ' A' ' 9' ' ' LEU . 13.6 p -65.14 -44.8 95.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.85 179.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.573 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.4 mm? -55.23 -48.72 73.52 Favored 'General case' 0 CA--C 1.543 0.696 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.19 -36.9 76.18 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.984 0.897 . . . . 0.0 109.558 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.01 -36.07 92.35 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.692 HG21 HG12 ' B' ' 13' ' ' VAL . 39.3 mm -66.72 -43.67 89.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 C-N-CA 120.577 -0.449 . . . . 0.0 110.95 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -56.7 -42.44 76.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 118.513 -1.275 . . . . 0.0 108.651 179.457 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.6 t -55.64 -42.54 69.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.33 -32.04 81.42 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -61.61 -47.23 86.4 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.448 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.1 mp -61.04 -38.87 87.68 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.022 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.5 t -62.41 -42.25 94.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.917 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.593 HD13 ' OG1' ' B' ' 20' ' ' THR . 16.2 mt -65.55 -45.65 82.55 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.751 0.31 . . . . 0.0 110.878 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.0 m -57.26 -51.58 68.78 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.24 -178.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.1 t -71.03 -34.2 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.267 -0.424 . . . . 0.0 112.003 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.7 tp -64.91 -56.46 13.16 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -178.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -68.6 -41.73 83.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 C-N-CA 120.03 -0.668 . . . . 0.0 109.252 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.56 -40.42 71.9 Favored 'General case' 0 CA--C 1.523 -0.091 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.566 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.1 tp -68.6 -37.82 80.1 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.52 -53.89 52.12 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.723 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.505 HG12 ' CG1' ' B' ' 27' ' ' VAL . 2.5 m -66.58 -43.04 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.622 -179.14 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.437 ' N ' HG23 ' A' ' 27' ' ' VAL . 81.3 t80 -59.09 -48.66 80.79 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.403 -179.011 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -67.93 -56.54 8.63 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.916 -0.314 . . . . 0.0 111.114 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 41.7 tp -175.39 78.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.026 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -43.6 149.64 0.68 Allowed Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.059 -0.817 . . . . 0.0 111.059 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 44.5 mmm-85 -59.21 -30.77 68.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.763 0.316 . . . . 0.0 110.267 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 9.9 tp . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.479 179.91 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.504 ' C ' ' H ' ' B' ' 3' ' ' THR . 2.0 p . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.418 ' OG ' ' O ' ' B' ' 1' ' ' CYS . 3.5 p 71.77 -17.34 0.35 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.732 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.522 ' O ' ' N ' ' B' ' 5' ' ' SER . 4.5 m 44.97 49.98 9.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.617 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 33.5 m 34.2 29.53 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.82 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.522 ' N ' ' O ' ' B' ' 3' ' ' THR . 40.0 m -166.59 72.46 1.13 Allowed Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.843 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -50.0 130.78 28.59 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.317 2.011 . . . . 0.0 111.771 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -46.17 -36.81 7.48 Favored Glycine 0 C--N 1.331 0.276 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.8 p -68.62 -40.83 82.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.601 -0.299 . . . . 0.0 110.367 179.228 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.573 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.8 mm? -66.96 -49.16 66.31 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.989 179.383 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.37 -28.89 68.55 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.838 0.828 . . . . 0.0 109.349 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.17 -33.98 69.55 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 76.4 mt -72.25 -37.63 59.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.351 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.686 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.692 HG12 HG21 ' A' ' 12' ' ' ILE . 3.0 m -69.47 -43.99 80.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.741 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.431 HG13 ' N ' ' B' ' 15' ' ' GLY . 5.7 p -61.44 -42.41 93.73 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 118.943 -1.103 . . . . 0.0 109.101 178.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . 0.431 ' N ' HG13 ' B' ' 14' ' ' VAL . . . -66.19 -27.95 73.33 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.505 ' OD1' HD12 ' A' ' 19' ' ' LEU . 47.3 t0 -65.42 -47.0 77.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.282 0.563 . . . . 0.0 109.639 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -59.41 -40.97 88.36 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -67.75 -24.34 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.686 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 3.1 tt -71.28 -53.25 14.94 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.095 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.593 ' OG1' HD13 ' A' ' 19' ' ' LEU . 23.8 m -59.67 -46.68 88.32 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.634 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 93.7 t -65.93 -43.73 92.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.739 -179.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.9 tp -58.53 -56.09 26.69 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -178.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 35.7 mt -65.61 -41.7 91.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.959 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.12 -32.9 64.63 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.485 0.66 . . . . 0.0 109.462 178.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.498 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -69.23 -42.3 75.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.278 179.524 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.98 -53.7 52.31 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.791 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.505 ' CG1' HG12 ' A' ' 27' ' ' VAL . 15.4 m -58.94 -43.28 88.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 C-N-CA 120.171 -0.612 . . . . 0.0 110.487 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.92 -40.97 81.71 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.902 0.382 . . . . 0.0 110.553 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 52.8 t80 -61.81 -44.93 95.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 94.1 mt -56.91 -38.03 72.28 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.461 -179.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.31 125.91 38.75 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 58.5 ttt85 -70.8 92.49 0.9 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.823 0.344 . . . . 0.0 110.55 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.607 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.281 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 85.1 m . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.6 m -69.45 149.52 48.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.608 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 10.5 m -64.2 -46.09 85.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.755 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.425 ' O ' HG11 ' B' ' 4' ' ' VAL . 9.3 t 49.17 55.35 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.141 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.6 p -91.69 148.23 36.8 Favored Pre-proline 0 CA--C 1.532 0.284 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.288 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.448 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 72.3 Cg_endo -74.56 78.98 2.62 Favored 'Trans proline' 0 N--CA 1.496 1.644 0 C-N-CA 122.214 1.942 . . . . 0.0 112.262 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -73.0 -63.11 2.93 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.43 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.2 p -63.98 -43.9 97.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.185 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.624 ' HB3' HD12 ' B' ' 9' ' ' LEU . 3.4 mm? -54.32 -48.75 70.99 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 121.253 0.549 . . . . 0.0 109.64 178.442 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.448 ' HB2' ' O ' ' A' ' 6' ' ' PRO . . . -56.73 -39.28 73.67 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.909 0.861 . . . . 0.0 109.275 179.475 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.02 -35.02 90.11 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.626 HG21 HG12 ' B' ' 13' ' ' VAL . 39.8 mm -66.41 -44.25 90.78 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 120.434 -0.507 . . . . 0.0 111.065 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.527 HG12 HG21 ' B' ' 12' ' ' ILE . 1.0 OUTLIER -59.41 -41.06 83.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 118.544 -1.262 . . . . 0.0 109.089 179.774 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 69.1 t -54.5 -42.09 57.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.65 -33.37 86.49 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.744 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -58.86 -49.74 76.61 Favored 'General case' 0 CA--C 1.52 -0.207 0 CA-C-O 121.025 0.44 . . . . 0.0 109.848 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.494 HD12 ' N ' ' A' ' 17' ' ' LEU . 10.9 mp -61.09 -39.04 88.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.672 179.352 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -60.62 -42.58 92.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.833 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.411 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 62.3 mt -63.85 -43.73 95.27 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.772 0.32 . . . . 0.0 110.785 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.7 m -58.0 -51.87 67.86 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.85 0.357 . . . . 0.0 111.277 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 52.9 t -71.31 -29.03 34.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.628 -179.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.49 -51.84 21.57 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.573 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.1 mm -70.23 -38.46 74.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 C-N-CA 120.173 -0.611 . . . . 0.0 110.011 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.18 -44.25 80.15 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.634 -0.427 . . . . 0.0 111.214 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 47.5 tp -70.53 -35.78 73.36 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.377 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.48 -49.78 51.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.865 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 23' ' ' ILE . 21.2 m -68.33 -44.59 83.56 Favored 'Isoleucine or valine' 0 C--O 1.23 0.078 0 C-N-CA 120.049 -0.66 . . . . 0.0 111.193 -178.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.528 ' N ' HG23 ' A' ' 27' ' ' VAL . 58.3 t80 -63.25 -46.89 84.79 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.032 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -61.94 -52.29 64.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.964 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.7 tp -173.71 77.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.177 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.05 129.8 35.27 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 29.7 mmm-85 -66.04 -39.92 90.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.786 0.327 . . . . 0.0 110.492 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 32.6 tp . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.296 179.941 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.489 ' C ' ' H ' ' B' ' 3' ' ' THR . 7.4 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 3.1 p 73.65 -30.66 0.21 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.743 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.489 ' H ' ' C ' ' B' ' 1' ' ' CYS . 23.5 m 54.71 99.61 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.449 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.425 HG11 ' O ' ' A' ' 4' ' ' VAL . 90.3 t -94.91 115.02 32.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.953 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 30.9 t -152.37 90.96 3.67 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.785 -179.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -80.44 81.59 2.71 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.018 1.812 . . . . 0.0 111.68 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -70.68 -37.98 67.36 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.445 HG13 ' N ' ' B' ' 9' ' ' LEU . 14.7 p -53.46 -42.14 47.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.7 mm? -51.32 -52.2 47.51 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.37 -35.25 65.06 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.914 0.864 . . . . 0.0 109.302 179.284 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.01 -33.97 88.7 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . 0.527 HG21 HG12 ' A' ' 13' ' ' VAL . 1.8 mp -71.69 -39.5 69.15 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.923 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.626 HG12 HG21 ' A' ' 12' ' ' ILE . 1.4 m -63.84 -44.92 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 C-N-CA 118.526 -1.269 . . . . 0.0 110.314 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -60.59 -35.76 65.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 C-N-CA 118.277 -1.369 . . . . 0.0 107.702 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -66.48 -30.14 76.01 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.919 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.411 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 3.3 t0 -64.35 -48.61 74.89 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.433 ' N ' HD12 ' B' ' 17' ' ' LEU . 11.1 mp -59.26 -43.99 92.43 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.0 t -67.12 -25.46 34.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.46 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 2.9 tt -70.47 -50.26 39.95 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 120.981 0.419 . . . . 0.0 110.268 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 69.7 m -62.25 -45.3 93.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -68.79 -31.06 49.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.6 -179.231 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 28.6 tp -68.5 -52.15 35.42 Favored 'General case' 0 C--N 1.326 -0.421 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.833 -178.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 63.9 mt -71.36 -40.62 73.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 C-N-CA 120.284 -0.566 . . . . 0.0 110.487 -179.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -63.74 -40.9 97.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.382 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 49.0 tp -72.82 -31.2 64.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.049 0.452 . . . . 0.0 109.99 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.49 -52.51 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.972 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.404 HG23 ' N ' ' B' ' 28' ' ' TYR . 23.1 m -70.38 -36.33 66.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.815 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . 0.404 ' N ' HG23 ' B' ' 27' ' ' VAL . 80.2 t80 -62.16 -48.67 79.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.551 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.8 t80 -63.27 -47.66 81.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.78 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 59.8 mt -63.72 -40.75 97.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.54 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -46.29 -24.17 1.47 Allowed Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 73.5 ttp85 50.98 80.13 0.08 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.834 0.349 . . . . 0.0 110.538 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.151 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 15.3 m . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.9 t -151.14 -88.18 0.07 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.395 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.402 ' H ' HG23 ' A' ' 3' ' ' THR . 21.7 p -62.84 -144.97 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.511 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 3.2 t 59.34 34.94 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 121.331 0.586 . . . . 0.0 109.636 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -70.28 159.13 85.74 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.809 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -73.97 59.33 4.34 Favored 'Trans proline' 0 C--N 1.308 -1.56 0 C-N-CA 122.377 2.051 . . . . 0.0 111.759 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.17 -56.75 16.26 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.402 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.7 p -64.94 -41.8 93.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 C-N-CA 120.577 -0.449 . . . . 0.0 109.928 179.547 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.489 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.0 mm? -59.17 -49.39 78.04 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.29 -36.96 66.71 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 122.158 0.98 . . . . 0.0 108.82 179.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.12 -37.71 95.37 Favored Glycine 0 CA--C 1.521 0.43 0 CA-C-N 114.582 -1.19 . . . . 0.0 110.43 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 36.4 mm -64.53 -43.42 96.83 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 120.491 -0.484 . . . . 0.0 110.632 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -57.5 -44.64 85.23 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.552 179.424 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 76.0 t -54.98 -39.78 50.84 Favored 'Isoleucine or valine' 0 C--O 1.233 0.229 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 178.186 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.13 -35.11 91.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 178.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -58.08 -49.44 76.92 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-O 121.159 0.504 . . . . 0.0 109.693 179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.495 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.0 -39.01 88.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.769 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.74 -38.92 81.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.984 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.479 HD22 ' OG1' ' B' ' 20' ' ' THR . 72.5 mt -67.65 -39.09 84.62 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.761 0.315 . . . . 0.0 110.633 -179.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.3 m -61.73 -51.85 66.66 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.635 -0.426 . . . . 0.0 111.19 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.5 t -72.76 -29.6 30.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.765 -179.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 54.2 tp -72.38 -52.25 16.87 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.441 -178.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.75 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.5 mm -68.75 -38.98 79.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.066 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.47 -42.69 78.38 Favored 'General case' 0 C--N 1.333 -0.138 0 C-N-CA 120.755 -0.378 . . . . 0.0 111.262 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 50.2 tp -70.53 -36.77 73.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.996 0.426 . . . . 0.0 110.331 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.56 -49.38 48.62 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.824 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.75 HG22 ' O ' ' A' ' 23' ' ' ILE . 28.8 m -69.04 -41.82 81.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.451 -178.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.451 ' N ' HG23 ' A' ' 27' ' ' VAL . 77.6 t80 -64.66 -46.07 84.07 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.73 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.0 t80 -61.6 -51.1 69.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.02 -179.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 42.5 tp -172.4 76.47 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.309 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -70.24 127.98 18.4 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 31.1 mmm-85 -82.86 100.53 10.41 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.763 0.316 . . . . 0.0 110.432 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 51.5 tp . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.405 -179.983 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 2.1 p . . . . . 0 N--CA 1.489 1.478 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 90.0 p 44.51 24.9 0.11 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.666 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 3.4 m 48.33 41.73 16.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.313 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 3.6 t 39.06 72.34 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.717 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 32.2 t -147.84 77.83 10.05 Favored Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.268 -179.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 80.8 Cg_exo -46.13 101.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.582 2.188 . . . . 0.0 111.816 179.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -46.79 -29.46 4.3 Favored Glycine 0 C--N 1.332 0.342 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.429 ' CG1' ' N ' ' B' ' 9' ' ' LEU . 5.6 p -61.68 -42.88 95.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.489 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.5 mm? -60.96 -48.5 81.53 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 119.723 -0.791 . . . . 0.0 109.628 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.71 -35.65 56.04 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 122.131 0.967 . . . . 0.0 108.877 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.58 -42.88 99.84 Favored Glycine 0 CA--C 1.521 0.409 0 CA-C-N 114.293 -1.322 . . . . 0.0 110.084 179.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -65.34 -29.12 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 C-N-CA 120.357 -0.537 . . . . 0.0 109.832 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 61.4 t -64.2 -57.03 13.25 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 119.947 -0.701 . . . . 0.0 109.826 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 5.0 p -57.8 -28.14 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.2 -31.9 78.67 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 178.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -65.6 -46.06 80.79 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.468 ' N ' HD12 ' B' ' 17' ' ' LEU . 8.0 mp -58.87 -44.3 91.05 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.424 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.9 t -68.9 -23.05 26.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.064 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.484 ' O ' HD13 ' B' ' 19' ' ' LEU . 0.3 OUTLIER -70.05 -55.47 9.43 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-O 121.016 0.436 . . . . 0.0 110.412 -179.353 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.479 ' OG1' HD22 ' A' ' 19' ' ' LEU . 77.2 m -61.56 -43.9 98.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 85.3 t -67.04 -38.46 81.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.623 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 30.0 tp -63.13 -51.66 65.62 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.176 0.436 . . . . 0.0 112.176 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 47.0 mt -69.34 -39.73 79.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 119.964 -0.695 . . . . 0.0 110.397 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.2 -44.79 96.72 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.631 -0.428 . . . . 0.0 110.583 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -71.73 -27.55 63.07 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -64.03 -53.78 44.5 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.649 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.451 HG11 HG21 ' A' ' 27' ' ' VAL . 33.2 m -71.01 -38.81 73.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.373 -0.531 . . . . 0.0 111.321 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . 0.451 ' N ' HG23 ' B' ' 27' ' ' VAL . 48.6 t80 -60.75 -48.64 80.87 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.494 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -62.52 -45.95 90.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.667 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 52.8 mt -61.28 -41.39 96.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.414 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.84 101.9 1.07 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 72.1 ttt180 -64.36 87.11 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.801 0.334 . . . . 0.0 110.467 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.607 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.272 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 79.6 m . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 72.7 m -68.88 154.28 42.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.551 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 24.3 m -46.5 103.13 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.542 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 23.7 m -75.17 -158.94 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.552 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.2 p -135.47 99.5 11.8 Favored Pre-proline 0 CA--C 1.535 0.376 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.32 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -79.47 27.87 0.52 Allowed 'Trans proline' 0 N--CA 1.488 1.168 0 C-N-CA 121.838 1.692 . . . . 0.0 112.089 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.38 -57.14 4.79 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.402 HG13 HD22 ' A' ' 9' ' ' LEU . 6.9 p -56.47 -27.73 25.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.967 0.413 . . . . 0.0 109.952 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.561 HD13 HG11 ' B' ' 13' ' ' VAL . 3.4 mm? -61.61 -48.74 79.53 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.5 -39.38 83.62 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 122.258 1.028 . . . . 0.0 109.172 179.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.45 -37.24 92.93 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 114.592 -1.185 . . . . 0.0 110.174 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 4.9 mm -66.14 -43.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.888 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.53 -43.07 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 C-N-CA 118.907 -1.117 . . . . 0.0 108.486 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 66.9 t -55.18 -41.49 60.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.46 -30.94 79.1 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.796 178.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -61.4 -49.32 77.38 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.506 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.0 mp -61.8 -40.17 94.27 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.591 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -61.51 -43.19 96.44 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.225 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 40.0 mt -64.31 -45.83 86.22 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.717 0.294 . . . . 0.0 111.116 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 10.7 m -57.11 -51.86 67.6 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.883 0.373 . . . . 0.0 110.913 -179.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.6 t -71.89 -27.68 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.882 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 42.4 tp -72.09 -52.65 15.81 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.568 ' O ' HG22 ' A' ' 27' ' ' VAL . 5.1 mm -69.8 -38.77 76.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.317 -0.553 . . . . 0.0 109.885 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.37 -42.94 82.61 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.327 -179.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.2 tp -70.63 -38.01 73.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.901 0.381 . . . . 0.0 110.214 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.49 -49.27 64.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.746 -179.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.568 HG22 ' O ' ' A' ' 23' ' ' ILE . 18.3 m -70.28 -39.67 77.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.285 -178.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.411 ' N ' HG23 ' A' ' 27' ' ' VAL . 88.0 t80 -63.51 -46.52 85.71 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.866 -0.334 . . . . 0.0 110.898 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -64.69 -53.96 39.23 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.336 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.6 tp -173.89 77.95 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.88 0.372 . . . . 0.0 110.201 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -57.46 164.91 6.51 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 34.8 mmm-85 -68.0 -8.41 37.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.749 0.309 . . . . 0.0 110.324 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 54.9 tp . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.391 -179.993 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 37.0 t . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 8.3 p 48.05 65.45 1.31 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.471 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 60.3 m 53.23 99.56 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.511 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 20.6 m -65.32 -33.8 66.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.83 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.502 ' O ' ' N ' ' B' ' 7' ' ' GLY . 0.0 OUTLIER -71.24 169.84 13.75 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.243 -179.813 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -42.54 88.22 0.01 OUTLIER 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.33 2.02 . . . . 0.0 112.019 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' B' ' 5' ' ' SER . . . -47.18 -28.26 4.21 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.548 HG13 ' N ' ' B' ' 9' ' ' LEU . 14.4 p -58.92 -43.46 88.63 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.548 ' N ' HG13 ' B' ' 8' ' ' VAL . 0.6 OUTLIER -54.27 -48.52 71.12 Favored 'General case' 0 C--O 1.236 0.356 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.488 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.416 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -54.59 -38.06 66.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.47 -35.6 91.29 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.166 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -69.47 -38.84 77.78 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 CA-C-O 119.111 -0.471 . . . . 0.0 111.131 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.561 HG11 HD13 ' A' ' 9' ' ' LEU . 1.2 m -65.71 -45.65 91.33 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.651 -179.545 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.405 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -60.84 -32.73 52.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 C-N-CA 118.285 -1.366 . . . . 0.0 107.524 178.374 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -68.9 -28.64 72.88 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.703 178.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.0 t0 -65.33 -49.26 70.12 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.475 ' N ' HD12 ' B' ' 17' ' ' LEU . 10.6 mp -59.95 -42.28 93.72 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.405 HG23 ' O ' ' B' ' 14' ' ' VAL . 96.6 t -67.2 -26.4 36.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.348 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.422 HD23 ' O ' ' B' ' 19' ' ' LEU . 2.0 tt -70.65 -48.58 54.2 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.938 0.399 . . . . 0.0 110.228 -179.478 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 12.1 m -62.59 -45.61 92.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.679 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 86.9 t -70.22 -27.5 32.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.622 -179.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 27.4 tp -70.86 -53.13 16.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.758 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 55.0 mt -71.08 -38.98 73.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -65.77 -41.6 91.84 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.584 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 57.2 tp -72.56 -31.68 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.028 0.442 . . . . 0.0 109.979 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -65.31 -52.35 54.64 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.037 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' B' ' 31' ' ' GLY . 28.3 m -70.81 -37.41 68.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.979 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . 0.426 ' N ' HG23 ' B' ' 27' ' ' VAL . 80.6 t80 -61.32 -49.31 77.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.619 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -64.11 -48.66 75.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.788 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 48.3 mt -71.93 -25.79 62.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.387 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' B' ' 27' ' ' VAL . . . -61.57 -148.9 0.01 OUTLIER Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.0 ttt85 -163.88 78.19 0.39 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.781 0.324 . . . . 0.0 110.552 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.589 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.304 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.0 p . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.2 m -154.79 114.92 3.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.525 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 32.9 m -164.9 76.72 0.3 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.631 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 22.2 t -144.47 -22.49 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.292 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.435 ' O ' HG12 ' A' ' 8' ' ' VAL . 50.8 m 53.74 63.81 7.44 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.872 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.59 -6.95 18.24 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.644 2.229 . . . . 0.0 112.097 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -62.61 -32.62 84.0 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 5' ' ' SER . 7.4 p -56.08 -42.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.675 -0.41 . . . . 0.0 110.172 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.504 ' HB3' HD12 ' B' ' 9' ' ' LEU . 3.1 mm? -56.66 -48.59 77.24 Favored 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.81 -37.6 60.12 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-O 122.107 0.956 . . . . 0.0 108.824 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.49 -39.55 97.97 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.6 mm -61.91 -40.2 86.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.687 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 13' ' ' VAL . 0.6 OUTLIER -62.92 -42.4 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 C-N-CA 119.257 -0.977 . . . . 0.0 109.276 -179.993 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.432 ' O ' HG23 ' A' ' 18' ' ' VAL . 99.5 t -53.44 -44.59 55.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.1 -32.36 83.81 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.3 179.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.434 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 16.6 t0 -61.8 -51.46 68.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.772 0.32 . . . . 0.0 110.538 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.476 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.1 mp -61.15 -38.3 85.93 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.36 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 14' ' ' VAL . 78.2 t -64.32 -33.33 62.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.29 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.437 HD22 ' OG1' ' B' ' 20' ' ' THR . 35.6 mt -72.71 -49.55 30.5 Favored 'General case' 0 N--CA 1.463 0.179 0 C-N-CA 120.761 -0.375 . . . . 0.0 111.134 -179.305 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.1 m -59.6 -48.62 80.94 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.097 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 97.0 t -70.74 -38.57 73.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 24.3 tp -62.53 -54.58 37.68 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.712 -0.395 . . . . 0.0 111.753 -178.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 4.3 mm -69.04 -41.87 81.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 C-N-CA 120.086 -0.646 . . . . 0.0 109.82 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -56.6 -39.51 73.7 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.446 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.9 tp -69.96 -37.05 75.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.3 -53.6 52.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.422 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.45 HG23 ' N ' ' A' ' 28' ' ' TYR . 5.4 m -67.84 -40.83 84.3 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.514 -179.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.45 ' N ' HG23 ' A' ' 27' ' ' VAL . 75.4 t80 -59.68 -46.67 88.35 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.921 -179.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.9 t80 -63.42 -52.8 60.0 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.49 -0.323 . . . . 0.0 110.972 -179.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 52.1 tp -174.42 78.11 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.8 0.333 . . . . 0.0 110.494 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -64.93 160.58 41.85 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -78.68 13.16 1.74 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.784 0.326 . . . . 0.0 110.528 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 12.4 tp . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.404 -179.975 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 25.9 t -157.68 -32.65 0.08 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.524 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 86.9 m 47.17 96.22 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.7 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.493 HG13 ' O ' ' B' ' 4' ' ' VAL . 14.6 p -92.03 125.13 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.129 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.036 179.773 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 10.9 t -161.15 60.68 1.28 Allowed Pre-proline 0 C--N 1.332 -0.192 0 C-N-CA 120.893 -0.323 . . . . 0.0 111.287 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -66.78 84.7 0.3 Allowed 'Trans proline' 0 N--CA 1.495 1.581 0 C-N-CA 122.54 2.16 . . . . 0.0 111.583 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -52.02 -30.84 31.45 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.477 HG13 ' N ' ' B' ' 9' ' ' LEU . 8.8 p -60.79 -44.6 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.601 -0.44 . . . . 0.0 109.912 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.504 HD12 ' HB3' ' A' ' 9' ' ' LEU . 2.9 mm? -58.57 -48.52 80.66 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 119.919 -0.713 . . . . 0.0 109.295 179.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.74 -33.36 55.49 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.561 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.37 -39.73 98.11 Favored Glycine 0 CA--C 1.52 0.348 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.8 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.05 -25.51 27.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.463 -0.368 . . . . 0.0 110.135 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 99.0 t -68.13 -53.84 26.5 Favored 'Isoleucine or valine' 0 C--O 1.243 0.73 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.554 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.485 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -58.86 -31.26 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 178.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.96 -26.12 73.26 Favored Glycine 0 CA--C 1.531 1.038 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -68.23 -60.9 2.12 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 111.761 0.282 . . . . 0.0 111.761 -178.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.728 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.39 -24.37 62.93 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.57 -179.684 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.485 HG23 ' O ' ' B' ' 14' ' ' VAL . 17.9 t -68.82 -38.37 78.65 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 177.281 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.434 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 15.6 mt -64.43 -50.16 68.68 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.309 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.437 ' OG1' HD22 ' A' ' 19' ' ' LEU . 13.9 m -58.26 -50.58 73.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.775 -178.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 90.8 t -71.39 -27.04 27.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 20.9 tp -69.84 -57.09 5.49 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.212 -178.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 14.0 mt -70.82 -39.54 75.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.21 -39.49 90.42 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 109.895 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.1 tp -70.31 -33.21 71.26 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.02 -51.61 68.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.548 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 15.6 m -64.07 -40.71 90.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.843 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -59.54 -46.33 89.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.582 -179.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 85.3 t80 -62.43 -46.8 86.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.806 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 67.4 mt -62.43 -42.04 99.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.517 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -65.7 77.56 0.1 OUTLIER Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 51.9 ptt85 -65.83 176.29 1.65 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.321 . . . . 0.0 110.668 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.601 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.237 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.53 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 83.9 m . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.7 m -73.42 154.63 39.92 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.58 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 77.6 p -47.53 108.76 0.17 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.531 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 46.3 t -65.51 -24.38 34.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.409 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.5 m 58.45 59.76 5.88 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.803 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_endo -76.29 12.88 1.44 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.712 2.274 . . . . 0.0 111.503 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -61.82 -36.59 92.99 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 9' ' ' LEU . 11.8 p -55.37 -45.94 78.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.164 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.575 HD12 ' HB3' ' B' ' 9' ' ' LEU . 2.9 mm? -51.7 -48.8 63.39 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.424 ' O ' HG22 ' A' ' 13' ' ' VAL . . . -55.96 -37.73 69.43 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-O 122.078 0.942 . . . . 0.0 109.427 179.087 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.85 -37.99 94.59 Favored Glycine 0 CA--C 1.521 0.451 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.652 HG21 HG12 ' B' ' 13' ' ' VAL . 1.9 mp -66.57 -40.87 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.32 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.424 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -57.82 -42.02 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 118.664 -1.214 . . . . 0.0 108.759 179.691 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.409 ' O ' HG23 ' A' ' 18' ' ' VAL . 89.6 t -55.54 -43.34 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.2 -33.83 87.18 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.06 178.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.487 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 19.7 t0 -60.02 -51.17 70.81 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-O 120.949 0.404 . . . . 0.0 110.361 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.477 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.1 mp -60.38 -37.87 82.12 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 179.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 14' ' ' VAL . 75.5 t -64.01 -33.91 65.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.302 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.534 HD22 ' OG1' ' B' ' 20' ' ' THR . 51.7 mt -71.72 -46.97 56.96 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.94 -0.304 . . . . 0.0 111.231 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.7 m -59.59 -49.39 77.94 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.871 -179.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 99.8 t -70.94 -35.43 59.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.404 -179.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.79 -55.7 18.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.746 -0.381 . . . . 0.0 111.763 -178.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 mm -68.77 -40.96 82.12 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.638 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -57.55 -39.51 76.83 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.621 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.5 tp -69.37 -37.06 77.43 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -62.14 -54.55 39.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.579 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.511 HG23 ' N ' ' A' ' 28' ' ' TYR . 4.6 m -66.23 -43.9 91.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 C-N-CA 120.413 -0.515 . . . . 0.0 111.696 -179.078 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.511 ' N ' HG23 ' A' ' 27' ' ' VAL . 73.1 t80 -59.02 -45.4 90.79 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.78 -179.389 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -61.46 -50.91 70.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.082 -179.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 45.8 tp -172.5 76.72 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.416 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -72.33 157.31 52.75 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 92.8 mtt-85 -77.44 144.44 37.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.817 0.341 . . . . 0.0 110.463 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 25.7 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.38 -179.982 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.53 ' SG ' ' N ' ' A' ' 1' ' ' CYS . 36.3 t . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.454 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 14.4 t -61.72 -43.09 99.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.523 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 67.8 m 51.88 96.24 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.485 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 15.5 m -65.5 -168.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.68 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 13.6 t -160.38 62.28 1.73 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.691 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -73.72 54.07 2.91 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 122.482 2.121 . . . . 0.0 111.57 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.06 -46.69 90.59 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.438 ' H ' HG12 ' B' ' 8' ' ' VAL . 1.5 p -63.48 -44.92 98.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.29 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.575 ' HB3' HD12 ' A' ' 9' ' ' LEU . 3.7 mm? -61.09 -50.16 74.37 Favored 'General case' 0 C--O 1.239 0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 110.233 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.406 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.71 -37.42 70.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 122.053 0.93 . . . . 0.0 109.222 179.086 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.98 -36.77 93.35 Favored Glycine 0 CA--C 1.519 0.297 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 89.9 mt -66.04 -42.79 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 C-N-CA 120.242 -0.583 . . . . 0.0 111.3 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.652 HG12 HG21 ' A' ' 12' ' ' ILE . 1.0 OUTLIER -60.25 -38.73 78.46 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 C-N-CA 118.558 -1.257 . . . . 0.0 108.793 179.25 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.466 ' O ' HG23 ' B' ' 18' ' ' VAL . 95.1 t -57.51 -35.98 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 177.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.45 -25.4 75.39 Favored Glycine 0 CA--C 1.533 1.183 0 CA-C-N 114.529 -1.214 . . . . 0.0 110.945 178.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -69.35 -60.95 2.0 Allowed 'General case' 0 C--O 1.237 0.413 0 O-C-N 122.479 -0.424 . . . . 0.0 111.776 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.736 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -70.12 -24.42 63.19 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 119.039 -1.064 . . . . 0.0 110.382 -179.6 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.518 ' N ' HD22 ' B' ' 17' ' ' LEU . 7.2 t -66.07 -45.08 91.52 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.381 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.487 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 38.1 mt -63.35 -49.43 73.92 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.033 -179.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.534 ' OG1' HD22 ' A' ' 19' ' ' LEU . 10.4 m -56.54 -50.73 71.01 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.507 -0.477 . . . . 0.0 111.293 -178.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 96.5 t -67.57 -43.05 87.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.133 -0.485 . . . . 0.0 112.167 -178.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 36.0 tp -57.9 -57.83 11.05 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -178.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 29.0 mt -64.67 -41.82 93.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.716 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.53 -32.33 62.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.421 0.629 . . . . 0.0 109.601 178.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.485 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.06 -43.4 71.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.426 179.662 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -54.67 -53.1 59.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.722 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.436 ' CG1' HG12 ' A' ' 27' ' ' VAL . 17.1 m -60.29 -41.83 88.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.647 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 56.9 t80 -58.64 -42.76 89.03 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.556 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -61.29 -44.6 96.95 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.824 -179.794 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 95.3 mt -59.28 -42.33 90.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.512 -179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -77.28 128.29 8.89 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 60.2 ttt85 -70.73 94.88 1.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.734 0.302 . . . . 0.0 110.584 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.585 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.431 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 50.4 m . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 40.8 t -158.24 172.16 18.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.441 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 33.0 m -60.69 122.94 16.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.542 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 10.1 t -90.15 97.92 7.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.394 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.8 p -79.86 148.53 68.78 Favored Pre-proline 0 CA--C 1.534 0.332 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.375 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.93 40.54 0.95 Allowed 'Trans proline' 0 N--CA 1.494 1.555 0 C-N-CA 122.213 1.942 . . . . 0.0 112.312 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -70.4 -60.52 4.69 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.249 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.449 HG13 ' N ' ' A' ' 9' ' ' LEU . 8.1 p -62.99 -43.14 98.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 C-N-CA 120.436 -0.506 . . . . 0.0 109.759 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.506 ' HB3' HD12 ' B' ' 9' ' ' LEU . 2.7 mm? -57.38 -47.41 81.75 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 178.681 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.44 -38.56 59.48 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.147 0.975 . . . . 0.0 108.482 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -40.07 98.51 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 114.487 -1.233 . . . . 0.0 110.639 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.6 mm -60.61 -41.53 88.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.516 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -61.29 -43.95 97.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.291 179.72 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 78.7 t -52.6 -45.75 48.12 Favored 'Isoleucine or valine' 0 C--O 1.237 0.424 0 C-N-CA 119.652 -0.819 . . . . 0.0 108.867 178.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.95 -31.35 80.52 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 41.0 t0 -60.54 -48.48 81.61 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.459 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.2 mp -61.77 -40.93 96.9 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 80.5 t -59.44 -41.88 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.707 179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.517 HD13 ' OG1' ' B' ' 20' ' ' THR . 57.4 mt -64.5 -44.7 90.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.4 m -57.52 -51.64 68.62 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 -179.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -71.73 -24.19 23.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.781 -179.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 52.9 tp -70.17 -56.44 6.84 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.478 -0.489 . . . . 0.0 111.774 -178.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.3 mm -73.06 -38.09 54.67 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.552 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -61.19 -38.51 86.78 Favored 'General case' 0 N--CA 1.457 -0.092 0 CA-C-O 120.906 0.384 . . . . 0.0 110.074 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 34.5 tp -70.59 -36.65 73.67 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.325 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -63.39 -54.41 37.13 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.172 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.52 HG23 ' N ' ' A' ' 28' ' ' TYR . 17.8 m -66.31 -42.47 90.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 C-N-CA 120.73 -0.388 . . . . 0.0 111.292 -179.499 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.52 ' N ' HG23 ' A' ' 27' ' ' VAL . 83.9 t80 -60.35 -45.15 94.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.797 0.332 . . . . 0.0 110.867 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.2 t80 -62.0 -52.87 62.24 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.101 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.8 tp -174.28 78.57 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.739 0.304 . . . . 0.0 110.447 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -58.19 157.26 18.45 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 31.9 mmm-85 -71.56 134.13 46.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.905 0.383 . . . . 0.0 110.515 -179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.9 tp . . . . . 0 C--N 1.331 -0.21 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.664 179.916 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.422 ' SG ' ' N ' ' B' ' 2' ' ' SER . 26.8 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.422 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 77.1 p -83.18 66.56 8.79 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.61 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 41.9 m -80.18 121.88 26.13 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.395 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 14.5 p -167.08 143.17 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.583 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 177.73 162.71 0.58 Allowed Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.212 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_exo -33.58 92.39 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 123.079 2.519 . . . . 0.0 112.588 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -58.06 -29.41 62.36 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.438 HG13 ' N ' ' B' ' 9' ' ' LEU . 7.2 p -58.69 -41.09 81.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.506 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.5 mm? -56.89 -50.52 72.27 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.17 -30.99 40.4 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.82 -34.47 87.35 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 178.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' B' ' 9' ' ' LEU . 1.7 mp -74.02 -29.3 25.2 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.448 -0.31 . . . . 0.0 110.902 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -72.0 -45.6 63.02 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.689 179.612 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.41 ' O ' HD13 ' B' ' 17' ' ' LEU . 3.4 p -62.09 -39.66 84.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 C-N-CA 119.778 -0.769 . . . . 0.0 108.944 178.815 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.92 -29.02 71.13 Favored Glycine 0 CA--C 1.528 0.847 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 6.7 t0 -66.47 -62.6 1.38 Allowed 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.757 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -63.93 -27.5 69.18 Favored 'General case' 0 C--O 1.232 0.146 0 C-N-CA 119.039 -1.064 . . . . 0.0 109.759 -179.891 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.526 ' N ' HD22 ' B' ' 17' ' ' LEU . 6.8 t -68.57 -28.86 41.87 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 177.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.529 HD23 ' O ' ' B' ' 19' ' ' LEU . 3.1 tt -69.17 -55.46 10.58 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.092 0.472 . . . . 0.0 110.142 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.517 ' OG1' HD13 ' A' ' 19' ' ' LEU . 7.5 m -57.43 -46.15 83.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.317 -179.514 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 87.2 t -68.26 -41.98 84.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.831 -178.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 24.1 tp -59.45 -57.18 14.09 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 54.0 mt -64.74 -42.04 93.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 120.206 -0.598 . . . . 0.0 109.903 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -54.36 -32.2 56.36 Favored 'General case' 0 C--O 1.233 0.195 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.496 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -69.8 -45.29 68.26 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.522 179.327 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.81 -52.01 58.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.744 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 16.3 m -63.51 -41.56 93.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.017 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -57.5 -45.75 84.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.813 0.34 . . . . 0.0 110.565 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 57.0 t80 -62.28 -46.17 89.98 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.658 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 88.5 mt -61.81 -41.9 98.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.409 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.18 122.86 10.05 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -70.88 93.82 1.01 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 0.0 110.548 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.603 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.281 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.2 m . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 70.2 m -159.57 -6.58 0.06 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.554 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 6.1 m -160.67 -61.31 0.06 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.402 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.8 t 61.71 6.59 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.361 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.8 m 53.05 79.21 0.36 Allowed Pre-proline 0 N--CA 1.463 0.218 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.382 179.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.406 ' CD ' ' H ' ' A' ' 7' ' ' GLY . 44.6 Cg_endo -94.5 -41.81 0.02 OUTLIER 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 123.273 2.649 . . . . 0.0 112.417 179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.406 ' H ' ' CD ' ' A' ' 6' ' ' PRO . . . -63.89 -29.61 75.31 Favored Glycine 0 CA--C 1.526 0.767 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.998 -179.072 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.557 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.5 p -59.31 -48.91 85.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.831 -179.27 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.557 ' N ' HG13 ' A' ' 8' ' ' VAL . 2.8 mm? -51.81 -46.84 64.42 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.078 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -54.98 -41.61 71.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.851 0.834 . . . . 0.0 108.838 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.33 -29.87 69.91 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.591 HG21 HG12 ' B' ' 13' ' ' VAL . 42.5 mm -70.29 -42.71 78.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.51 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -57.53 -42.31 80.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.145 179.272 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 85.7 t -55.06 -42.76 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.255 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -61.75 -33.08 83.96 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -58.95 -50.52 73.77 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.047 0.451 . . . . 0.0 109.925 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.505 HD12 ' N ' ' A' ' 17' ' ' LEU . 11.0 mp -61.35 -39.27 89.97 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.907 179.587 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -59.21 -42.09 85.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.738 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.489 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 35.7 mt -65.72 -45.12 83.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.701 0.286 . . . . 0.0 111.198 -179.695 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.2 m -56.29 -53.04 61.98 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.088 -178.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 65.9 t -71.9 -27.3 27.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.819 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 34.8 tp -72.15 -51.4 21.49 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -178.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.593 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.9 mm -70.37 -37.49 70.93 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.22 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.753 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -67.46 -43.78 80.22 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.083 -179.704 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.4 tp -71.94 -32.92 67.8 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.089 0.471 . . . . 0.0 110.246 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.41 -50.61 36.8 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.698 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.593 HG22 ' O ' ' A' ' 23' ' ' ILE . 22.8 m -68.98 -42.86 82.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 C-N-CA 120.625 -0.43 . . . . 0.0 111.332 -178.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.505 ' N ' HG23 ' A' ' 27' ' ' VAL . 49.1 t80 -63.07 -47.05 84.59 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.699 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.5 t80 -64.21 -53.78 43.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.187 -179.484 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.9 tp -174.75 78.44 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.311 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -59.71 166.2 10.0 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 35.7 mmm-85 -62.12 -40.22 95.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 0.0 110.487 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 13.2 tp . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.35 179.959 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.573 ' SG ' ' N ' ' B' ' 2' ' ' SER . 51.5 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . 0.573 ' N ' ' SG ' ' B' ' 1' ' ' CYS . 53.5 m -76.26 -1.11 24.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.612 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 4.8 m 63.56 -69.3 0.08 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.462 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.494 ' N ' ' O ' ' B' ' 2' ' ' SER . 21.7 t 44.61 65.32 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.111 0.481 . . . . 0.0 109.928 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . 0.534 ' O ' ' N ' ' B' ' 7' ' ' GLY . 73.7 m -133.81 57.99 29.13 Favored Pre-proline 0 N--CA 1.465 0.31 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.356 -178.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . 0.406 ' C ' ' O ' ' B' ' 5' ' ' SER . 7.5 Cg_exo -34.45 88.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.49 1.294 0 C-N-CA 122.743 2.296 . . . . 0.0 111.627 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' B' ' 5' ' ' SER . . . -65.2 -43.08 95.97 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.29 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -57.86 -43.84 85.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.758 -179.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . . . . . . . . . 13.7 mt -64.83 -35.02 79.77 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 119.002 -1.079 . . . . 0.0 109.651 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.45 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -56.47 -39.81 73.83 Favored 'General case' 0 CA--C 1.521 -0.146 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 177.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.99 -36.32 92.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 109.529 -1.429 . . . . 0.0 109.529 178.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.7 mp -70.31 -31.31 46.57 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-O 119.155 -0.45 . . . . 0.0 111.518 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.591 HG12 HG21 ' A' ' 12' ' ' ILE . 1.3 m -73.01 -41.58 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.573 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 p -62.37 -37.48 78.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 C-N-CA 118.325 -1.35 . . . . 0.0 107.547 178.026 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.87 -29.38 73.61 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.763 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.489 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 4.1 t0 -64.08 -49.07 73.72 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.114 0.483 . . . . 0.0 109.754 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 1.8 mt -59.63 -44.35 93.5 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.084 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 87.3 t -64.53 -24.61 36.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.541 179.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 1.3 tt -70.67 -48.51 54.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.929 0.395 . . . . 0.0 110.255 -179.473 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 19.7 m -61.63 -45.84 92.35 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.555 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.8 t -71.0 -26.49 27.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.668 -179.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 25.2 tp -71.07 -52.88 16.92 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.31 -179.075 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 46.5 mt -69.81 -42.13 79.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.831 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -60.68 -43.92 97.12 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.759 -0.376 . . . . 0.0 110.572 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 54.1 tp -72.02 -29.95 64.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.956 0.408 . . . . 0.0 109.988 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -66.6 -51.66 53.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.046 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.445 HG23 ' N ' ' B' ' 28' ' ' TYR . 26.5 m -70.62 -38.81 74.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.121 -179.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . 0.445 ' N ' HG23 ' B' ' 27' ' ' VAL . 78.5 t80 -62.59 -48.48 79.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.726 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 83.3 t80 -62.27 -49.77 74.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.904 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 74.7 mt -62.9 -42.06 99.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.42 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -61.47 107.6 1.57 Allowed Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 72.6 mtp85 -68.38 144.4 54.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.824 0.345 . . . . 0.0 110.6 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.598 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.2 mm? . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.243 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.46 ' C ' ' H ' ' A' ' 3' ' ' THR . 8.5 p . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.3 t -76.08 32.82 0.12 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.627 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.46 ' H ' ' C ' ' A' ' 1' ' ' CYS . 26.5 m -60.85 -45.46 94.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.54 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' A' ' 5' ' ' SER . 98.9 t -78.25 -86.12 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.394 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 4' ' ' VAL . 3.8 p 59.06 150.51 0.08 OUTLIER Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.143 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.13 69.16 4.86 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.034 1.823 . . . . 0.0 111.984 179.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.57 -56.62 10.92 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.495 HG13 ' N ' ' A' ' 9' ' ' LEU . 8.4 p -66.05 -44.98 91.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 179.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.501 ' HB3' HD12 ' B' ' 9' ' ' LEU . 2.1 mm? -57.64 -47.61 81.76 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.19 -38.27 68.15 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-O 122.082 0.944 . . . . 0.0 108.521 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.89 -37.52 93.87 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 44.2 mm -62.76 -43.23 98.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.811 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -60.69 -43.42 94.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 119.046 -1.061 . . . . 0.0 109.576 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 18' ' ' VAL . 88.7 t -53.5 -42.39 49.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.335 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -34.66 90.54 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 178.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -57.23 -50.31 73.26 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 120.754 0.312 . . . . 0.0 110.177 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.503 ' N ' HD12 ' A' ' 17' ' ' LEU . 11.0 mp -61.39 -40.19 93.47 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.487 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 14' ' ' VAL . 78.7 t -62.11 -39.57 84.34 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.524 HD13 ' OG1' ' B' ' 20' ' ' THR . 46.7 mt -67.04 -44.23 80.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.866 0.365 . . . . 0.0 111.005 -179.453 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.1 m -59.76 -51.59 69.12 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.175 -179.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 61.3 t -71.83 -27.98 29.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.187 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 23.3 tp -68.99 -56.48 7.66 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.716 -178.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.8 mm -70.47 -39.88 76.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.323 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.99 -39.82 82.97 Favored 'General case' 0 CA--C 1.521 -0.167 0 C-N-CA 120.867 -0.333 . . . . 0.0 110.714 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.9 tp -69.72 -37.48 76.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.59 -53.7 52.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.771 -179.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.519 HG23 ' N ' ' A' ' 28' ' ' TYR . 6.4 m -67.53 -43.13 87.42 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 C-N-CA 120.46 -0.496 . . . . 0.0 111.744 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.519 ' N ' HG23 ' A' ' 27' ' ' VAL . 62.8 t80 -59.29 -46.97 87.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.083 -179.355 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -67.09 -55.84 12.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.148 -179.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 48.2 tp -174.56 77.66 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.315 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -50.36 115.74 3.53 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -74.09 133.91 42.89 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.678 0.275 . . . . 0.0 110.579 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 5.5 tt . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.598 -179.985 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 42.1 t . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 22.3 p -159.2 -22.71 0.07 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.597 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 16.3 m 46.67 81.14 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.559 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 10.5 m -73.42 142.54 14.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.336 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 13.6 t -144.46 60.6 7.83 Favored Pre-proline 0 N--CA 1.465 0.312 0 CA-C-O 120.822 0.344 . . . . 0.0 110.887 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -78.39 75.49 4.89 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 C-N-CA 122.954 2.436 . . . . 0.0 111.529 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -63.19 -34.98 91.44 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.48 HG13 HD22 ' B' ' 9' ' ' LEU . 14.3 p -55.13 -43.09 68.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.501 HD12 ' HB3' ' A' ' 9' ' ' LEU . 3.8 mm? -54.55 -52.47 61.96 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 120.391 -0.524 . . . . 0.0 109.765 179.239 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -51.41 -36.33 43.12 Favored 'General case' 0 C--O 1.241 0.658 0 CA-C-O 121.968 0.89 . . . . 0.0 109.11 179.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.21 -37.79 95.12 Favored Glycine 0 CA--C 1.524 0.624 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.123 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.8 mp -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.174 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . . . . . . . . . 33.2 t -69.64 -52.82 28.39 Favored 'Isoleucine or valine' 0 C--O 1.246 0.901 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.491 178.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 p -58.53 -32.38 45.7 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.418 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.3 -25.2 75.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -69.79 -61.72 1.67 Allowed 'General case' 0 C--O 1.235 0.334 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.737 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -67.52 -23.47 65.46 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 118.368 -1.333 . . . . 0.0 109.954 -179.557 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.494 ' N ' HD22 ' B' ' 17' ' ' LEU . 9.4 t -70.32 -38.91 75.82 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.863 177.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.476 HD23 ' O ' ' B' ' 19' ' ' LEU . 1.9 tt -66.47 -52.07 50.13 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 120.996 0.427 . . . . 0.0 110.531 -179.219 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.524 ' OG1' HD13 ' A' ' 19' ' ' LEU . 9.7 m -58.8 -49.01 79.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.025 -179.398 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 72.0 t -65.24 -42.01 92.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.609 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 35.6 tp -57.73 -56.51 21.0 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 112.006 0.372 . . . . 0.0 112.006 -178.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 52.7 mt -66.02 -41.71 90.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 C-N-CA 120.084 -0.646 . . . . 0.0 110.082 -179.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.45 -31.72 62.17 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.32 0.581 . . . . 0.0 109.484 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.457 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -70.77 -44.56 66.45 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.25 179.541 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -52.38 -51.97 56.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.661 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.436 ' CG1' HG12 ' A' ' 27' ' ' VAL . 18.0 m -63.04 -40.67 89.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.742 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -57.09 -47.93 79.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.83 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -62.29 -45.58 92.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.872 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 73.9 mt -61.9 -42.03 98.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.452 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -71.33 91.64 0.47 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 61.0 ttt85 -47.33 97.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.745 0.307 . . . . 0.0 110.452 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.62 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.391 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.404 ' CB ' ' H1 ' ' B' ' 1' ' ' CYS . 4.4 m . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.6 m -67.87 141.41 56.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.445 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.547 ' O ' ' N ' ' A' ' 5' ' ' SER . 68.8 p -81.09 -16.39 53.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.599 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 5' ' ' SER . 59.1 t 52.91 -82.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.401 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.547 ' N ' ' O ' ' A' ' 3' ' ' THR . 5.5 m 59.83 143.61 0.05 OUTLIER Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.623 179.499 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 61.7 Cg_endo -73.55 82.23 1.7 Allowed 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.153 1.902 . . . . 0.0 112.252 179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.31 -64.35 2.42 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 179.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.428 HG13 ' N ' ' A' ' 9' ' ' LEU . 7.7 p -64.52 -45.29 96.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.147 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.602 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.8 mm? -51.32 -49.48 61.28 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.339 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.454 ' HB2' ' O ' ' A' ' 6' ' ' PRO . . . -57.3 -37.5 72.56 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-O 121.968 0.889 . . . . 0.0 109.302 179.223 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.13 -38.49 94.46 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.641 HG21 HG12 ' B' ' 13' ' ' VAL . 1.8 mp -66.26 -44.02 91.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.378 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -55.19 -42.62 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 C-N-CA 118.568 -1.253 . . . . 0.0 108.652 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.405 ' O ' HG23 ' A' ' 18' ' ' VAL . 95.6 t -55.21 -42.31 65.19 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 178.09 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.56 -32.9 84.88 Favored Glycine 0 CA--C 1.53 1.012 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.131 178.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -61.24 -49.59 76.47 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.84 0.352 . . . . 0.0 110.179 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.483 ' N ' HD12 ' A' ' 17' ' ' LEU . 10.5 mp -61.53 -38.57 87.89 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.402 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.405 HG23 ' O ' ' A' ' 14' ' ' VAL . 74.6 t -62.57 -41.44 92.09 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.265 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.009 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.484 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 36.6 mt -65.56 -44.61 86.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.749 0.309 . . . . 0.0 111.019 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.3 m -59.16 -51.48 69.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.229 -179.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 55.7 t -71.92 -30.59 37.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.754 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 35.4 tp -69.0 -52.87 24.24 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.698 -178.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.472 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.5 mm -69.9 -42.45 79.79 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.682 0 C-N-CA 119.713 -0.795 . . . . 0.0 109.25 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.88 93.02 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.435 -179.271 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 42.4 tp -70.1 -36.34 74.79 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.601 -179.632 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.19 -51.5 30.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.236 -178.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.472 HG22 ' O ' ' A' ' 23' ' ' ILE . 14.2 m -69.37 -41.02 80.71 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 C-N-CA 120.441 -0.503 . . . . 0.0 111.366 -178.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.443 ' N ' HG23 ' A' ' 27' ' ' VAL . 89.4 t80 -65.67 -45.9 81.16 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.91 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 91.5 t80 -63.36 -52.54 61.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.07 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 20.5 tp -173.15 77.29 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.111 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -62.98 151.37 47.8 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 33.6 mmm-85 -71.98 -16.39 62.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.831 0.348 . . . . 0.0 110.55 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 12.1 tp . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.347 -179.941 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . 0.467 ' C ' ' H ' ' B' ' 3' ' ' THR . 27.6 p . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 4.6 p 64.65 -2.12 0.7 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.579 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.467 ' H ' ' C ' ' B' ' 1' ' ' CYS . 20.5 m 46.2 89.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.634 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . 0.454 HG11 ' H ' ' A' ' 5' ' ' SER . 46.4 t -105.66 85.75 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 41.4 m -130.19 93.41 33.33 Favored Pre-proline 0 CA--C 1.536 0.41 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.817 -179.213 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -80.71 89.88 1.27 Allowed 'Trans proline' 0 N--CA 1.491 1.376 0 C-N-CA 122.235 1.957 . . . . 0.0 111.732 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.57 -35.65 92.2 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . 0.521 HG13 ' N ' ' B' ' 9' ' ' LEU . 8.5 p -54.39 -43.89 64.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 179.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.602 ' HB3' HD12 ' A' ' 9' ' ' LEU . 2.3 mm? -53.43 -50.47 65.16 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.432 ' O ' HG22 ' B' ' 13' ' ' VAL . . . -54.67 -33.66 61.1 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 121.781 0.8 . . . . 0.0 109.156 178.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.33 -35.55 92.1 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.172 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 1.9 mp -72.72 -33.12 43.31 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.397 0 CA-C-O 119.169 -0.443 . . . . 0.0 111.296 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.641 HG12 HG21 ' A' ' 12' ' ' ILE . 1.9 m -70.32 -41.48 78.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 118.884 -1.127 . . . . 0.0 110.378 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . . . . . . . . . 3.1 p -63.27 -38.06 81.11 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 C-N-CA 118.623 -1.231 . . . . 0.0 108.087 178.073 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -67.59 -29.43 73.96 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 178.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.484 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 5.3 t0 -64.67 -49.39 71.15 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.198 0.523 . . . . 0.0 109.631 179.816 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mt -58.82 -43.24 90.56 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.54 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.77 -24.39 30.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.102 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.418 HD23 ' O ' ' B' ' 19' ' ' LEU . 2.3 tt -70.54 -51.64 27.29 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 121.07 0.462 . . . . 0.0 110.139 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . 0.467 ' OG1' HD13 ' A' ' 19' ' ' LEU . 7.8 m -60.79 -48.89 79.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.626 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 95.0 t -63.66 -42.54 96.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.286 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 26.7 tp -57.36 -54.02 51.56 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . 0.405 ' O ' ' HB3' ' B' ' 26' ' ' ALA . 59.3 mt -64.02 -44.84 97.9 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.494 -178.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -55.52 -36.78 67.1 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 178.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . 0.492 HD13 ' O ' ' B' ' 25' ' ' LEU . 0.2 OUTLIER -66.39 -39.23 88.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.268 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . 0.405 ' HB3' ' O ' ' B' ' 23' ' ' ILE . . . -53.6 -55.65 23.96 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.262 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.415 HG11 ' CG1' ' A' ' 27' ' ' VAL . 12.7 m -63.68 -37.54 79.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 C-N-CA 119.387 -0.925 . . . . 0.0 111.02 179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -56.65 -47.36 79.95 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.784 -0.367 . . . . 0.0 110.568 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -62.6 -47.64 82.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.784 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 74.8 mt -62.67 -41.92 99.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.647 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.406 ' O ' ' N ' ' B' ' 33' ' ' LEU . . . -61.17 114.53 6.77 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 74.4 ttt180 -62.31 82.61 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.866 0.365 . . . . 0.0 110.475 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.599 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.4 mm? . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.396 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 72.1 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.401 ' O ' ' OG1' ' A' ' 3' ' ' THR . 68.1 m -76.53 -80.08 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.644 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.401 ' OG1' ' O ' ' A' ' 2' ' ' SER . 23.9 m -166.41 -27.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.644 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 47.0 t 52.96 94.17 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.65 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.4 p -78.02 135.18 63.05 Favored Pre-proline 0 CA--C 1.538 0.5 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.255 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.466 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 91.2 Cg_endo -79.07 75.91 4.82 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 121.998 1.799 . . . . 0.0 112.351 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -72.91 -64.8 2.45 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.4 p -65.32 -38.98 83.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.282 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.621 HD12 ' HB3' ' B' ' 9' ' ' LEU . 3.9 mm? -57.57 -46.27 84.17 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 6' ' ' PRO . . . -58.59 -40.93 84.56 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-O 122.1 0.952 . . . . 0.0 109.441 179.257 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -59.16 -38.87 93.74 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.596 HG21 HG12 ' B' ' 13' ' ' VAL . 36.0 mm -63.98 -42.76 96.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 C-N-CA 120.561 -0.456 . . . . 0.0 110.653 -179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.416 HG22 ' O ' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -57.04 -42.67 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 C-N-CA 118.789 -1.164 . . . . 0.0 108.864 179.651 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.433 ' O ' HG23 ' A' ' 18' ' ' VAL . 57.6 t -54.26 -45.08 67.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 C-N-CA 119.485 -0.886 . . . . 0.0 108.769 178.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.79 -33.27 86.78 Favored Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.407 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.462 ' OD1' ' CD1' ' B' ' 19' ' ' LEU . 15.0 t0 -62.12 -51.98 65.69 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.774 0.321 . . . . 0.0 110.706 -179.425 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.455 ' N ' HD12 ' A' ' 17' ' ' LEU . 10.8 mp -60.93 -37.79 83.56 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 14' ' ' VAL . 64.4 t -64.3 -33.19 61.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.141 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.401 ' CD1' ' OD1' ' B' ' 16' ' ' ASP . 27.3 mt -73.43 -46.7 46.94 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.188 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.0 m -60.28 -49.14 78.8 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.073 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.4 t -71.93 -37.27 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 22.9 tp -63.1 -55.18 27.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.408 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.426 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.6 mm -67.98 -44.68 84.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.684 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -53.46 -42.18 66.91 Favored 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 43.3 tp -66.96 -38.25 85.76 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.961 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -60.66 -50.87 71.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.243 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.434 HG22 HG11 ' B' ' 27' ' ' VAL . 3.0 t -68.7 -45.88 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.167 0 C-N-CA 120.614 -0.435 . . . . 0.0 111.497 -179.371 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -58.1 -47.82 82.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.42 -178.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 58.8 t80 -69.52 -56.9 6.06 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.239 -179.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.503 ' O ' ' N ' ' A' ' 32' ' ' ARG . 57.7 tp -177.9 80.34 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -42.2 92.03 0.01 OUTLIER Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.503 ' N ' ' O ' ' A' ' 30' ' ' LEU . 33.5 mmm-85 -61.32 -34.93 76.05 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.684 0.278 . . . . 0.0 110.455 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 9.4 tp . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.53 -179.879 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 1' ' ' CYS . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 2' ' ' SER . . . . . . . . . . . . . 21.3 m 57.0 98.5 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.624 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . . . . . . . . . 7.0 m 60.12 121.61 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.703 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 4' ' ' VAL . . . . . . . . . . . . . 74.2 t -145.38 113.6 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.242 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -177.96 154.3 0.96 Allowed Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.54 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 6' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -59.82 107.96 0.44 Allowed 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.612 2.208 . . . . 0.0 112.116 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.62 -34.55 90.2 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 179.494 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 8' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.71 -35.04 53.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.445 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 9' ' ' LEU . . . . . 0.621 ' HB3' HD12 ' A' ' 9' ' ' LEU . 1.6 mm? -62.47 -46.78 86.96 Favored 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.129 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -59.0 -32.32 69.6 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.89 -32.93 84.25 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 178.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' ILE . . . . . . . . . . . . . 88.9 mt -72.77 -34.7 47.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-O 119.091 -0.48 . . . . 0.0 111.812 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.596 HG12 HG21 ' A' ' 12' ' ' ILE . 1.4 m -69.54 -44.85 79.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 C-N-CA 119.025 -1.07 . . . . 0.0 109.95 179.266 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' VAL . . . . . 0.512 ' O ' HG23 ' B' ' 18' ' ' VAL . 3.2 p -60.09 -33.73 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 177.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' GLY . . . . . . . . . . . . . . . -71.61 -25.9 74.18 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 178.329 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.401 ' OD1' ' CD1' ' A' ' 19' ' ' LEU . 9.3 t70 -69.08 -61.49 1.77 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -178.391 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.747 ' C ' HD22 ' B' ' 17' ' ' LEU . 0.0 OUTLIER -68.15 -25.82 65.46 Favored 'General case' 0 C--O 1.233 0.206 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.238 -179.724 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.512 HG23 ' O ' ' B' ' 14' ' ' VAL . 14.6 t -66.74 -39.2 83.13 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.462 ' CD1' ' OD1' ' A' ' 16' ' ' ASP . 14.2 mt -63.29 -47.31 82.86 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.024 0.44 . . . . 0.0 110.157 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' THR . . . . . . . . . . . . . 10.3 m -57.55 -50.26 73.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.561 -178.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 98.7 t -72.31 -28.49 29.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.292 0.479 . . . . 0.0 112.292 -178.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 22' ' ' LEU . . . . . . . . . . . . . 22.0 tp -68.51 -56.62 7.74 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.456 -0.498 . . . . 0.0 111.311 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' ILE . . . . . . . . . . . . . 30.1 mt -69.82 -41.69 79.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 C-N-CA 120.471 -0.491 . . . . 0.0 109.991 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' ALA . . . . . . . . . . . . . . . -58.3 -38.82 77.82 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 121.127 0.489 . . . . 0.0 109.73 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' LEU . . . . . . . . . . . . . 37.9 tp -69.54 -35.75 75.73 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.675 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' ALA . . . . . . . . . . . . . . . -57.6 -51.76 68.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.518 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.434 HG11 HG22 ' A' ' 27' ' ' VAL . 16.4 m -64.99 -38.26 82.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.656 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 28' ' ' TYR . . . . . . . . . . . . . 88.9 t80 -57.97 -48.57 79.58 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.472 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 84.6 t80 -62.96 -46.07 89.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.866 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 30' ' ' LEU . . . . . . . . . . . . . 72.8 mt -62.24 -42.21 99.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.649 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . . . . . . . . . . . -54.0 95.18 0.02 OUTLIER Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 32' ' ' ARG . . . . . . . . . . . . . 76.4 ttt180 -72.73 89.97 1.38 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.834 0.35 . . . . 0.0 110.573 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.601 ' N ' HD22 ' B' ' 33' ' ' LEU . 3.3 mm? . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.306 179.956 . . . . . . . . 1 1 . 1 stop_ save_